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ABSTRACT

A number of recent works have emphasized the need to isolate nanometer-scale
analytes, like extracellular vesicles (EVs), from various biologically-relevant fluids.
Exosomes are a subset of small EVs that range from 30-200 nm in diameter that serve as
biomolecular snapshots of their cell of origin containing mother cell-specific DNA,
miRNA, mRNA, and proteins. As critical components of intercellular communication,
exosomes and other EVs play significant roles in many physiological and pathological
processes. Diverse populations of these vesicles can be collected from biofluids,
including blood, saliva, and urine, from cell culture conditioned media and primary cells,
and even from plant fluid stocks. With their characteristic vector-like activities and
accessible collection from renewable sources, the large-scale processing of EVs from
patient biofluids for clinical diagnostics and from plant fluids or high-yield bioreactors
for use as therapeutic vectors has been previously proposed. However, these applications
are limited by extremely impure, low-yield exosome recoveries, despite the large
availability of exosome sources. Hence, an isolation method that provides high
concentrations of pure, bioactive EVs from diverse sources on reasonable scales of time
and cost is of much interest.
Employed in this work is a rapid EV isolation method using a hydrophobic
interaction chromatography (HIC) workflow on a capillary-channeled polymer (C-CP)
fiber spin-down tip. Here, EVs are isolated from several biofluid sources, including mock
biofluid matrices, clinical patient biofluid samples, cellular milieu from mammalian and
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amoeba cell lines, and over 20 fruit and vegetable sample stocks. Representative
populations of EVs are obtained using the C-CP tip method, where up to 12 samples are
simultaneously processed in a standard tabletop centrifuge in less than 15 minutes. This
batch solid-phase extraction technique allows up to 1 x 1012 EVs to be obtained from
each µL-scale aliquot of the original biofluid. The tip-isolated EVs were characterized
using transmission electron microscopy (TEM), multi-angle light scattering (MALS),
nanoparticle tracking analysis (NTA), absorbance quantification, protein purity assay,
and immunoassays to EV and source-specific proteins. The efficient HIC C-CP tip
isolation method produces the required integrity and purity of recovered EVs to enable
fundamental research to be performed and their therapeutic vector and clinical diagnostic
potentials to be better explored.
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CHAPTER ONE
INTRODUCTION
1.1

Extracellular Vesicles
A diverse population of nanometer-scale extracellular vesicles (EVs) are secreted

by all living cells as a part of their normal physiology and serve critical biological roles
during cellular communication.1 Though the area of EV research is a currently
developing field, EVs are now known to be involved in a variety of functions, including
immune modulation,2 viral pathogenicity,3 and disease progression.4, 5 In each case, the
physiological activities initiated by the release and uptake of EVs are allowed by the
biomolecules incorporated into the internal and transmembrane EV spaces during their
biogenesis.6 In general, EVs are 30 – 1000 nm phospholipid bilayer membrane-bound
vesicles that contain DNA, RNA, lipids, metabolites, and cytosolic and/or surface
proteins from their cell of origin.5, 6 As originally referred to as “cellular trash bags”,7-9
the purpose of EV secretion is to remove unneeded or excess cell by-products and
maintain cellular homeostasis, though the entirety of their functional roles has yet to be
fully understood.1, 6 Still, EVs have been generically classified by size and creation
mechanism as microvesicles– 30 to 1000 nm vesicles formed by the blebbing of the
plasma membrane,6, 10-12 apoptotic bodies– 100 to 1000 nm EVs stochastically formed
during cell death,10, 13 and exosomes– 30 to 200 nm sized-vesicles strategically created
through the multivesicular body-mediated endosomal pathway.5-7, 10, 14 Of most interest is
the exosome EV sub-type, which has been suggested in many clinical and therapeutic
applications because of the strategic biogenesis process, which allows them to contain
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specific components that aid in the regulation of cellular signaling and communication. 1,
15, 16

Still, because of the overlap of size and the inability to differentiate between EV sub-

types, vesicles in the 30 – 200 nm exosome size range have been generically referred to
as EVs or small EVs (sEVs).17

1.2

EV Sources and Applications
Because EVs are secreted from all cells, they may be collected from many

biofluids, including from cell culture milieu,18 urine,19, 20 saliva,21 cervical mucus,22 blood
(serum and plasma),19, 23 and breast milk.24 With the ability to collect EVs non-invasively
from patient biofluids (i.e., from urine or saliva), liquid biopsy approaches are currently
under development, where there are numerous opportunities for the detection,
monitoring, and characterization of diseases without direct contact with the primary area
of infection.25-27 EV-based liquid biopsies have shown particular promise for early cancer
detection, as EVs are able to be collected from patient blood/urine effluents and allow for
the assessment of the diseased state without direct contact with the cancerous tissues.25, 26
In the realm of therapeutics, EVs have been proposed as candidates for use as
delivery vehicles to transport novel gene and/or drug therapies.28-30 Therapeutically, EVs
have been used in a variety of ways. Since EVs are innately bioactive nanovesicles that
are reflective of their source, they have been isolated from environments that have been
shown to promote cellular regeneration and healing (i.e., mesenchymal stem cells or
ginger roots), where they are directly applied as therapeutic agents.2, 31, 32 Alternatively,
EVs have been isolated from generic cell culture environments (i.e., HEK293 cells), then
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bioengineered to contain specific gene, drug, or protein cargos before being applied as
therapeutic vectors for the targeted delivery of bioactive materials.33, 34 A variety of
studies have reported the use of EVs in the treatment of diseases, including
Alzheimer’s,35 cancers,36 liver disease,37 opioid addiction,38 and immune disorders.39 But
despite the promising performance of EVs as therapeutic vectors, the comprehensive
assessment of EV fundamentals has been prevented by the lack of methods to isolate,
quantify, and characterize EVs efficiently.

1.3

Approaches for Extracellular Vesicle Isolation
To date, several methods for EV isolation have been introduced. However, none

of the available isolation methods can provide highly concentrated, pure collections of
EVs in a manner that is fit for clinical or therapeutic use. Most commonly,
ultracentrifugation, polymer precipitation, or ultrafiltration methods are used for EV
isolation. However, all of these create low-yield un-representative vesicle recoveries that
are consistently contaminated with protein and lipoprotein aggregates, limiting the
downstream characterization/application of EVs. There is currently no consensus
regarding the most efficient procedure to harvest pure, concentrated collections of EVs,
causing an inevitable compromise between yield and purity of EVs obtained using the
chosen isolation method.
Because of the limitations introduced by EV isolation, the characterization and
quantification of EV populations has been prevented. Most commonly, to verify the
presence of EVs, a combination of electron microscopy, immunoassay, and size
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determination-based protocols are used. But with the challenge of EV isolation, many of
the results obtained from these methods reveal that recovered EV populations are
contaminated with proteins/lipoproteins and other matrix contaminants and are often
structurally damaged and un-representative of the entire population of EVs. For the future
progression of EV research, an isolation method able to efficiently provide high
concentrations of pure, structurally-preserved EVs is essential.

1.4

Capillary-Channeled Polymer (C-CP) Fiber-based EV Isolations using

Hydrophobic Interaction Chromatography
To address the shortcomings of currently-available EV isolation methods, Marcus
and colleagues have developed a highly efficient EV isolation method using patented
capillary-channeled polymer (C-CP) fiber stationary phases via a hydrophobic interaction
chromatography solvent system.40-48 In recent decades, Marcus and coworkers have
demonstrated the use of C-CP stationary phases using a variety of separation modalities,
including reversed phase (RP),49-52 ion exchange (IEX),50, 53, 54 affinity,55 protein A
(proA),56, 57 and hydrophobic interaction (HIC)40-44, 47, 48, 58-60 chromatography modes. In
these applications, the C-CP phase has repeatedly demonstrated the ability to provide a
platform for a variety of highly efficient separations to be performed, operating at lower
back pressures (< 1000 psi) and higher linear velocities (> 50 mm sec-1) than traditionally
utilized packed bed stationary phases during traditional HPLC. The C-CP fibers
employed in these separations are able to be created from commodity polymers such as
polypropylene (PP), polyester (PET), and nylon-6, and have been created in eight-prong
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or y-shaped configurations about their periphery. When collinearly aligned and packed
into a column format, the finger-like protrusions along the fiber periphery interdigitate to
create micron-wide channels with a low flow resistance, enabling excellent fluid transport
characteristics and high throughput separations without the sacrifice of separation
efficiency.
Recent works have demonstrated that a solvent-assisted HIC-based isolation
mode employing the 8-prong shaped PET C-CP fiber stationary phase enables highly
efficient EV isolations using solid-phase extraction (SPE) spin-down tip41, 44-47 and
traditional HPLC column40-42, 48 formats. In the case of both applications, highly pure and
concentrated EV yields (up to 7 x 1012 EVs) are able to be obtained from complex
biofluid samples, including cell culture milieu, urine, saliva, cervical mucus, blood
serum, and milk, with isolation performance uncompromised by matrix effects. Even
further, the applied chromatographic solvents are able to be tailored for the downstream
characterization of the recovered EVs by using acetonitrile, glycerol, or even detergentbased elution solvents. Overall, the HIC-based C-CP isolation of EVs is able to provide
concentrated populations of EVs on relevant scales of time (< 10 min), cost (< $1), and
practicality for fundamental research to be performed and application potential to be
explored. The C-CP tip approach specifically, allows the simultaneous processing of up
to 12 biofluid samples (which is only limited by the capacity of the tabletop centrifuge)
and is able to rapidly provide concentrated EV aliquots ready for virtually any
downstream characterization method, even with the ability to perform immunoaffinitybased biomarker probing and imaging directly on the isolation phase. The work presented

5

here outlines the foundational development of the C-CP spin-down tip method, where the
rapid isolation of clean, pure EVs from cell culture, clinical biofluid, and plant fluid
stocks has been allowed.
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SUMMARY OF CHAPTERS
CHAPTER TWO
SOLID PHASE EXTRACTION OF EXOSOMES FROM DIVERSE MATRICES VIA
A POLYESTER CAPILLARY-CHANNELED POLYMER (C-CP) FIBER
STATIONARY PHASE IN A SPIN-DOWN TIP FORMAT

Exosomes, a subset of the extracellular vesicle (EV) group of organelles, hold
great potential for biomarker detection, therapeutics, disease diagnosis, and personalized
medicine applications. The promise and potential of these applications are hindered by
the lack of an efficient means of isolation, characterization, and quantitation. Current
methods for exosome and EV isolation (including ultracentrifugation, microfiltration, and
affinity-based techniques) result in impure recoveries with regard to remnant matrix
species (e.g., proteins, genetic material) and are performed on clinically irrelevant time
and volume scales. To address these issues, a polyethylene terephthalate (PET) capillarychanneled polymer (C-CP) fiber stationary phase is employed for the solid-phase
extraction (SPE) of EVs from various matrices using a micropipette tip-based format.
The hydrophobic interaction chromatography (HIC) processing and a spin-down
workflow are carried out using a table-top centrifuge. Capture and subsequent elution of
intact, biologically active exosomes are verified via electron microscopy and bioassays.
The performance of this method was evaluated by capture and elution of exosome
standards from buffer solution and three biologically relevant matrices: mock urine,
reconstituted non-fat milk, and exosome-depleted fetal bovine serum (FBS). Recoveries
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were evaluated using UV-Vis absorbance spectrophotometry and ELISA assay. The
dynamic binding capacity (50%) for the 1-cm-long (~ 5 μL bed volume) tips was
determined using a commercial exosome product, yielding a value of ~ 7 × 1011 particles.
The novel C-CP fiber spin-down tip approach holds promise for the isolation of
exosomes and other EVs from various matrices with high throughput, low cost, and high
efficiency.

CHAPTER THREE
RAPID ISOLATION OF EXTRACELLULAR VESICLES FROM DIVERSE
BIOFLUID MATRICES VIA CAPILLARY-CHANNELED POLYMER FIBER SOLIDPHASE EXTRACTION MICROPIPETTE TIPS

Extracellular vesicles (EVs) play essential roles in biological systems based on
their ability to carry genetic and protein cargos, intercede in cellular communication and
serve as vectors in intercellular transport. As such, EVs are species of increasing focus
from the points of view of fundamental biochemistry, clinical diagnostics, and
therapeutics delivery. Of particular interest are 30–200 nm EVs called exosomes, which
have demonstrated high potential for use in diagnostic and targeted delivery applications.
The ability to collect exosomes from patient biofluid samples would allow for
comprehensive yet remote diagnoses to be performed. While several exosome isolation
methods are in common use, they generally produce low recoveries, whose purities are
compromised by concomitant inclusion of lipoproteins, host cell proteins, and protein
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aggregates. Those methods often work on lengthy timescales (multiple hours) and result
in very low throughput. In this study, capillary-channeled polymer (C-CP) fiber
micropipette tips were employed in a hydrophobic interaction chromatography (HIC)
solid-phase extraction (SPE) workflow. Demonstrated is the isolation of exosomes from
human urine, saliva, cervical mucus, serum, and goat milk matrices. This method allows
for quick (<15 min) and low-cost (<$1 per tip) isolations at sample volume and time
scales relevant for clinical applications. The tip isolation was evaluated using absorbance
(scattering) detection, nanoparticle tracking analysis (NTA), and transmission electron
microscopy (TEM). Exosome purity was assessed by Bradford assay, based on the
removal of free proteins. An enzyme-linked immunosorbent assay (ELISA) to the CD81
tetraspanin protein was used to confirm the presence of the known exosomal-biomarker
on the vesicles.

CHAPTER FOUR
COMPARISON OF THE CAPILLARY-CHANNELED POLYMER (C-CP) FIBER
SPIN-DOWN TIP APPROACH TO TRADITIONAL METHODS FOR THE
ISOLATION OF EXTRACELLULAR VESICLES FROM HUMAN URINE

Capillary-channeled polymer fiber (C-CP) solid-phase extraction tips have
demonstrated the ability to produce clean and concentrated extracellular vesicle (EV)
recoveries from human urine samples in the small EV size range (< 200 nm). An organic
modifier-assisted hydrophobic interaction chromatography (HIC) approach is applied in
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the spin-tip method under non-denaturing conditions-preserving the structure and
bioactivity of the recovered vesicles. The C-CP tip method can employ either acetonitrile
or glycerol as an elution modifier. The EV recoveries from the C-CP tip method (using
both of these solvents) were compared to those obtained using the ultracentrifugation
(UC) and polymer precipitation (exoEasy and ExoQuick) EV isolation methods for the
same human urine specimen. The biophysical and quantitative characteristics of the
recovered EVs using the five isolation methods were assessed based on concentration,
size distribution, shape, tetraspanin surface marker protein content, and purity. In
comparison to the traditionally used UC method and commercially available polymeric
precipitation-based isolation kits, the C-CP tip introduces significant benefits with
efficient (< 15 min processing of 12 samples here) and low-cost (< $1 per tip) EV
isolations, employing sample volumes (10 µL-1 mL) and concentration (up to 4 × 1012
EVs mL-1) scales relevant for fundamental and clinical analyses. Recoveries of the target
vesicles versus matrix proteins were far superior for the tip method versus the other
approaches.

CHAPTER FIVE
FACILE, GENERIC CAPTURE AND ON-FIBER DIFFERENTIATION OF
EXOSOMES VIA CONFOCAL IMMUNOFLUORESCENCE MICROSCOPY USING
A CAPILLARY-CHANNELED POLYMER FIBER SOLID-PHASE EXTRACTION
TIP

19

There is great interest in advancing methodologies for the isolation and
characterization of exosomes (30–150 nm, extracellular vesicles (EVs)) for fundamental
biochemical research and liquid biopsy applications. This is due to the accessibility of
exosomal surface biomarkers, providing relevant biochemical information from their
cells of origin. Exosome-based techniques hold potential for diagnostic applications
through less invasive sampling (versus the physical extraction methods of pathology).
This study demonstrates a simple spin-down tip methodology for generic exosome
capture, followed by immunoaffinity-based fluorescent labeling to classify EVs captured
on a polyester capillary-channeled polymer (C-CP) fiber stationary phase. An antibody to
the generic EV tetraspanin protein (CD81) is employed to confirm the presence of
biologically active EVs on the fiber surface. An antibody to the CA125 protein,
upregulated in the case of ovarian cell stress, is included as a cancer marker protein.
Scanning electron microscopy and confocal fluorescence microscopy were performed
directly on the capture fibers to visualize the morphology and assess the
bioactivity/identity of captured vesicles. This report provides a proof-of-concept for an
efficient means of isolating, purifying, immunolabeling, and fluorescent imaging for the
biomarker assessment of extracellular vesicles on a single platform. Herein lies the
novelty of the overall approach. The ability to affect the entire isolation, immunolabeling,
and imaging process in <5 hours is demonstrated. The C-CP fiber spin-down tip is an
efficient exosome isolation methodology for microliter samples from diverse media
(human urine and cell culture media here) towards diverse means of characterization and
identification.
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CHAPTER SIX
A RAPID CAPILLARY-CHANNELED POLYMER (C-CP) FIBER SPIN-DOWN TIP
APPROACH FOR THE ISOLATION OF PLANT-DERIVED EXTRACELLULAR
VESICLES (PDEVS) FROM 20 COMMON FRUIT AND VEGETABLE SOURCES

In the emerging field of phyto-nanotechnology, 30-200 nm plant-derived
extracellular vesicles (PDEVs) are now known to contain active biomolecules that
mediate cell-to-cell communication processes in a manner very similar to exosomes in
mammalian cells. The ability to deliver cargo across cellular membranes suggests that
botanical systems could be used in the mass production of therapeutic vectors to transport
exogenous molecules into human cells. The fundamental biochemical characteristics of
PDEVs remain poorly understood due to the lack of efficient methods to isolate and
characterize these nanovesicles. Described here is a rapid PDEV isolation method using a
hydrophobic interaction chromatography (HIC)-based extraction performed on a
capillary-channeled polymer (C-CP) fiber spin-down tip. The C-CP solid-phase
extraction method is performed using a standard table-top centrifuge, enabling the
isolation and concentration of PDEVs (>1 x 1010 particles from 100 µL of sample).
PDEVs of 189 nm average diameter were obtained from 20 common fruit and vegetable
stocks. The size, integrity, and purity of the recovered PDEVs were assessed using
transmission electron microscopy (TEM), multi-angle light scattering (MALS),
absorbance quantification, a protein purity assay, and an enzyme-linked immunosorbent
assay (ELISA) to the PEN1 PDEV surface marker protein. The HIC C-CP tip isolation
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method allows for concentrated PDEV recoveries (up to 2 x 1011 EVs) on reasonable time
scales (<15 min) and low cost (<$1), with the purity and integrity fit for fundamental
research and downstream applications.

CHAPTER SEVEN
RAPID ISOLATION AND QUANTIFICATION OF EXTRACELLULAR VESICLES
FROM SUSPENSION-ADAPTED HUMAN EMBRYONIC KIDNEY CELLS USING
CAPILLARY-CHANNELED POLYMER FIBER SPIN-DOWN TIPS

Exosomes, a subset of extracellular vesicles (EVs, 30-200 nm diameter),
serve as biomolecular snapshots of their cell of origin and vehicles for intercellular
communication, playing roles in biological processes including homeostasis maintenance
and immune modulation. The large-scale processing of exosomes for use as therapeutic
vectors has been proposed, but these applications are limited by impure, low-yield
recoveries from cell culture milieu (CCM) across all volumes. Current isolation methods
are also limited by tedious and laborious workflows, especially during the isolation of
EVs from CCM for therapeutic applications. Employed is a rapid (<10 minute) EV
isolation method on a capillary-channeled polymer (C-CP) fiber spin-down tip format.
EVs are isolated from the CCM of suspension-adapted human embryonic kidney cells
(HEK293), one of the candidate cell lines for commercial EV production. This batch
solid-phase extraction technique allows 1012 EVs to be obtained from only 100 µL
aliquots of milieu, processed using a benchtop centrifuge. The tip-isolated EVs were
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characterized using transmission electron microscopy (TEM), multi-angle light scattering
(MALS), absorbance quantification, an enzyme-linked immunosorbent assay (ELISA) to
tetraspanin marker proteins, and a protein purity assay. It is believed that the
demonstrated approach has immediate relevance in research and analytical laboratories,
with opportunities for production-level scale-up projected.
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CHAPTER TWO
SOLID PHASE EXTRACTION OF EXOSOMES FROM DIVERSE MATRICES VIA
A POLYESTER CAPILLARY-CHANNELED POLYMER (C-CP) FIBER
STATIONARY PHASE IN A SPIN-DOWN TIP FORMAT

2.1 Introduction
Exosomes are 30–130 nm-sized extracellular vesicles (EVs) containing genetic,
proteomic, and intracellular content that reflect the biophysical characteristics of the cells
of origin, and engage in diverse pathological and physiological roles [1, 2]. Exosomes are
released from most cell types through multivesicular bodies (MVBs), which are distinctly
created through the endosomal pathway [1, 3, 4], different from the biogenesis of many
other extracellular vesicles [5, 6]. Exosomes carry intravesicular cargo, including DNA,
RNA, miRNA, as well as surface biomarker proteins—all promising tools for unraveling
the inner-workings of disease progression [7]. Exosomes mediate a plethora of inter- and
intracellular processes, including cellular communication and signaling phenomena, and
contain essential cargo for local and distal cargo transport processes [8]. Because the
dysregulation of intercellular communication processes leads to cancers and immunephysical malfunctions, exosomes/EVs have become relevant to understanding many
complex biochemical interactions [9,10,11]. Additionally, as the rate of exosome
biogenesis differs based on the cell of origin, the simple ability to readily determine the
concentration of exosomes is of high interest. An upregulation of exosome biogenesis is
indicative of active disease progression [12, 13]. Increased exosome-mediated signaling
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is characteristic of invasive tumor phenotypes [12], so it is essential to be able to
efficiently quantify exosomes in various types of samples. A pool of cells is well
represented by a collection of exosomes, making them a promising analytical target for
liquid biopsy applications.
Exosomes/EVs are expressed by most cells and, as such, can be collected from
bodily fluids, including urine [14], saliva [15], blood (plasma [15] and serum [16]), breast
milk [17, 18], and cerebrospinal fluids [19, 20], and are also released in vitro by cultured
cells [21]. Furthermore, exosomes and other extracellular vesicles have been identified in
all three physiological domains of life (archaea [22], bacteria [23, 24], and eukarya [22])
and are active agents of nutrient delivery by interspecies communication through intake
of foods like raw vegetables [25]. A challenge in the progression of exosome/EV-based
applications lies in the recovery of clean, stable, and biologically relevant vesicles for
genetic profiling, bioengineering, and biomarker classification.
A large number of approaches have been used for exosome/EV isolation,
including ultracentrifugation, differential centrifugation, density-gradient centrifugation,
size exclusion chromatography, affinity chromatography, and several polymer-based
precipitation techniques [8, 26, 27]. These separation techniques rely on either the size
and density of the EVs, or the affinity of the exosomes for antibodies to specific surface
marker proteins such as Alix, CD9, CD81, TSG101, and HSP70 [27]. Current
exosome/EV isolation methods are tedious and are often used following multiple highspeed ultracentrifugation (> 100,000×g) steps to remove debris and pelletize the
exosomes [26]. While the high-speed ultracentrifugation method is the most widely used
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technique for generic exosome isolation, it does not always efficiently isolate exosomes
from large protein aggregates or other vesicular structures efficiently. In all, these
techniques are time-consuming and sample-size burdensome to the point of limiting the
use of exosomes on the clinical scale [27, 28]. Because biological sample matrices are
extremely complex and varied, robust separation techniques are crucial for future clinical
applications and fundamental research [29].
Marcus and co-workers have described the use of capillary-channeled polymer
(C-CP) fibers as stationary phases for liquid chromatography (LC) separations of proteins
via reversed-phase (RP), ion exchange (IEC), hydrophobic interaction (HIC), and affinity
modalities [30,31,32,33,34,35,36]. The combination of high column permeability and low
surface porosity provides high throughput and yield macromolecule separations
[37,38,39]. Bruce, Marcus, and colleagues have also recently reported a method for
exosome/EV isolation using an HIC mode on a poly (ethylene terephthalate) (PET) C-CP
fiber phase [40,41,42,43]. The use of the HIC elution strategy allows for exosome
isolations based on the vesicles’ inherent hydrophobicity (partially a function of their
size), allowing non-destructive bulk recoveries of exosomes/EVs for further interrogation
and applications. Capture/elution under HIC solvent conditions preserves the morphology
of the vesicles isolated from various matrices, including cell culture milieu [40], urine
[40, 42], and human plasma [41]. In terms of potential implementation scenarios,
isolations are performed on < 100 μL sample volumes on time scales of < 10 min. The
simple chromatographic method also shows promise for bulk recovery of EVs for
fundamental biochemistry and preparative applications.

28

While a standard liquid chromatograph is not overly burdensome in the analytical
chemistry laboratory, it is not practical in many biochemical and clinical situations.
Solid-phase extraction (SPE) techniques are widely applied for sample preparation of
biological specimens, as they allow for efficient separation of analytes from the
originating complex matrices [44,45,46]. SPE is a form of step-wise chromatography that
is designed to extract and adsorb components of interest from a liquid phase onto a
stationary phase (similar to LC separations), thus serving as a means of pre-concentration
and affecting a matrix modification. Many modalities influence the passage of sample
solutions through an SPE bed, but the use of a table-top or microcentrifuge is particularly
attractive in terms of very low operational complexity and overhead [47, 48]. In this
regard, C-CP fibers can be employed either as the stationary phase column for HPLC or
employed in 1-cm segments fit to a micropipette tip to affect SPE in a spin-down mode
using a table-top centrifuge [49,50,51]. In these applications, fiber phases have also been
used as a means of desalting proteins before MS characterization [52] and also to affect
immunoaffinity capture [51].
Here, PET C-CP fiber micropipette tips are employed in a novel spin-down HIC
protocol for the timely, efficient, and structurally preserving isolation and quantification
of exosomes from various matrices (aqueous solution, mock urine, reconstituted non-fat
milk, and an exosome-depleted fetal bovine serum). Mock matrices were used to
normalize and control the exosome quantity input, while also presenting basic sample
constituents. The goal is to quantify and characterize exosome recoveries of known spike
concentrations from the various matrices without interference or introduced bias from
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native exosome-containing biofluids. The sequential aspects of immobilization and
recovery are affected for multiple tips in parallel, in a total processing time of < 5 min.
The capture of intact exosomes is verified via scanning electron microscopy (SEM) and
confocal microscopy, with the efficacy of the elution confirmed via transmission electron
microscopy (TEM) and dot blot analysis. The binding capacity of the 1 cm fiber tips is
evaluated via sequential applications of sample aliquots until an observed breakthrough,
with the recoveries determined spectrophotometrically. Finally, the ability to quantify EV
recoveries via absorbance measurements is demonstrated and employed in the evaluation
of recoveries of exosomes spiked into various mock-biofluid matrices. This simple and
straightforward method for exosome isolation and quantification opens the door for
future fiber platform optimization for selective EV-type isolations for clinical diagnostics
and fundamental biochemistry research.

2.2 Materials and Methods
2.2.1 Materials
HPLC-grade acetonitrile (ACN) was obtained from ThermoFisher Scientific
(Pittsburgh, PA, USA). Deionized water (DI-H2O, 18.2 MΩ-cm) was obtained from a
Milli-Q water purification system (Millipore Sigma, Merck, Germany, USA). Ultra-pure
ammonium sulfate was obtained from VWR (Radnor, PA, USA). Biotechnology-grade
glycerol was purchased from VWR (Sokon, OH, USA). Non-fat dry milk was purchased
from Bio-Rad (Hercules, CA, USA). Phosphate-buffered saline (PBS, 0.067 M (PO4), pH
7.4) and exosome-depleted fetal bovine serum (FBS) were obtained from ThermoFisher
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Scientific (Waltham, MA, USA). Tris-buffered saline (TBS, 0.1 M, pH 8.0) was obtained
from Sigma Aldrich (St. Louis, MO, USA). Uranyl acetate, 16% paraformaldehyde
(formaldehyde) aqueous solution, and formvar/carbon film 10 nm/1 nm thick on square
200 mesh copper grids were obtained from Electron Microscopy Sciences (Hatfield, PA,
USA). The 1-Step Ultra TMB-ELISA substrate was purchased from ThermoFisher
Scientific (Pittsburgh, PA, USA). The Anti-rabbit IgG (H+L) 10nm Silver Conjugate
(OD 7.5) and Silver Enhancer Kit for membranes were obtained from Cytodiagnostics
(Burlington, ON, Canada).
The mock urine was prepared based on the recipe as reported by Khan et al. [52],
consisting of an aqueous solution of potassium chloride (0.2 g L−1), sodium chloride (8 g
L−1), disodium hydrogen phosphate (1.14 g L−1), potassium dihydrogen phosphate (0.2 g
L−1), 200 μL L−1 McCormick yellow food coloring (water, propylene glycol, FD&C
yellow 5, and propylparaben), urea (114.1 g L−1) and DI-H2O up to 1 liter. Hydrochloric
acid and sodium hydroxide were used to adjust the pH to 7.5. The solution of 2% non-fat
dry milk was dissolved in DI-H2O to create the milk matrix.
2.2.2 Instrumentation
Three absorbance spectrophotometers were employed in these studies, based on
the required sample volume for measurement, the instrument’s sensitivity to changes in
absorbance, and the sample introduction method. A NanoVue Plus UV-Vis
spectrophotometer (GE Healthcare, Chicago, IL, USA) was used to measure the direct
absorbance of the concentrated exosome eluates (1 μL) from the C-CP fiber tip (as shown
in Fig. 2.4). A GENESYS 10S UV-Vis spectrophotometer (ThermoFisher Scientific,
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Waltham, MA, USA) was used to measure the absorbance of diluted exosome eluate. (as
shown in Fig. 2.5). The Synergy H1 Hybrid Multi-Mode Reader (BioTek, Winooski, VT)
was used to determine the UV-Vis absorbance (450 nm) of samples in the 96-well format
as employed in an ELISA assay employing the 1-Step Ultra TMB Substrate.
Electron microscopy was employed as a confirmatory tool for the structural
integrity of both immobilized and eluted EVs. Scanning electron microscopy (SEM) was
performed using a Hitachi S-4800 (Chiyoda, Tokyo, Japan) to confirm the capture of
intact EVs on the C-CP fiber surface. Transmission electron microscopy (TEM) was
performed using a Hitachi HT7830 (Chiyoda, Tokyo, Japan) to confirm the release of
intact EVs from the C-CP fiber surface. STEM imaging was performed using the Hitachi
SU9000 CFE SEM/STEM to observe the integrity of eluted exosomes. The methods for
fixing and imaging of these populations, which are not innovative in their own right, are
described in Appendix A.
Confocal microscopy was used to image the C-CP fiber tip-captured exosomes
after undergoing immune-recognition procedures for the confirmation of the capture of
exosomes exhibiting the CD81 tetraspanin marker protein. In preparation for this
technique, the fiber-captured vesicles were stained using a mouse primary antibody to
CD81 (Santa Cruz Biotechnology, Dallas, TX) followed by a goat anti-mouse secondary
antibody labeled with AlexaFluor 647 before super-resolution confocal imaging with a
Leica SP8 confocal microscope with Hyvolution super-resolution software (Leica
Microsystems, Buffalo Grove, Illinois). A sandwich enzyme-linked immunosorbent assay
(ELISA) was used to detect and quantify the expression of the tetraspanin exosomal
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marker protein, CD81, in exosome recoveries following elution from the C-CP fiber tip
from various matrices. CD81 expression in the recoveries of exosomes isolated by the CCP spin-down tip was further confirmed using an immuno-dot blot assay. Briefly,
recovered exosomes were captured by the immobilized CD81 mouse antibody on a
PVDF membrane, and subsequently detected using rabbit primary antibodies to generic
tetraspanin antibodies (CD9, CD81, CD63), and visualized using a goat anti-rabbit silver
nanoparticle conjugate, followed by the use of a silver enhancement kit to amplify the
resultant response (see Appendix A).
2.2.2 Methods
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Figure 2.1: The practical steps of C-CP fiber tip fabrication and the spin-down approach to isolation and
purification of EVs.

The C-CP fiber SPE tip assembly process is depicted in Fig. 2.1. Poly (ethylene
terephthalate) (PET) capillary-channeled polymer fibers were extruded by the Clemson
University School of Materials Science. The C-CP fiber tips were constructed as
previously reported [48] (see Appendix A). Ultimately, tips of 1 cm-length, having an
inner diameter of 0.8 mm, and an interstitial fraction of ~0.6, yielded bed volumes of ~3
L. The method for mounting the spin-down tips for processing and collection of EV
fractions has also been described previously [48] (see Appendix A). The efficient reuse
(n>15) of the C-CP fiber stationary phase has been demonstrated in a column format used
in HPLC isolation of exosomes from a mock urine matrix 1. However, given the low
consumable cost (<$0.5 USD per tip) and for the sake of convenience, new C-CP
micropipette tips were employed for each exosome isolation here.
Lyophilized and purified exosomes from the urine of reportedly healthy donors
were obtained from Galen Laboratory Supplies (North Haven, CT, USA) with a prepared
suspension concentration of 2.27 x 1012 particles mL-1 (provider-determined by
nanoparticle tracking analysis (NTA)). For HIC-based processing, EVs in the mock
sample matrices were mixed 1:1 with 2 M ammonium sulfate at pH = 7.5. Aliquots of
100 µL per trial were passed through the C-CP fiber tips under 300 x g centrifugal force
for 1 minute each. Under the high salt conditions, the target vesicles and latent proteins
(from the original sample) were retained on-fiber. After the capture of the vesicles, the
fiber surfaces were washed with 100 µL of DI-H2O. Protein elution was induced by
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passage of 50 µL of 25% glycerol in PBS under the same centrifugation conditions, with
the final elution of the captured EVs induced using 50 µL of 50% glycerol in PBS. The
elution of proteins by 25% glycerol and exosomes by 50% glycerol has been confirmed
by SEM imaging of the fiber surfaces after the various steps in this workflow as well as
in the use of acetonitrile as the mobile phase modifier 1, 2, as it is here. The eluted EVs
were quantified by diluting a 3 µL aliquot to 1.5 mL with DI-H2O. Absorbance
measurements were performed using a GENESYS 10S UV-Vis spectrophotometer.
Additionally, an enzyme-linked immunosorbent assay (ELISA) was used to confirm the
presence of CD81-expressing EVs in the spin-down tip recoveries.
To determine dynamic binding capacity, breakthrough experiments were
performed using 21 successive 50 μL aliquots of the diluted exosome standard (4.65 x
107 particles per 50 μL aliquot in 1M ammonium sulfate with 25% glycerol), spun
through the tips (300 x g, 1 minute each). Use of the glycerol modifier inhibits the
adsorption of adventitious proteins. The fiber surfaces were then washed five times with
50 µL aliquots of diH2O.

2.3 Results and Discussion
2.3.1 Capture and elution fidelity
As with all forms of biomolecule/particle isolation, a successful SPE spin-down
methodology for exosome/EV isolation and recovery must provide not only for
separation, but must do so without compromising the physical and biological attributes of
the EVs. In this case, EVs must be isolated with respect to the components of the sample
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matrix, including salts, small molecules, such as amino acids, sugars, proteins, and
genetic material. Previous reports have illustrated this capability via HIC separation of
exosomes from diverse media 1, 3, 4. In the case of the spin-down tip processing, the
integrity of the physical and biological attributes of the exosomes was evaluated via SEM
and immunofluorescence, respectively, following the elution steps to remove salts and
adventitious proteins.
In Fig. 2.2a (for the case of the commercial exosomes dispersed in water), the
surface of the C-CP fibers at this stage is pristine, as indicated by the presence of globular
vesicles without any remnants of salt crystals or the like.

Figure 2.2: Physical and biologic imaging of exosomes adsorbed to PET C-CP fiber surface via a scanning
electron microscopy and b super-resolution confocal fluorescence microscopy.

To further illustrate the integrity of the captured exosomes, super-resolution
confocal microscopy imaging was performed. Exosomes captured on C-CP fiber surfaces
were immuno-labeled using a primary antibody to the tetraspanin surface marker protein,
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CD81, and a fluorescent secondary antibody (AlexaFluor 647 goat anti-mouse). As seen
in Fig. 2.2b, there are dispersed nanobodies (of the size range expected for the target
exosomes) within the ~25 x 25 μm2 viewing region. Due to the resolution limits of the
confocal microscope system used (~140 nm), it is important to note that the fluorescent
particles observed here are not necessarily individual exosomes, but perhaps small
aggregates producing a more intense fluorescent response. Nevertheless, with regards to
capture, the target exosomes are well dispersed on the fiber surface (without substantial
debris), while maintaining their basic physical morphology and surface protein makeup.
Indeed, the characteristics depicted in Fig. 2.2 are the first steps towards affecting a
practical exosome diagnostic platform.
In those cases where further exosome characterization is required, such as in the
search for surface biomarkers or genetic analysis (e.g., RNA-Seq) of the vesicular cargo,
the organelles must be recovered (eluted) while maintaining their physical integrity and
biological function. The most common method for assessment of the morphology of
individual exomes is transmission electron microscopy, where both the size and vesicular
structure are revealed.

Figure 2.3: Physical and biological characterization of exosomes eluted from PET C-CP fiber spin-down
tips via a) transmission electron microscopy and b) dot blot immunoassay.

37

The TEM micrograph of an HIC-eluted EV (Fig. 2.3a) illustrates the successful
maintenance of the physical structure through the isolation process. The biological
fidelity of exosome populations is readily assessed through the use of dot blot assays
(Fig. 2.3b), wherein a positive immune-response is obtained for the CD9, CD81, and
CD63 antibodies in the post-tip isolation eluates. As seen in the various exposures, the
recovered exosomes do indeed retain the surface markers of the three tetraspanin proteins
confirming the presence and viability of the exosomes. While the dot blots do not reflect
the retention of the encapsulated genetic materials, they suggest that the expected
membrane-bound proteins remain intact.
2.3.2 Dynamic binding capacity (DBC)
The ability to effectively isolate and purify EVs is only relevant to the extent that
it yields the required density of EVs necessary to provide meaningful sample data. As a
general rule, most RNA-sequencing analyses require 109-10 exosomes for accurate
profiling, while LC/MS proteomics studies require on the order of 1010-11 exosomes. 5-11
To this end, the dynamic binding capacity of the 1 cm C-CP fiber spin-down tips was
determined (Fig. 2.4).
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Figure 2.4: Breakthrough analysis of 50 μL aliquot additions of 4.65 × 1010 particles per dose. The 50%
dynamic binding capacity is surpassed during trial 15 at 6.98 × 1011 particles.

Unlike in the case of continuous processes 12, a frontal analysis was required. This was
performed using discrete 50 μL aliquots of test solutions (exosomes in 25% glycerol:1 M
(NH4)2 SO4), with the pass-through exosome content used to assess
breakthrough/overload. Fig. 2.4 shows the determined absorbance values, obtained by
diluting 3 μL of the eluate in DI-H2O in a 1.5 mL cuvette. The absorbance response is not
significant until aliquot #14, wherein the pass-through content increases rapidly, and a
plateau is reached beyond aliquot #16, suggestive of surface saturation. Based on the
general response, the eluate absorbance reaches one-half of the steady maximum value (a
measure of reaching DBC) with aliquot #15. At this point, based on per-aliquot particle
densities of 4.65 x 1010, a DBC value on the order of ~7 x 1011 is achieved for a total
volume of 750 L. Though there is no consensus regarding a “healthy range” for
exosome concentration, this value is in line with that expected in many native biofluids,
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including urine, milk, serum, and plasma. The capacity demonstrated at this early stage
is on-par for what would be desired in the clinical and biochemical laboratory arenas.
2.3.3 Quantification
In previous EV separations employing PET C-CP fiber columns in a Dionex
Ultimate 3000 HPLC system (ThermoFisher Scientific, Waltham, MA, USA), UV-vis
absorbance at 203, 216, and 280 nm was used as a method for EV detection 3. Even with
the well-known optical absorbance of some buffer/matrix components at these
wavelengths, a successful method of exosome isolation should alleviate their
contributions and allow ready quantification. The absorbance response observed in this
instance is not due to the molecular absorption of an innate biomolecule, but rather
corresponds to the light scattering due to the presence of the particles. Ultimately, the
absorbance response was found to be directly proportional to the exosome content, for
particles of different sources. As most methods of EV isolation carry along remnant
proteins, there is a potential that the absorbance (scattering)-based measurement could be
affected by their presence.
Based on the fact that the extent of scattering would be (nominally) inversely
related to the incident wavelength, and that proteins (being composed of aromatic amino
acids) absorb at 280 nm, response functions were prepared at 203, 216, and 280 nm.
Lyophilized exosome standards from the urine of reportedly healthy donors (previously
shown to have latent proteins present) were used to create standard curves. Here, 1-35 μL
of the exosome standards (2.3 x 1012 particles mL-1) were diluted to 1.0 mL in DI-H2O,
presenting a concentration range of ~2.3 x 109 – 8.0 x 1010 particles mL-1 (Table 1).
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Table 2.1: Absorbance response characteristics for exosome standards in aqueous solution at
203, 216, and 280 nm.

The slope of the 280 nm function is approximately 40% higher than the lower
wavelengths. The stronger absorbance at 280 nm reflects the inevitable presence of
proteins (which contain aromatic amino acids) in the commercial exosome material.
Indeed, the characteristics for the lower wavelengths are virtually identical, with much
better regression statistics than at the higher wavelength. Based on these figures of merit,
and fewer contributions from background proteins, the shorter wavelengths are preferred.
While the limits of detection and quantification are not as low as with other methods
(e.g., immunoassays) 13-18, the values are relevant for most biological and clinical systems
of interest, particularly in consideration of the total sample volume required (< 50 μL)
and ease of determination.
2.3.4 Isolation and quantification of EVs/exosomes in diverse media
As proof of concept towards the efficacy of the HIC spin-down tip approach to
exosome isolation and quantification, the commercial exosome standards (2.73 x1012
particles mL-1) were spiked into DI-H2O, mock urine, reconstituted non-fat milk, and
exosome-depleted fetal bovine serum (FBS) matrices. Two dilution factors were
employed (1/100;1/1000), as a quantitative test of the response, as well as tolerance
towards the challenges of the matrices themselves. The matrices were mixed (50:50 v/v)
with the HIC loading solvent (2M (NH4)2SO4) in PBS. While diH2O presents a pristine
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environment, the mock urine matrix presents high salinity and is small molecule-heavy,
the milk has high protein content, and the FBS contains fat and high protein content.
These model biofluids are obvious target matrices from which exosome/EVs may be
extracted for diagnostic purposes. In terms of loading and elution, the procedure involved
a spin-down under high salt conditions, followed by elution of proteins with 50 μL of
25% glycerol and 1M (NH4)2SO4 in PBS. This fraction was collected for absorbance
measurements of protein/exosome content. Finally, the EV fraction was eluted in 50 μL
of 50% glycerol in PBS and collected for the determination of vesicle content. Though
glycerol has been used as a biological preservative 19, it is not ideal for all downstream
analyses (i.e., proteomic analysis) where necessary vesicle lysing may be hindered. In
these cases, acetonitrile may be used as a substitute elution phase, as previously reported
1, 2.

Essential to the quantification process of EVs in different matrices is the
assumption that EVs may be quantitatively immobilized and recovered from the fiber
surfaces. The latter point has been evaluated in recent studies using the chromatographic
(column) platform, wherein recoveries of adsorbed EVs were greater than 80% 2.
Parallel evaluation of the recoveries was performed here via UV absorbance (using the
previously generated aqueous matrix calibration functions) and an ELISA assay.
The determined numbers of EV particles for the two dilution factors, as
determined via optical absorbance (203 nm), are presented in Fig. 2.5.
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Figure 2.5: Post-isolation of exosome standards spiked into various matrices (50 μL) using the PET C-CP
fiber tip spin-down method. The concentrations of exosomes recovered were determined based on
absorbance response (1 μL) when compared to the standard curve of Table 1. a) Quantified recovery of
exosomes from mock matrices of 1/100 concentration and b) quantified recovery of exosomes from mock
matrices of 1/1000 concentration. The loaded 1/100 and 1/1000 solutions theoretically contain 2E10 and
2E9 exosomes, respectively.

Aliquots (50 μL) for both the protein and exosome elution fractions were diluted to 1 mL
for the absorbance measurements. Starting with the lowest (1/100) dilution factor, no
absorbance response is seen in the protein fractions for aqueous and mock-urine phases,
but there is a measurable absorbance, equivalent to 5.3 x 109 and 2.4 x 1010 EVs, for the
milk and exosome-depleted FBS matrices, respectively. These respective responses are
not surprising, as the latter matrices have appreciable protein content, and corresponding
appreciable absorbance, while the aqueous and urine matrices do not. On the other hand,
absorbance measurements taken of the presumed EV fraction yield statistically identical
values for the aqueous, mock urine, and non-fat milk matrices, as they would be
expected. Interestingly, a much higher (~2x) recovery of EVs was observed in the

43

exosome-depleted FBS exosome elution fraction. The precision of triplicate
measurements for each of the matrices was better than 8.4 %RSD.
For the case of the higher dilution factor (1/1000), it would be expected that the
recoveries would be proportionally (~10x) less, but potential matrix effects would be
lessened as well. Here, the responses for the protein elution fractions for the aqueous,
mock urine, and non-fat milk matrices fall below the level for accurate determination.
The FBS protein elution still shows a measurable absorbance response, equivalent to 3.2
x 108 EVs. This is to be expected with the high concentration of total protein in the
original matrix. The greater than expected decrease in apparent concentration is due to
lessened amounts of protein aggregation in the more dilute solution. That noted, the
determined concentrations in the respective EV fractions are indeed ~10X less than the
more concentrated case for all matrices. Here again, a high level of precision in the EV
recovery is obtained (< 6.9 %RSD), with the determined particle numbers across the first
three matrices being virtually the same, and a significantly higher exosome recovery
again for the exosome-depleted FBS matrix. Thus, based on the absorbance-based
quantification method, there is no significant difference in EV recoveries across the
diverse aqueous, mock urine, and non-fat dry milk matrices. More importantly, the
fractional recoveries for the two dilutions are approximately 75% versus the initial
number of EVs applied to each tip for these matrices. This value reflects a significantly
more efficient recovery of exosomes when compared to the fractional recoveries of other
methods, such as ultracentrifugation, which results in equal or lesser concentrated
recoveries of exosomes, though requiring nearly 90 times the starting sample volume. As

44

previously mentioned, a significant increase in recovery was observed from the FBS
matrix. Marketed as an “exosome-depleted” FBS source, the manufacturer claims the
depletion of 90% or more of native endogenous exosomes. The increase in EV recovery
for the FBS matrix may be due to remnant exosomes from the native FBS matrix (known
to contain high concentrations of EVs).
To verify and quantify the presence of remnant (native) extracellular vesicles in
the exosome-depleted FBS matrix, the tip isolation of exosomes was performed on an
exosome-spiked aqueous solution, the exosome-depleted FBS, and the FBS spiked with
the exosome standard. In the spiked-solution cases, the primary stock solution was added
at a 1:100 µL ratio to the matrix. The optical absorbance of the eluate was detected at the
203 nm wavelength and used to quantify the exosomes based on the previous aqueoussolution calibration function.
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Figure 2.6: a) Quantification of exosomes in the eluates from aqueous solution (1/100), exosome-depleted
FBS, and a spiked exosome-depleted FBS matrix (1/100). b–d) STEM images of eluted exosomes, all
containing their characteristic spherical structure post isolation using the C-CP tip method.

Fig. 2.6a shows the resulting exosome concentrations, where approximately the same
number of exosomes were quantified in the eluates from the aqueous and native
exosome-depleted FBS solutions. Addition of the spike to the FBS yields an ~73%
increase in the determined density, a value in-line with a combination of the responses for
the aqueous solution and the FBS sample, as would be expected as the spike values are
the same for the first and third cases. Importantly, the levels of precision are very uniform
ranging from 5.4 – 8.2 %RSD for triplicate isolation and measurement sets. Based on the
determinations performed here, the exosome concentration in the “depleted” FBS is
approximately 1.5 x 1010 particles per mL. This value is less than recently published
values of 2.27-2.93 1011 particles per mL 20. Based on those values, the material
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employed here meets the stated 90% clearance target stated by the manufacturer, with
~6.6% remaining based on the published values.
The presence of exosomes in the depleted FBS was further confirmed physically
using STEM and nanoparticle tracking analysis. Figures 2.6b-d are micrographs of the
exosome eluted fractions for the same three cases, exosomes spiked (1:100) in aqueous
solution, the native FBS, and exosomes spiked into FBS. In all three cases, the typical
halo-structure objects associated with exosomes are clearly revealed, having diameters on
the order of 80-120 nm. NTA analysis was performed to analyze the size distribution of
the eluted exosome populations. The graphical size distributions of the eluted exosomes
are presented in Appendix A. Statistically, larger numbers of exosomes are observed in
the case of the spiked-FBS (as suggested in the data of Fig. 2.5), though the means (~96
nm) and modes (74.3 and 77.7 nm) of the distributions are very similar. What are quite
different are the broader distribution aspects, where the spiked-FBS displays a D90
(upper limit inclusive of 90% of the population) of 155.4 nm, while the spiked-aqueous
population exhibits a D90 of 130.1 nm. This relationship is not surprising as the FBS is a
far more diverse matrix than the human-urine originating spike matrix.
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As a complement to the use of absorbance spectrophotometry to perform
quantification, spin-down tip recoveries were also assessed via a standard ELISA assay
for the antibody response to the CD81 tetraspanin surface protein.

Figure 2.7: Post-isolation of exosome standards spiked into various matrices (50 μL) using the PET C-CP
fiber tip spin-down method; the concentration of exosomes recovered were determined based on ELISA
readout to an exosome standard curve of linear response was performed to quantitatively detect the
expression of the exosomal tetraspanin protein-CD81 (n = 3) employing a capture antibody of 1:250
concentration. Quantified recovery of exosomes from mock matrices of 1/100 and 1/1000 concentration.
The loaded 1/100 and 1/1000 solutions theoretically contain 2 × 1010 and 2 × 109 exosomes, respectively.

Presented in Fig. 2.7 are the determined number of particles is reported for the same two
dilution values (1/100 and 1/1000) as depicted in Fig. 2.5 aqueous, mock urine, and nonfat milk test matrices. (The FBS material was received after the University ELISA
facilities were closed due to COVID-19 protocols, and so were not part of this assay.)
The determinations were made on the same collected EV elution fractions as used in the
absorbance measurements. As reported for the 1/100 dilution samples, the numbers of
collected EVs are statistically identical for the three different matrices. As expected, the
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level of precision of the bioassay is somewhat degraded from the absorbance
measurements, but with a variability of < 9.1 %RSD, the results are in-line with what
would be expected. With increased dilution, the number of particles is statistically lower,
with similar repeatability, but not in the direct proportion seen in the absorbance case.
Again, the recoveries across the matrices are similar, maintaining the same relative
responses among each. The measured CD81 expression reflects the fact that the exosome
biogenesis process, and therefore, surface protein expression is due to many stochastic
processes. Though exosomes from identical cells may be produced via the same
mechanisms, exosome populations are heterogeneous, and differences in protein
expression are expected. Also, while glycerol in the elution buffer was used to increase
exosome stability and prevent aggregation, the presence of glycerol may also have an
effect on the conformation of exosome surface proteins in the eluate. Changes in protein
conformation due to the presence of glycerol has been previously reported 21, 22, where
proteins are altered to more compact states. This has been found to affect antigenantibody binding interactions, specifically in ELISA applications 23. The observation of
non-linear quantification of exosomes seen in Fig. 2.7 when compared to absorbancebased results in Fig. 2.5, is most likely due to these effects.

2.4 Conclusions
Presented here is an efficient, timely, and vesicle-preserving method for exosome/EV
isolation using a simple PET C-CP fiber tip workflow followed by quantitation via
absorbance and ELISA assay quantification. There is a high demand for clean and
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reproducible EV recoveries from complex matrices for potential uses as targets of
clinical, diagnostic, and therapeutic relevance. The isolation of exosomes using
hydrophobicity-based chemical separation allows for the gentle and effective capture and
subsequent release of exosomes despite the complexity of the matrix of origin. It should
be pointed out that the process is not directly related to, nor is it impacted by, traditional
size-exclusion effects as the fibers are non-porous and the inter-fiber channels have
widths of 1-4 µm. That said, there may be some size-based effects in terms of elution
characteristics as size will affect the extent of hydrophobic interactions with the fiber
surface. The combination of low-volume, high throughput processing, high recoveries,
and practical simplicity of the method bodes well in comparison to other approaches,
particularly for clinical situations.
The HIC mode C-CP fiber tip workflow introduces a plethora of potential
capabilities as modes of fiber capture selectivity are explored and optimized. The present
method would be classified as a generic exosome/EV capture approach, but previously
demonstrated methods of fiber surface modification could be implemented for selective
capture based on the presence of target surface proteins [50,36]. Likewise, as shown
here, protein-specific immunofluorescent labeling could be affected for on-fiber
detection. Continued optimization of this technique and characterization of the purity
(freedom from matrix species) and the proteomic and genetic cargo are essential to the
future implementation of this technique to complex biofluid samples. To this end, there
indeed may be instances, such as mass spectrometry-based proteomics, where the use of
acetonitrile will be the preferred elution phase modifier, allowing more efficient
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processing to recover surface and sequestered proteins. Ultimately, the use of other C-CP
fiber platforms could be implemented to affect point-of-care (POC) assays. Importantly,
each of these aspects could be scaled-up to volumes necessary for the isolation and
purification of exosomes/EVs for various biotherapeutic applications.
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CHAPTER THREE
RAPID ISOLATION OF EXTRACELLULAR VESICLES FROM DIVERSE
BIOFLUID MATRICES VIA CAPILLARY-CHANNELED POLYMER FIBER SOLIDPHASE EXTRACTION MICROPIPETTE TIPS

3.1 Introduction
Extracellular vesicles (EVs) are a diverse group of cell-derived membrane
vesicles, typically ranging in size from 30 nm to 1 μm in diameter.1,2 EVs are released by
all cell types and contain the biomolecular characteristics of the mother cell (i.e., DNA,
RNA, miRNA, mRNA, biomarker proteins).3–7 While no official EV classification
system exists, three main EV subtypes have been identified based on size and mechanism
of biogenesis.8,9 Microvesicles are 100 nm to 1 μm vesicles created by the outward
budding of a cell membrane. Apoptotic bodies (reflective of cell death10) are 1 to 5 μm
vesicles created during the programmed cell death process. Exosomes are 30 to 200 nm
vesicles created through the multivesicular body (MVB) endosomal pathway. Due to
their similarities in composition, overlapping size range, and characteristic cup/dimpled
shape when observed by electron microscopy, the exosome and microvesicle subtypes are
difficult to differentiate. For this reason, the vesicles are generically referred to as EVs.11
Not surprisingly, within the heterogeneity in EV sources, size, and content, the specific
mechanisms of action and distribution of potential biomarkers varies immensely.12
EVs are primary vehicles in intercellular communication, signal transduction, and
local and distal transport processes.13,14 The exosome subset of EVs has become
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increasingly targeted both as mediums for diagnostic information and cargo
transmission.15,16 The lack of understanding of EV physiochemical and biological
characteristics, along with a lack of field-wide consensus, has hindered the progress of
the fundamental and clinical use of exosomes. A thorough understanding of exosome
biophysical attributes would allow for details of several vital cell interaction mechanisms
to be revealed (i.e., immune regulation, communication, and disease progression).17,18
The analysis of EV-associated biomarker components during liquid biopsies has become
a valued tool for cancer detection, allowing for the surveillance of progression and
treatment with a reduced physical burden on the patient.16,19 Alternatively, the large-scale
processing of exosomes has become a key goal for researchers in many areas, including
in the biopharmaceutical industry. EVs from mesenchymal stem cell (MSC) origin are of
particular interest, having demonstrated the ability to enhance therapeutic transport of
targeted drugs,20 initiate tissue regeneration,21 and support immune response
modulation.14 Nevertheless, for the full extent of EV analyses to be realized, the
inefficient tools for EV retrieval must be addressed.
Due to their ubiquitous nature in terms of the cells of origin, exosomes and other
EVs are found in diverse biofluids, including urine,22–24 saliva,25–27 blood (serum and
plasma),28–30 cervical mucus,25,31,32 breast milk,20–22 and cerebrospinal,33,34 lymph,35,36
synovial,37 and amniotic38 fluids. As such, these media are reservoirs to derive clinical
and research scale populations. EVs may also be harvested from cell culture media during
the cell growth process for fundamental studies or subsequent use as biotherapeutic
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vectors.39 Despite the high bioavailability of EVs, the extraction of EVs from biofluids
has proven to be a challenge due to sample and vesicle heterogeneity and intense matrix
effects. In terms of characterizing the effectiveness of generic EV isolation processes,
several metrics exist relative to the final product’s quality (versus the cost/time aspects of
the procedures). The first, most obvious feature is the yield; how many microvesicles can
be extracted per unit volume of the primary matrix. Practical working volumes can range
from tens of microliters of cerebrospinal fluid (CSF) to milliliters of urine and liters of
cell culture media. The second is the purity of the isolate. In the case of EVs, the primary
contaminants/co-eluates are matrix and host cell proteins. In the case of serum/plasma
samples, these would typically include albumins and, most problematically,
lipoproteins.40,41 Finally, the most critical aspect is the retention of biological
functionality. Whether the end-use is clinical analysis, fundamental research, or
production of biotherapeutic vectors, the recovered EVs’ physical and chemical integrity
must remain intact. Additional metrics come into play during high-specificity isolations
of targeted EV populations. In all instances, aspects regarding processing time, capital
and supply costs, and operational complexity must be considered.
It has been documented the needs for the development and optimization of
methods specifically for the isolation and quantification of EVs from complex biofluid
samples.42 The available methods for these purposes limit the downstream
characterization and application of EV recoveries due to concentration and purity
concerns. The lack of efficient EV isolation methods has become the rate-limiting step
towards realizing the full potential of EVs in clinical and fundamental research and
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prevents large-scale processing of EVs. Many EV isolation methods are available based
on a wide variety of chemical/physical properties. Riekkola and co-workers have recently
presented an excellent review of the topic,43 with many papers describing comparisons of
the methods. At this point, it is clear that no single method can be universally applied.44,45
The employed isolation method is usually chosen based on the subsequent means of
characterization and utilization of the EVs. At present, ultracentrifugation (UC) methods
are most commonly used to isolate EVs.46 The UC isolation method consists of several
differential centrifugation steps, potentially reaching 200 000g.13 UC introduces highcosts regarding time (2 hours to overnight), sample volume (10–45 mL), and capital (up
to $100 000 for equipment, and $3000 in running costs per year), producing low
recovery/yields (5–25%) which are typically contaminated with protein/lipoprotein
aggregates.46,47 Variations of this technique employing density gradients and other
reagents have also been implemented but continue to present the previously-mentioned
challenges.46,48 Other size/density-based methods include ultrafiltration, size-exclusion
spin downs, and field flow fractional.49–51 Here again, low purity recoveries are
problematic. As a final class of methods, immune-affinity and polymer precipitation
“kits” are finding increased use.52,53 Still, concerns lie in the low yield and impure
recoveries, skewing the downstream characterization of the vesicles. Ultimately, an
isolation method with the ability to efficiently produce high-yield, high-purity EVs on
practical time/cost scales is of critical importance.
To address the aforementioned issues, researchers from the Bruce and Marcus
groups have demonstrated the use of a polyester (PET) capillary-channeled polymer (C-
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CP) fiber stationary phase in hydrophobic interaction chromatography (HIC) workflows
for EV isolation.54–60 The C-CP fibers consist of an 8-legged periphery that creates 1 to 4
μm-wide channels upon colinear packing in a column format. The relative
hydrophobicity of the stationary phase and the high-salt retention of the EVs allows for
the capture and elution of the vesicles based on hydrophobicity. HIC has been
traditionally applied to protein separations61 due to the non-denaturing, on–off
partitioning of the solute, allowing the preservation of structure/function.62–64 Taking
advantage of this, the efficient and vesicle-preserving isolation of EVs from urine,54,56
blood plasma,55 and cell culture milieu54,58 have been demonstrated in a 10 min HPLC
workflow enabling simultaneous EV isolation and quantification. Importantly, recent
proteomics analysis of the eluates has revealed a very efficient removal of serum proteins
and lipoproteins, yielding extremely high purity fractions in comparison to other
methods.59 The method has been extended to a more clinically-favorable EV isolation
workflow using 1 cm C-CP fiber phases attached to micropipette tips, allowing for the
solid-phase extraction (SPE) of EVs to occur in a table-top centrifuge.57 Both methods
have proven to be beneficial in terms of efficiency, purity, and yield, producing
recoveries of EVs on clinically relevant scales of time (<15 minutes) and cost (<$1 per
column per tip). Here, the versatility of the C-CP fiber spin-down tip to produce
concentrated and contaminant-free EV recoveries is demonstrated for the complex
matrices of urine, saliva, cervical mucus, serum, and milk. The tip recovery of exosomes
was evaluated using absorbance (scattering) detection, nanoparticle tracking analysis
(NTA), and transmission electron microscopy (TEM). The exosome purity was assessed
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by Bradford assay of free proteins. The bioactivity and identity of the recovered vesicles
was confirmed with an enzyme-linked immunosorbent assay (ELISA) to the CD81
tetraspanin protein. It is believed that the methodology presented here will have relevance
to both clinical and fundamental biology research settings.

3.2 Experimental
3.2.1 Chemicals and reagents
Deionized water (DI-H2O, 18.2 MΩ cm) was obtained from a Milli-Q water
purification system (Millipore Sigma, Merck, Darmstadt, Germany). Biotechnologygrade glycerol and ammonium sulfate were purchased from VWR (Sokon, OH, USA).
Phosphate buffered saline (PBS, pH = 7.4), bovine serum albumin (BSA), and Pierce™
Coomassie Plus (Bradford) Assay Reagent were purchased from ThermoFisher Scientific
(Waltham, MA, USA).
3.2.2 Instrumentation
A NanoVue Plus UV-Vis spectrophotometer (GE Healthcare,Chicago, IL, USA)
was used to measure the absorbance/scattering (203 nm) of the EV fractions. A Synergy
H1 Hybrid Multi- Mode Plate Reader (BioTek, Winooski, VT, USA) was used to
measure the UV-Vis absorbance (595 nm) of samples in the 96 cell-well format during
the Bradford assay of protein content, employing the colorimetric Pierce™ Coomassie
Plus (Bradford) Assay Reagent. The plate reader was also used in the chemiluminescent
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detection of the Pierce™ ECL Substrate during the enzyme-linked immunosorbent
(ELISA) assay. A Hitachi HT7830 transmission electron microscope (Chiyoda City,
Tokyo, Japan) was used for TEM imaging to determine the structural integrity, size, and
purity of the EVs in the C-CP tip recoveries from various biofluids. A Malvern
Panalytical NanoSight NS300 nanoparticle tracking analysis (NTA) system (Malvern,
Worcestershire, United Kingdom) was used to determine the concentration and size
distribution of isolated vesicles.
3.2.3 Extracellular vesicles
Commercial lyophilized “exosome standards” from the urine of healthy donors
were obtained from Galen Laboratories Supplies (Craigavon, Northern Ireland). To be
clear, the material has not been certified as a reference standard. No information
regarding purity or classification was supplied from the manufacturer. However, the
product is a means of preparing EV solutions of known concentration (2.7 x 1012 particles
per mL), though vesicles exceeding typical exosome diameter, lipoproteins, and other
protein contaminants have been previously identified in the material.65 Despite the
potential of systematic error (impurities) introduced by these standards, they have proven
useful for order-of-magnitude estimation of recovered EV concentrations. Fresh-morning
urine, saliva, and cervical mucus (collected using a cotton swab and dissolved in PBS)
were obtained from consenting, anonymous donors. After sample collection, the cervical
mucus samples were stored at −80 °C until thawed for EV processing. Corning™ Human
AB Blood Serum was obtained from ThermoFisher Scientific (Waltham, MA, USA). The
frozen human serum was thawed and aliquoted before use. Unpasteurized raw goat milk
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(serving as a surrogate for human breast milk) was obtained from Split Creek Farm
(Anderson, SC, USA). All biofluid samples were filtered using a sterile syringe filter of
0.22 μm pore size (Frogga Bio, Toronto, Canada) prior to processing.
3.2.4 C-CP fiber tip creation and methodology
The C-CP fiber micropipette tips were assembled as previously reported,57 with
the same HIC isolation workflow employed. Briefly, the 1 cm long C-CP fiber tips were
cut from 30 cm long, 0.8 mm inner diameter fluorinated ethylene–propylene (FEP) C-CP
packed columns consisting of ∼450 PET C-CP fibers. The C-CP tips had an interstitial
fraction of ∼0.6, with ∼3 μL of bed volume, which was press-fit to 200 μL low-retention
micropipette tips and secured with a small amount of superglue, as depicted in Fig. 3.1.

Figure 3.1: The capillary-channeled polymer (C-CP) fiber solid-phase extraction up setup for the isolation
of EVs from complex biofluids in a tabletop centrifuge.

The EV isolation methodology for the various biofluids was initiated by mixing
100 μL of the raw biofluid with 100 μL of ammonium sulfate (2M final concentration) to
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induce the hydrophobic interaction between the biofluid components and the fibers. The
total volume was vortexed, then deposited inside the sample reservoir of the C-CP tip
assembly. The apparatus was then placed inside a 15 mL conical, table-top centrifuge
tube and spun-down at 300g for 1 minute. (Due to the high viscosity of the saliva matrix,
the tip containing the saliva sample was centrifuged at 500g for 10 minutes.) Next, the
fiber-bound vesicles were washed with 200 μL of DI-water (300g, 1 min) before inducing
the elution of free proteins (including lipoproteins59,60) using 200 μL of 25% glycerol
with 1 M ammonium sulfate in PBS (300g, 1 min). For the protein-rich serum and milk
matrices, two protein elution steps were employed to minimize protein carryover in the
EV elution. Finally, the elution of the EVs was induced using 50 μL of 50% glycerol in
PBS (300g, 1 min) and the final fraction collected. Based on the respective
sample/elution volumes, a 2X concentration factor is realized.
3.2.5 Quantification and characterization of EV recoveries
Previous reports have demonstrated the validity of using standard absorbance
(scattering) measurements as a means of quantifying isolated exosomes.54–56 In those
efforts, quantification was achieved by generating linear response curves based on serial
dilutions of the commercial exosome standards in the elution solvent. Given the high
complexity and presence of matrix-associated components in the diverse biofluid
matrices, the method of standard addition was also used to more accurately quantify the
EVs. For the method, 10 μL of the unknown sample (S0) was spiked once (S1), twice (S2),
and three times (S3) with 10 μL of EV standards of known concentration (2.7 × 1010
particles per mL), with the total sample volumes adjusted to 50 μL using DI-water. The
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absorbance of each sample was measured at 203 nm (n = 5). The optical absorbance of
the raw and spiked samples (S0–4) and the known added concentrations of exosome
standards were used to create a standard addition response curve for EV quantification.
The resulting linear regression was extrapolated to determine the concentration of EVs in
the unknown sample.
The structure, size, and concentration of the recovered EVs were evaluated using
TEM and NTA. The sample preparation for TEM imaging was performed as previously
reported.57 The size distribution of the eluted EVs was determined using the NanoSight
NS300 NTA system, equipped with a 532 nm laser. Throughout NTA experimentation,
five replicates were collected for each sample in 60-second intervals, with a minimum of
200 valid tracks recorded per video and a minimum of 1000 valid tracks recorded per
sample. The focal plane for each sample was manually adjusted using the focus knob to
achieve the best optical field of view. The syringe pump for sample introduction was set
to a constant flow rate of 50 μL per minute. The camera level was set to 14, and the
detection threshold was set to 3, as optimized by Vestad et al. 66 To clarify, the
concentration values based on the NTA data are not the direct concentration values of the
EV recoveries. Instead, the recovered EVs were diluted to be compatible with the NTA
system’s working concentration range (107–109 particles per mL).
Protein components of the biofluids and EV recoveries were evaluated using a
Bradford assay and an indirect enzyme-linked immunosorbent assay (ELISA). The
Bradford assay was used to determine the total protein concentration of both the whole
samples and EV elution fractions. For the total protein determinations, 250 μL of
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Bradford reagent was added to 25 μL of each sample and allowed to incubate at room
temperature for 20 minutes before detecting the absorbance response at 595 nm using the
Synergy H1 Plate Reader. The absorbance responses were compared to a standard curve
using BSA standards. All samples and standards were applied to the cell well plate in
triplicate.
The presence of EVs in biofluids is commonly confirmed using antibodies to the
CD81, CD63, and CD9 tetraspanin proteins, which are incorporated in the
transmembrane space of EVs during biogenesis.67 Despite their wide use as marker
proteins, tetraspanins are in fact not universally expressed in EVs, and the overall
expression is also heterogeneous among singular EV populations.68 Therefore, the
presence of EVs may be confirmed by the detection of these proteins, but their absence
does not preclude the presence of EVs. Prior to chemical processing for the CD81 ELISA
assay, the tip-isolated EVs were applied to a 100 kDa filter unit to remove latent glycerol,
as high concentrations of glycerol are known to interfere with antibody binding.69,70 The
EVs isolated from the target biofluids were first diluted in 1:1 ELISA coating buffer
(0.05 M carbonate–bicarbonate in PBS) and then incubated on a shaker overnight at 4 °C
to coat the cell well plate with the analytes. An exosome standard positive control and
negative controls of PBS, protein elution buffer, and EV elution buffer were also applied
to the cell well plate. All samples and controls were applied to the cell well plate in
triplicate. After incubation, the cell well plates were washed with sterile PBS (200 μL per
well, 30 min, 6 buffer changes) and then blocked with 5% BSA in PBS at room
temperature for 30 min. The wells were incubated overnight with 50 μL of a mouse
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monoclonal antibody to the CD81 protein (1 μg mL−1) on an orbital shaker (4 °C). The
washing and blocking steps were repeated before applying 200 μL of the goat anti-mouse
HRP conjugated secondary antibody (1 μg mL−1, 200 μL, RT, 2 hours). The cell well
plate was washed using 200 μL of PBS per well and 6 buffer changes. Finally, the Pierce
ECL Substrate was applied and incubated at room temperature for 30 minutes before
detection. The Synergy H1 microplate reader was used to measure the chemiluminescent
response resulting from the HRP catalyzed oxidation of the substrate, correlating to the
concentration of species containing the CD81 antigen.

3.3 Results and Discussion
3.3.1 EV quantification via standard addition
Concentrated EV recoveries with high purity, preserved morphology, viability,
and stability are essential for the most efficient use of EVs derived via any isolation
method. Given the complexity and diversity of the biofluids (and culture media),
removing matrix contaminants is of utmost importance. Carryover of matrix species with
the target EV isolates, including proteins and genetic material, hinders the
implementation of downstream characterization techniques (i.e., MS proteomics or RNASeq), their use in clinical analysis schemes, and use as vectors in gene therapy
applications. In this regard, the use of optical absorbance as an EV quantification tool is
particularly susceptible to interferences due to the presence of low concentrations of
matrix species. However, the quantification of isolated EVs by absorbance has been
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previously demonstrated using simple optical absorbance measurements at 203 nm.54–59,61
To be clear, the absorbance response observed at this wavelength is not credited to the
common electronic transitions typical of biomolecules in solution. Instead, the
“absorbance” response is caused by light scattering due to the presence of the
nanobodies, which is conveniently proportional to the EV concentration. A cause for
concern with this method for quantifying EVs is that matrix proteins and nucleic acids
will skew the absorbance detection, especially at the 216 and 280 nm wavelengths
traditionally used for determinations of proteins. These effects are lessened at 203 nm,
where a higher absorbance (light scattering) response is observed at shorter
wavelengths.48 In fact, absorbance spectra obtained for EV solutions follow the
anticipated responses (exponentially decreasing with wavelength) for particles of ∼150
nm, based on Mie scattering theory.
The method of standard addition is widely used for the quantification of analytes
whose responses (regardless of the methodology) are subjected to significant matrix
interferences. 71 The method has not been previously employed for the quantification of
EVs in biofluids, but could prove useful in this application as diverse matrices are being
evaluated. A proof of concept for this method is illustrated in Fig. 3.2, where the method
of standard addition was used to quantify EVs in aqueous solution using the commercial
exosome stock.
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Figure 3.2: Standard addition curve using a commercial exosome standard stock of 1.1 × 10 10 particles per
mL concentration based on absorbance measurement at 203 nm (red). Quantification of EVs based on
absorbance detection after employing aqueous EV solutions of known concentration to the C-CP tip (blue).

The method was first applied to test the “unknown”, which was the initial
exosome stock solution of 7.0 × 1010 particles per mL. The test unknown (S0) was spiked
once (S1), twice (S2), and three times (S3) with aqueous aliquots of the EV standard,
increasing the theoretical concentrations by 1.1 × 1010, 2.2 × 1010, and 3.2 × 1010 particles
per mL, respectively. As shown in Fig. 2 (red line), the absorbance responses for the unspiked (S0) and spiked (S1, S2, S3) EV stock aliquots in DI-water are well behaved,
yielding a correlation coefficient (R2) of >0.999. Based on the linear regression, the
“unknown” concentration was determined to be 7.4 × 1010 particles per mL, a 5% error.
As a point of reference, the concentration of the same solution determined by a standard
calibration curve (R2 value = 0.998) yielded a concentration of 6.3 × 1010 particles per
mL, a 10% error (accuracy that would be considered outstanding by virtually any other
EV assay method).
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As mentioned previously, the stock exosome material is known to contain
undetermined amounts of proteinaceous material and other vesicular bodies. As a further
test of the use of the standard addition quantification method, the “unknown” sample and
the equivalent spike samples were put through the spin-down protocol. As seen in the
response curve (blue line), proportional recoveries are indeed maintained, reflecting a
lack of any sort of overloading of the fiber phase. Indeed, the recoveries are quite high
versus the EVs in the stock aqueous solution, ranging from 96–102% (concentration of
recovered EVs /raw stock), with the lower y-intercept being attributed to the removal of
the latent proteins in the original stock material. Also of relevance, the average variation
for the bulk measurements was 4%RSD, while for the full extraction process the
variability averaged 5%RSD. There is some level of degraded quantitative performance
(scatter) in the tip recoveries, as seen in the lessened goodness-of-fit (R2 = 0.970).
3.3.2 EV recoveries from diverse matrices
After confirming the ability of the standard addition method to determine the
concentration of EVs and the C-CP tip’s ability to produce quantitative EV recoveries,
the experimental protocol was applied to the raw biofluid matrices. The urine, saliva,
cervical mucus, serum, and milk biofluids samples were spiked as described above,
followed by tip isolation. The raw biofluids were spiked once, twice, and three times with
EV stock solutions of increasing concentration (1.1 × 1010 particles per mL per spike),
then diluted to 200 μL with ammonium sulfate (2M final concentration) before applying
to the C-CP spin-down tips for the isolation process (load, protein wash, EV elution). The
absorbance response of the EV eluates was measured at 203 nm. The relative absorbance
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responses presented in Fig. 3.3 reflect the fact that the C-CP tip does produce EV
recoveries of proportionally increasing concentrations, despite the biofluid sample
complexity.

Figure 3.3: Determined EV particle concentrations (n = 3) for human urine, saliva, cervical mucus, blood
serum and goat milk biofluid unknown samples spiked once, twice, and three times with a commercial
exosome standard stock of 1.1 × 1010 particle per mL before EV isolation using the C-CP tip workflow. The
biofluid-originating EV recoveries were quantified based on absorbance at 203 nm and compared to a
response curve of linear response.

The respective regressions of each have an R2 correlation coefficient of > 0.98. The
determined values for each of the biofluids are provided in each case, with respective
values each falling in line with expectations based on literature values.72–76 The relative
precision of the determined values (n = 3) is excellent, with an average value of ∼7%
RSD across the matrices.
The relative responses for the spikes across the different matrices are
fundamentally instructive. In theory, consecutive increases of 1.1 × 1010 particles per mL
EV concentration were applied. Therefore, given a homogenous and ideal biofluid
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sample, the difference between the determined concentrations of the S x and Sx+n samples
should be 1.1 × 1010 particles per mL. While the responses here are proportional within
each matrix type, there is a definitive difference in the slopes; i.e. the method of standard
addition reveals the existence of matrix effects. That said, given the vast physicochemical differences among these biofluids, the extent of the effects, based on the slopes
of the response curves, are less than a factor of 2X. As such, the use of a single
absorbance calibration function would deliver that level of accuracy, with higher levels
achieved with the use of matrix-matched standards. Analysis across multiple matrices
would benefit most using the standard addition method.
3.3.3 Physical characterization of EV isolates
To confirm that the C-CP tip elution fractions do indeed contain EVs in the
correct size range and consist of the expected characteristic shape, NTA and TEM
imaging were performed. Fig. 3.4 presents both the size distributions observed via NTA
and electron micrographs of the intact vesicles following isolation.
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Figure 3.4: Size distribution of vesicles in the EV recoveries resulting from the C-CP fiber tip isolation
from human urine, saliva, cervical mucus, blood serum, and goat milk, measured using the Nanosight
NS300 nanoparticle tracking analysis system. TEM micrographs of EVs isolated from biofluids using the
C-CP fiber tip, taken using the Hitachi HT7830.

The eluted EVs presented average diameters from 121.7–160.3 nm across the
matrices. Based on the NTA data, the populations of EVs recovered from the urine,
saliva, and milk samples presented the most “gaussian-like” size distributions, though
with minor subsets of vesicles detected at larger sizes (as is typical). On the other hand,
the EVs isolated from the cervical mucus and blood serum samples were far less
homogeneous, with several distinct subpopulations.
Visualization via transmission electron microscopy (TEM) is another benchmark
method to identify extracellular vesicles. The TEM micrographs presented in Fig. 3.4
confirm that EVs were isolated from the biofluids using the C-CP spin-down tips. In each
of the images, either cup-shaped, donut-shaped, or spherical-shaped vesicles with a dark
halo can be observed. The EVs observed in the TEM micrographs fall within the
exosome size range. One key aspect to emphasize is that, even in the potentially
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lipoprotein-heavy biofluids (cervical mucus, serum, milk), no vesicles are observed that
would correspond to the anticipated lipoprotein size range (∼20 nm) characteristic of
LDLs. The isolation of EVs from lipoproteins is a fundamental challenge due to the
similarities of the vesicles’ size, structure, composition, and biological interactions. 40,41
High purity recovery of EVs (i.e., the lack of matrix proteins/lipoproteins) using the fiber
isolation methodology has been demonstrated in recent mass spectrometric proteomics
analyses,59,60 and is a significant advantage of the C-CP tip isolation technique. This point
is further demonstrated in the following section. The TEM images show that the HICbased C-CP tip isolation preserves the characteristic vesicular shape with no visual
contamination.
Beyond the size distribution, NTA can also be used as a semi-quantitative means
of determining nanoparticle densities. As presented in Fig. 3.5a, the particle densities
determined for the raw biofluids via NTA can be appreciably higher than the
corresponding values generated by absorbance measurements.
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Figure 3.5: Comparison of the determined concentration of (a) EVs in each bulk biofluid sample and (b)
EVs recovered from each biofluid using the C-CP tip method as determined using the method of standard
addition by absorbance at 203 nm and by nanoparticle tracking analysis.

Not surprisingly, this is particularly true for the most proteinaceous matrices
(where agglomeration would likely occur). In these cases, the densities determined by
NTA can exceed those of absorbance by as much as an order of magnitude, with the
measurement variability also highest for those samples. Importantly, the same analyses
performed on the spin-down isolates (Fig. 3.5b) yield values in far better agreement
between the two quantification methods, with much-improved measurement precision
realized for the NTA. It is noteworthy that the relative concentrations across the matrices
parallel each other between the two independent measurement methods, with the values
not differing by more than 2X. This level of agreement is seen as validation of the
efficacy of the C-CP fiber spin-down tip methodology.
3.3.4 Characterization of EV purity
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To investigate the purity of EVs (based on the removal of matrix proteins)
isolated using the C-CP tip method, a Bradford assay was performed. The total protein
concentrations of the whole biofluid samples and the EVs eluted from those biofluids
using the C-CP tip isolation method were determined. To be clear, a Bradford assay
reflects the total proteinaceous material present in a sample. As such, in the ideal case of
perfect isolation of EVs, a positive response will still result due to the interaction between
the Bradford reagent and surface proteins and externally exposed basic and aromatic
amino acid residues.
The Bradford assay results for the raw matrix materials and the EV isolates are
presented in Fig. 3.6.

Figure 3.6: Bradford assay of raw biofluid matrices and concentrated EV recoveries after isolation with
the C-CP tip. The total protein concentration was determined using the absorbance measurement of
Bradford reagent at 595 nm, as compared to a BSA standard curve of linear response. n = 3.
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As would be anticipated, the goat milk and human blood serum matrices were the most
protein-dense, with the human urine matrix having the lowest amount of protein present.
After conducting the C-CP fiber spin-down tip EV isolation workflow, most of the
contaminating proteins were removed while leaving behind the EVs, which contribute to
only a small fraction of the total protein response for the protein-rich matrices.
Here, the 67–89% removal of “total protein” was demonstrated for the saliva,
cervical mucus, serum, and milk biofluid samples. A much lower (17%) removal of
proteins was observed from the human urine sample, as expected given the much lower
relative concentration of free protein in healthy urine samples. The EV recoveries present
a low (346–412 μg mL−1) total protein concentration based on the Bradford assay. While
not perceivable on this scale, the relative amounts of determined protein for the isolates
are a very close reflection of their relative EV densities determined via the standard
addition and NTA methods (Fig. 3.3 and 3.5), suggesting the efficacy of the method to
yield high-purity EVs. The C-CP tip method demonstrates here the ability to remove up
to 89% of protein contaminant species. The efficiency of the method is demonstrated by
the absence of proteinaceous aggregates in the TEM micrographs of EVs after the tip
isolation process. Perhaps most definitive, recent MS proteomic analysis work has
confirmed the removal of common contaminant lipoprotein species from serum samples
using this method, based on the virtual absence (<0.3% of total proteins) of the ApoB100 content in the EV isolates.60 The depletion of the lipid marker protein was
confirmed by ELISA analysis, as well.60
3.3.5 Verification of EV identity
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While no universally expressed EV/exosome marker exists, the CD81 tetraspanin
protein has been identified in high concentrations in many exosome populations.55 (The
CD63 and CD9 tetraspanins have been used as identifiers in previous works from this
laboratory,57 but CD81 generally exists in higher concentrations.) As such, the marker
has been accepted as a general marker for the presence of EVs, with the acknowledgment
that it is expressed to different extents even within the same EV population, and in some
cases not at all. To confirm the presence of EVs in the C-CP tip eluates and assess the
recovered vesicles’ bioactivity, a semi-quantitative ELISA using an antibody to the CD81
tetraspanin protein was employed.
As shown in Fig. 3.7, serial dilutions of the commercial exosome standard stock
were used to create a standard curve for the ELISA response quantification.

Figure 3.7: Indirect ELISA standard curve employing an antibody to the CD81 tetraspanin protein using
serial dilutions of a commercial exosome standard (2.7 × 1012 particles per mL), and the CD81 responses
of the C-CP tip isolated EVs from biofluid samples.
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With this standard curve of linear response (R2 = 0.985), the concentration of
recovered EVs containing the CD81 tetraspanin protein was estimated. When the
concentration of EV standards presenting a CD81 response was compared to the EV
concentration as determined by absorbance detection (Fig. 3.3), the relative
concentrations show the same general trends among the matrices. Even so, the
quantitative numbers for the exosome concentrations reflect recoveries of 53–91% across
the matrix types versus the absorbance-determined concentrations (Fig. 3.3). This level of
agreement between the highly generic (absorbance) and highly specific (ELISA) means
of quantification is quite remarkable. Based solely on the CD81 ELISA, the highest
percentage of recovery for EVs containing CD81 was found for the blood serum sample
(91%), followed by the saliva (70%), urine (59%), cervical mucus (58%), and the goat
milk (53%). This level of variation is not at all surprising because CD81 is not
universally expressed and is upregulated/downregulated in EVs of different origins.

3.4 Conclusions
The C-CP fiber tip isolation method has proven to be an efficient means of EV
isolation, with the ability to withstand potentially complex matrix effects from human
urine, saliva, cervical mucus, blood serum, and goat milk. The HIC-based EV isolation
technique presents significant benefits regarding time, cost, and ease of use. The C-CP
spin-down tip workflow enables the processing of multiple samples simultaneously in 15
min, limited only by the table-top centrifuge capacity. The method of standard addition
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employing a commercial exosome standard stock was demonstrated as an accurate means
to determine the concentration of EVs, regardless of the matrix type. That said, the
respective responses showed very little difference in sensitivity (i.e., minimal matrix
effects). NTA analysis provided the determination of particle size distributions and
overall particle densities for the different matrices. TEM analysis confirms that the EVs
isolated from all biofluids retained the characteristic cup or donut-shaped morphology
after the isolation process. The purity of the EV isolates was confirmed through Bradford
assays, revealing total protein content before and after isolation, with up to 89% of
biofluid-originating proteins being removed. The efficacy of the method to isolate
bioactive EVs was demonstrated through an ELISA assay for the CD81 tetraspanin
marker protein. Overall, there was a self-consistency in the relative (and absolute)
amounts of EVs isolated from the different matrices based on the multiple, independent
measurement approaches. This agreement serves to validate the quantitative aspects of
the isolation process.
The bench-top C-CP spin-down tip protocol introduces a relatively facile means
of EV isolation. The C-CP tip HIC isolation method’s capabilities make it an ideal
candidate for use in laboratory settings. The ability to work with microliter volumes
while achieving high EV yields and purity lends itself to both clinical and fundamental
EV research applications. For example, the ability to alleviate the complicating aspects of
serum/lipoproteins is an essential element in performing high-fidelity proteomics
analysis. Likewise, the same factors are key in developing bioassays based on the
presence of targeted surface marker proteins. Finally, while likely requiring the use of
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preparative scale columns, the characteristics demonstrated here are essential in the
development of EVs as gene therapy vectors.
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CHAPTER FOUR
COMPARISON OF THE CAPILLARY-CHANNELED POLYMER (C-CP) FIBER
SPIN-DOWN TIP APPROACH TO TRADITIONAL METHODS FOR THE
ISOLATION OF EXTRACELLULAR VESICLES FROM HUMAN URINE

4.1 Introduction
Extracellular vesicles (EVs) are phospholipid bilayer–bound vesicles released by
cells to mediate various intercellular communication processes through the delivery of
essential biomolecular cargos, including proteins, nucleic acids, and lipids [1,2,3].
Though no official nomenclature classification system exists, EVs are roughly
categorized based on size and theoretical modes of biogenesis [4, 5]. Among EV
subtypes, exosomes, microvesicles, and apoptotic bodies are the most commonly studied.
Exosomes (or small EVs, sEVs) have become targets for EV–based diagnostic and
therapeutic applications [6,7,8] by virtue of inherent characteristics derived from their
creation through a multivesicular body (MVB) endosomal pathway [9]. Because of this,
exosomes serve as “genetic snapshots” of their cell of origin, encompassing DNA, varied
RNA types, and surface biomarker proteins from the mother cell [10]. Microvesicles and
apoptotic bodies, while generally < 1000 nm in diameter, are similar, but highly variable
in size [11]. However, they have distinctive proposed biogenesis modes: apoptotic bodies
are formed as a by-product of cell death, while microvesicles result from generic cell
membrane budding. With the size overlap between exosomes and microvesicles (30–
200 nm), classifying EVs based on size alone is not necessarily indicative of their origin.
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Thus, an EV nomenclature system based on size alone may lead to incorrect conclusions
about EV biogenesis. Despite these classification difficulties, due to their similar contents
and sizes, exosomes and microvesicles are targeted in fundamental biochemical studies
and clinical analyses, where they are generically referred to as EVs.
Mother cell–originating species like DNA, RNA, and biomarker proteins are
incorporated during EV biogenesis and facilitate transfer of essential biomolecules to
recipient cells [12]. Their small size, biocompatibility, and stability through the varying
microenvironmental conditions of biological systems make EVs ideal for communication
between cells in close and distant proximity, even across the blood–brain barrier [13].
EVs have been identified in over 30 biofluid types in all biological domains, including
urine [14], saliva [15], blood serum [16], and plasma [17], and analysis of their contents
has provided insights into the progression and transmission of several diseases [4, 18].
Yet, the efficient collection, isolation, and characterization of EVs remain challenging. A
lack of clear standardization and the complexity of their biofluid matrices of origin have
become limiting factors in advancing the EV studies [19].
One obstacle to EV research is efficient isolation. Current methods often produce
recoveries unfit for analysis and contaminated with unwanted matrix species. For
example, the presence of background proteins, particularly lipoproteins, can affect highquality exosome-specific proteomics. Thus, development of a method that consistently
provides high-concentration, pure, structurally preserved EVs is still needed. The most
widely employed EV isolation methods rely upon vesicle harvesting by size, density, or
the presence of surface biomarkers [20,21,22,23,24,25]. These methods include
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ultracentrifugation (UC) [26], ultrafiltration [27], size exclusion [28], and immunoaffinity
[29] approaches, but there is no optimal technique for all situations [30]. The method
should be chosen based on the post-isolation intent and/or application of the isolated EVs.
The scale of the process is also relevant, ranging in size from clinical diagnostics to
fundamental studies and preparative scales for vector production.
Inevitably, the choice of EV isolation method presents a compromise between
specificity (referring to both vesicle type and contaminant content) and efficiency [31].
Of the available techniques, the UC method, consisting of several sequential low- to
high-speed centrifugation steps, has become the most utilized [31]. However, despite its
wide use, this labor-intensive, time-consuming method results in low EV recoveries
contaminated by protein and lipoprotein aggregates [32]. Several commercial EV
isolation kits are available, including the exoEasy (Qiagen, Hilden, Germany) and
ExoQuick (System Biosciences, Palo Alto, CA) kits [33, 34]. Though many commercial
kits are marketed to produce “pure” EV recoveries, concerns about concentration and
purity (defined here as the freedom from matrix proteins and other materials) remain, as
proprietary polymeric precipitation reagents can present an additional source for eluate
complexity and challenges downstream. Many groups have conducted studies to compare
various isolation techniques, including evaluation of the isolated exosomes for stability
and biochemical efficacy [35,36,37,38,39,40]. Unfortunately, when examined together,
these studies have shown contradictory or inconclusive results.
A hydrophobicity-based isolation method on a capillary-channeled polymer (CCP) fiber stationary phase has been previously applied to EV isolations on both high-
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performance liquid chromatography (HPLC) [41,42,43,44,45] and spin-down
micropipette tip [46, 47] formats. The method is driven by an organic modifier-assisted
hydrophobic interaction chromatography (HIC) solvent system, which efficiently
harvests EVs from biofluids, while excluding free proteins and lipoprotein aggregates
[42]. The purity of isolates from human serum has been confirmed by mass spectrometric
proteomic analysis [42]. Subsequently, a synthetic mixture of LDLs and EVs was
separated using the method, with the relative abundance of Apo B-100 within the sample
accounting for only 0.3% of the protein content (279 identified) in the EV fraction [48].
In the development of the HIC–based technique, both acetonitrile and glycerol solvent
modifiers were used to quicken the EV isolation while preserving vesicle integrity [45].
The acetonitrile solvent modifier has proven best for EVs undergoing post-isolation
immunoaffinity characterization. While high acetonitrile concentrations are not ideal for
long-term EV preservation, the majority of latent acetonitrile can be off-gassed under
minimal vacuum. The glycerol solvent modifier is ideal when long-term preservation of
EV structure is required, as glycerol is a common cryoprotectant for cell preservation
[49]. However, high glycerol concentrations can interfere with some immunoassays
[50, 51], potentially hindering some downstream characterization. However, latent
glycerol can be readily removed using a post-isolation filtration step [42]. Still, the C-CP
tip methods have repeatedly demonstrated the ability to provide highly concentrated, pure
EVs from a number of complex biofluid matrices (including urine, saliva, blood
plasma/serum, and cervical mucus) with up to 99% removal of contaminant
proteins/lipoproteins.
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Here, the HIC C-CP tip method performance (using both aforementioned organic
modifiers) is compared to UC and two commercial kits for isolation of EVs from the
same human urine sample. The EVs recovered via each method are assessed using UV–
VIS absorbance (scattering) quantification, Nanosight nanoparticle tracking analysis
(NTA) for quantification and sizing, transmission electron microscopy (TEM) for vesicle
structure validation, an enzyme-linked immunosorbent assay (ELISA) utilizing
antibodies to accepted EV marker proteins as a means of quantification and validation of
surface chemical integrity, and a purity assessment by protein assay. It is believed that the
C-CP fiber spin-down tip methodology offers pronounced benefits over the commonly
employed methods across the metrics of practicality and target EV collection efficiency
and purity. Furthermore, once isolated, EVs extracted by this method are ready for
downstream characterization and utilization.

4.2 Materials and Methods
4.2.1 EV Sources
Commercial lyophilized exosome standards of 9.3 x 1012 particles mL-1
concentration from the urine of healthy patients were obtained from Hansa BioMed
(Tallinn, Estonia). The exosome standards were reconstituted in 100 µL of Milli-Q water
as instructed by the manufacturer and used to prepare the absorbance-based response
curves. To be clear, these EV "standards" are not EV reference standards but are EVs of
known concentration (methods not disclosed) for quantitative measures. Therefore, no
quantitative/qualitative variables (e.g., purity) apart from concentration are supplied,
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which is acknowledged here. For the inter-method comparison, first-morning urine was
collected from a healthy, consenting, anonymous donor in accordance with a standing
Clemson University IRB protocol. The sample was filtered with a 0.22 µm sterile
polyethersulfone (PES) syringe filter (FroggaBio, Toronto, Canada) then immediately
employed in the various isolation workflows.
4.2.2 Chemicals, Solvents, and Antibodies
The deionized water (DI-H2O, 18.2 MΩ-cm) used here was obtained from a
Milli-Q water purification system (Millipore Sigma, Merck, Darmstadt, Germany).
Biotechnology-grade glycerol and ammonium sulfate were purchased from VWR
(Sokon, OH, USA). Phosphate buffered saline (PBS, pH = 7.4), bovine serum albumin
(BSA), a Pierce™ BCA Protein Assay Kit, and a Pierce™ ECL Substrate were purchased
from ThermoFisher Scientific (Waltham, MA, USA). Paraformaldehyde and
formvar/carbon 200 mesh copper grids were obtained from Electron Microscopy
Sciences (Hatfield, PA). The mouse monoclonal antibody to CD81 (200 µg mL-1) was
obtained from Santa Cruz Biotechnology (Dallas, TX). Mouse monoclonal antibody to
CD63 (0.5 mg mL-1) was obtained from ThermoFisher Scientific. Goat anti-mouse
horseradish peroxidase (HRP)-conjugated secondary antibody (0.7 mg mL-1) was
obtained from MP Bio (Santa Ana, CA).
4.2.3 Isolation Methods
In order to assure the efficacy and validity of the inter-method comparison, each
of the isolation methods was carried out explicitly as described in either the commercial
manufactures’ instructions or by following well-described methods in the literature, as in
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the case of the C-CP fiber tips and the UC. All extractions/ determinations were
performed in parallel, triplicate. Every effort was exercised to ensure that the singular,
pooled human urine sample was in a state of homeostasis throughout the samplings. That
is, all isolation procedures were commenced at the same time, and/or the sub-samplings
were performed at the same time and held at 4 ºC until use, with the solutions agitated to
ensure homogeneity.
4.2.3.1 C-CP Tip Construction and Workflow
The capillary-channeled polymer (C-CP) fiber micropipette tips were created
through the previously described process. [46,52] Polyester (polyethylene terephthalate,
PET) C-CP fibers were melt-extruded from commodity bulk polymer into an 8-pronged
periphery by the Clemson University School of Materials Science. Eight rotations of the
PET fiber phase, approximately 450 polymer fibers per tip, were packed collinearly into
fluorinated ethylene propylene (FEP) tubing of 0.8 mm inner diameter. Next, the column
was repeatedly pulled and cut to create 1 cm of fiber-packed tubing with 0.5 mm of
empty tubing to allow for attachment to a 200 µL micropipette tip. The micropipette tip
with the C-CP fiber phase attached was placed inside a 1 mL micropipette tip, then set
into a 15 mL conical receiver with an adapter-modified cap to hold the C-CP phase
connected tip in place.
Two hydrophobic interaction chromatography solvent systems were employed,
including acetonitrile and glycerol organic modifiers. In both cases, 200 µL of filtered
urine was mixed with an equal part of ammonium sulfate (2M final concentration), then
applied to the C-CP tip's sample reservoir, placed into the tabletop centrifuge, and spun
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down at 300 x g for 1 minute. Here, the method diverts to employ the two different
organic modifier solvents. For the acetonitrile method, the elution of proteins was
induced using 100 µL of 25% acetonitrile in 1M ammonium sulfate, with the elution of
EVs induced using 100 µL of 50% acetonitrile in PBS. Similarly, for the glycerol solvent
modifier, the elution of proteins was induced using the same volumes of 25% glycerol in
1M ammonium sulfate, and EV elution was induced using 50% glycerol in PBS.
4.2.3.2 Commercial EV Isolation Kits
EVs were extracted from the filtered urine samples by the Qiagen exoEasy and
System Biosciences ExoQuick isolation kits by following the manufacturer's instructions
explicitly. For the ExoQuick-TC isolation, 10 mL of filtered urine was centrifuged at
3,000 x g for 15 minutes, then mixed with 2 mL of ExoQuick-TC by inverting the conical
tube several times. The sample mixed with the ExoQuick reagent was incubated upright
at 4°C overnight. Next, the ExoQuick-biofluid mixture was centrifuged at 1,500 x g for
30 minutes. The supernatant was removed, and the EV pellet was resuspended in 100 µL
of PBS. For the Qiagen exoEasy isolation, 8 mL of filtered urine was mixed with equal
parts of buffer "XBP" and mixed by inverting the conical tubes several times before
applying the 16 mL of the mixture to the exoEasy spin column and centrifuging at 500 x
g for one minute. This step was repeated 8 times to allow the entire volume to pass
through the membrane. The flow-through solution was discarded, and 10 mL of buffer
"XWP" was added before centrifuging at 5,000 x g for 5 minutes. Again, the flowthrough solution was discarded. Then 400 µL of buffer "XE" was added to the membrane
and incubated for 1 minute before centrifuging at 500 x g for five minutes to collect the
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eluate. The eluate was reapplied to the column and incubated for one minute before
centrifuging twice at 5,000 x g for 5 minutes to collect the EVs.
4.2.3.3 Ultracentrifugation
EVs were isolated from the filtered urine using an ultracentrifugation protocol for
urine similar to that as published by Gheinani et al.,[53] using several differential
centrifugation steps. First, 45 mL of the filtered urine sample was centrifuged at 200 × g
for 20 minutes. The resulting pellet was discarded, and the supernatant was centrifuged at
2,000 × g for 20 minutes to remove remnant cellular debris and protein contaminants.
Next, the supernatant was centrifuged at 16,000 × g for 20 minutes to remove larger
particles, and the resulting supernatant was ultracentrifuged at 120,000 × g for 70
minutes. Finally, the supernatant was removed, and the resulting EV pellet was
resuspended in 500 µL of PBS.
4.2.4 EV Characterization
4.2.4.1 Transmission Electron Microscopy (TEM)
TEM is the gold standard in the physical identification of EVs, where the
vesicular structure and cup-like forms are characteristic features. The sample preparation
for electron microscopy imaging was adapted from the negative staining protocol
described by Jung et al. [54] The isolated EVs were fixed for five minutes using 2%
paraformaldehyde, and 7 µL of the EV suspension was loaded onto the copper grid and
incubated for 10 minutes. The grids were blotted dry before washing with water for 5
minutes, and a 50 µL drop of 2% paraformaldehyde was placed on the grid for 5 minutes.
The grid was immediately stained using 20 drops of filtered 1% uranyl acetate solution.
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Excess uranyl acetate solution was removed, and the grip was rinsed with a drop of water
before allowing it to dry in a cell culture dish for 10 minutes at room temperature.
4.2.4.2 UV-Vis Absorbance Quantification
Previous reports from this laboratory have proven the efficacy of using HPLC
post-column absorbance detectors to quantify EVs very simply based on their scattering
of light.[43-45] Likewise, standalone UV-Vis spectrometers can be employed to
determine concentrations following spin-down tip processing.[46,48] EVs were
quantified using absorbance (scattering) detection at 203 nm using a NanoVue Plus UVVis spectrophotometer (GE Healthcare, Chicago, IL, USA).[46,48] The absorbance
response of each EV isolate at 203 nm was compared to a response curve generated using
serial dilutions of the commercial exosome standards (9.3 x 1012 particles mL-1 stock).
Again, because this commercial exosome standard stock is not a well-characterized or
standardized reference material, only general approximations of the EV concentration
method can be made here. No purity or antigen expression metrics were provided by the
exosome standard manufacturer; therefore, no conclusions of this sort are able to be
drawn based on comparison to the exosome “standard” stock.
4.2.4.3 Nanoparticle Tracking Analysis (NTA)
Nanoparticle tracking analysis is the benchmark method for the sizing, and to a
lesser extent, EV concentration measurement, though its limitations and peculiarities are
well documented.[55] The NanoSight NS300 (Malvern Panalytical, Westborough, MA)
NTA system was used to analyze the size distribution of the eluted EVs. For all NTA
experiments, replicates of 5 runs were used for each sample in 60-second intervals, with
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the syringe pump set to a constant flow of 50 μL min -1. A minimum of 200 valid tracks
per video and 1000 valid tracks per sample were recorded. The camera level was set to
14, and the detection threshold was set to 3 as optimized by Vestad et al. [56] Each
sample was diluted 500X to be in the operating range (1 x 107- 109 particles mL-1) of the
NS300 instrument.
4.2.4.4. Enzyme-Linked Immunosorbent Assay (ELISA)
An indirect ELISA was used to detect the presence of the EVs in the isolates
based on antibodies to the CD63 and CD81 tetraspanin proteins present on the vesicle
surfaces. Before this assay, the latent solvents from the tip-isolated EVs were removed by
off-gassing overnight at 4°C (for acetonitrile isolates) and using a 100-kDa filter unit (for
glycerol isolates), as high concentrations of these solvents have been previously shown to
affect antibody binding interactions specifically in ELISA assays [50,51,57]. The isolated
EVs (25 µL) were loaded onto the ELISA 96-well plate in triplicate, using equal volumes
(25 µL of ELISA coating buffer - 0.05 M carbonate-bicarbonate in PBS) and incubated
overnight at 4°C. An exosome standard positive control, along with negative controls of
the PBS, protein elution buffers, and EV elution buffers, were also employed here in
triplicate. After sample incubation, each well was washed with 200 µL of sterile PBS
over 30 minutes, with six buffer changes. The wells were then blocked using 200 µL of
5% BSA in PBS at room temperature for 30 minutes before incubation with 50 µL of the
CD63 and CD81 mouse monoclonal antibodies, both of 1 µg mL-1 concentration. The
primary antibody was allowed to incubate on a shaker overnight at 4°C. The washing and
blocking steps using PBS and 5% BSA, respectively, were repeated here before applying
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50 µL of the goat anti-mouse HRP conjugated secondary antibody. Finally, 100 µL of the
chemiluminescent substrate was applied, and the chemiluminescent response was
detected using a Synergy H1 Hybrid (BioTek, Winooski, VT) plate reader.
4.2.4.5 microBCA Protein Assay
A standard BCA assay determined the concentration of proteins present in the EV
isolates. For the microBCA assay, a 25 µL aliquot of the isolated EVs was added to 125
µL of PBS and 150 µL of the assay working reagent. The 96 well plates were covered
and allowed to incubate at 37°C for 2 hours, then cooled to room temperature. The
absorbance response at 562 nm was measured using the Synergy H1 Hybrid plate reader.
A standard curve using BSA standard solutions was used to determine the concentration
of protein in each unknown sample. The average absorbance reading of the blank (PBS)
was subtracted from all standards and the UC isolated EVs. The average absorbance
reading of the elution buffers for the commercial kit and C-CP tip isolates from a blank
sample (PBS) were used for the blank subtraction of the urine isolates. The standards and
samples were applied in triplicate to the 96 well plate, and the absorbance response for
each well was measured in triplicate.

4.3 Results and Discussion
4.3.1 Structural Verification via TEM
Despite the variety of available EV characterization methods, electron microscopy
techniques, like TEM, are definitive methods to confirm the presence of EVs based on
their physical structure. TEM analysis visually confirms the presence of EVs by revealing
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the characteristic size and cup shape. There is a universality in the approach, as there is
little concern relative to purity or complications that arise from too much chemical
selectivity, which also brings a high susceptibility to errors/contamination. TEM analysis
was used in this study to compare the size, shape, and integrity of the EV populations
obtained using the various isolation methods. Representative micrographs of human
urine-derived EVs isolated using each method are presented in Fig. 4.1, along with the
as-delivered commercial EVs.

Figure 4.1: Transmission electron micrographs of commercial urine exosome standards (a), and
extracellular vesicles (EVs) from the same urine sample, isolated using the capillary-channeled polymer
(C-CP) fiber tip methods (acetonitrile (b) and glycerol (c)), exoEasy (d) and ExoQuick (e) kits, and the
traditionally used ultracentrifugation method (f). The SEM images were taken using the Hitachi SU9000.

As expected, the TEM micrograph of the exosome standard stock (Fig. 4.1a)
reveals the cup or donut-shaped EVs from the reconstituted EV standard stock. Smaller,
more cup-shaped vesicles are observed in the human subject urine EVs recovered by the
C-CP fiber tips, employing both the acetonitrile and glycerol organic solvent modifiers
(Figs. 4.1b and 4.1c). A somewhat more pronounced cup shape is observed in the vesicles
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recovered using the C-CP tip with the glycerol solvent system (Fig. 4.1c), confirming the
EV preservation qualities of the glycerol solvent. The TEM images visually confirm the
ability of the C-CP tip method to isolate EVs from urine samples and reveal the
production of concentrated, structurally preserved vesicle recoveries.
Significant differences in vesicle populations are observed in Figs. 4.1d-f, where
many large and agglomerated collections of EVs are shown for the commercial and UC
methods. This is not surprising for the EVs obtained by the polymeric precipitation
techniques (Fig. 4.1d and e) as they isolate the vesicles based on an overall entrapment
mechanism, capturing the vesicles from the biofluid samples using a polymer network.
Large aggregates are also observed in the EVs obtained by the ultracentrifugation-based
method, which is a basic characteristic of the process. In the UC EVs (Fig. 4.1f), many
agglomerate particles are observed in protein/contaminant aggregates, but still, the
characteristic cup-shaped EV morphologies are observed here. As visualized in Fig. 4.1,
one of the main issues in EV isolation techniques is the co-precipitation of biofluidoriginating contaminants and the creation of large agglomerated and contaminated EV
recoveries. Comparing the visual integrity of EV isolates from the C-CP tips to those
recovered by the commercial kits and traditional EV isolation method, significant
differences are revealed in the overall shape and degree of aggregation. As shown in Figs.
4.1b and 4.1c, the observed average diameters of vesicles isolated via the C-CP tip
acetonitrile and glycerol solvent systems are approximately 100 nm. The C-CP tip
methods allowed for more dispersed EV isolations to be obtained with fewer visual
contaminants. Most importantly moving forward, the tip method allows for the structural
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preservation of the EVs with the characteristic cup shape, suggesting retention of
structural integrity.
4.3.2 Recovery Quantification via UV-Vis Absorbance
EV quantification using commercial stocks of EVs based on the absorbance at
203 nm has been previously reported. [46] With serial dilutions of a commercial exosome
stock of known concentration, a calibration curve enables the quantification of EVs based
on a simple absorbance measurement at 203 nm. This detected absorbance response is not
credited to the electronic transitions that typically cause spectrophotometric absorbance
responses, but more accurately, the scattering response due to the presence of the EVs.
To be sure, scattering characteristics are a function of particle size/composition, but in
this single-source case, the relative responses should be solely related to numbers. As
such, the resulting measured absorbance at the 203 nm wavelength is proportional to the
concentration of EVs in solution. Figure 4.2 shows the concentration of EVs obtained
from human urine by the employed isolation methods.
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Figure 4.2: Bar graph representing the concentration of EV yields obtained from the C-CP tip (acetonitrile
and glycerol), exoEasy, ExoQuick, and ultracentrifugation methods based on absorbance detection and
comparison to a calibration curve of linear response (y = 2E − 13x + 0.0264, R2 = 0.9935, n = 3).

Based on absorbance quantification, concentrations of approximately 4 x 1012 EV
mL-1 in the 200 µL test aliquots were obtained using the two C-CP tip methods,
recoveries of 2 to 4X lower concentration are obtained using the other EV isolation
methods. Both polymeric precipitation techniques resulted in recoveries of approximately
1 x 1012 EV particles mL-1, with the ultracentrifugation method resulting in an EV
recovery of ~2 x 1012 EV particles mL-1. With the significant contaminants observed in
the TEM images of EVs from the polymeric precipitation and UC isolation methods, this
absorbance-based quantification of EVs is potentially skewed by the protein/contaminant
aggregates, actually overrepresenting the EV concentrations in those isolates.
It is important to draw a distinction between the respective starting volumes of the
applied EV isolation methods, wherein the tip isolations began with 200 µL volumes of
the human urine, the commercial kits began with 8 to 10 mL (ExoQuick-TC and
exoEasy, respectively) of the urine sample, and the UC was performed with a 45 mL
starting volume. In all, the C-CP tip method using both the acetonitrile and the glycerol
solvent systems were able to produce higher concentrations of EVs than commonly
employed EV isolation methods, despite using less than 3% of the initial urine sample
volume. As such, there may be significant advantages to using the tip isolation methods
in critical sample volume-limited applications.
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Currently, there are no standardized methods for EV isolation, quantification, or
characterization. Limiting EV research is the lack of reference standards to serve as a
comparison point for the classification, purity, concentration, and composition of EVs.
Commercial stocks of “exosome standards” have been used in many proof-of-concept EV
demonstrations (as included here), but the characterization of these products has
introduced concerns regarding vesicle size, purity, and concentration of those materials
themselves.[58] Field-wide standardization has become a focal point for many scientists,
including the International Society for Extracellular Vesicles (ISEV), whose efforts have
established minimal guidelines for the studies of EVs (MISEV).[30] Important factors
emphasized in the MISEV guidelines[30] are the revelation of physical (size and
structure) surface species and cargo-related characteristics. In these defined guidelines,
no standard experimental approaches for EV research were established. Since the
upregulated release of EVs has been shown to be an indicator of stress or disease, EV
quantification in itself could serve as a method to monitor disease or treatment
effectiveness. [59,60] However, the MISEV guidelines emphasize a lack of EV
quantification techniques, and the consortium was unable to suggest efficient approaches
for EV quantification [30]. Again, an EV reference standard would be an essential
catalyst towards the optimization and development of EV quantification techniques.
Despite these shortcomings of employing commercial EV stocks during quantitative
approaches, the commercially obtained exosome standard stock was included and
enabled a sufficient approximation of EV concentration to be performed despite this
potential area for systematic error.
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4.3.3 Vesicle Sizing and Densities via NTA
To assess the size distribution, and to a lesser extent concentration, of the
recovered EVs, nanoparticle tracking analysis was employed. In doing so, it is important
to understand that such interpretations are extremely subjective as the species which
contribute to “signals” in the NTA experiment are highly varied. This is because a
number of species exist across the relevant size range of ~ 30–300 nm, including the
different EV classes, other vesicles, lipoproteins, protein agglomerates, protein-vesicle
aggregates, and vesicle clusters. Apparent sizing can also be affected by the solvent
system, including its chemistry and viscosity, which can influence mobility and
intraparticle associations. Finally, NTA signals can be affected by “generic particles”
existing in the test solution and indeed the laboratory environment. Interpretations also
rely on the starting hypotheses; for example, isolated exosomes should fit in the 70–120nm size range, which again is not definitive, and everything else is a perversion. Shown
in Fig. 4.3 are the NTA–determined size distributions of EVs from the commercial
standard stock and the populations recovered from human-subject urine using the various
EV isolation methods.
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Figure 4.3: Size distribution and cumulative percentage of size distribution of commercial exosome
standards and EVs isolated using the C-CP tip (acetonitrile and glycerol), exoEasy, ExoQuick, and
ultracentrifugation methods as determined using the NanoSight NS300 NTA system. Average of n = 5 runs,
60 s each.

It is important to note that the EV concentration results presented in Fig. 4.3 are
not directly reflective of the total EV concentration. The isolated EVs were diluted for
compatibility with the working range of the NTA system (1 × 107 to 1 × 109 particles
mL−1 concentration). The NTA size distribution data indeed confirm the size variability
of the components included in the “exosome standard” source, as seen in Fig. 4.3. It is
important to note here that though marketed as an exosome standard product, variation in
size and large amounts of contaminating protein content are revealed. The exosome
standard presents a pseudo-Gaussian distribution of the vesicles centered at
approximately 200 nm (much larger than ascribed to EVs) and with some smaller
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populations of vesicles with diameters of 75 nm or less. The inclusion of smaller
populations of particulate species suggests protein and/or lipoprotein aggregates
contaminating the “standard” product. This confirms the inclusion of non-exosomal
materials in the commercial exosome standard stock as suggested in the TEM
micrograph, which is not surprising given that the material is isolated by UC. This
observation is not unique to this study, as issues with MV and non-sEV materials being
included in commercialized exosome standard products have been previously observed
[58]. This reiterates the need for standardization and regulation of exosome products, the
delivery of high-purity materials, and requirements for accurate nomenclature marketing
to be employed. The NTA–determined size distributions present a wide diversity of
recoveries or at minimum measurement environments. For example, the comparison of
the distributions of the two C-CP tip isolates is very telling. Two very distinct
populations are seen in the case of the acetonitrile-modified elution system, the
“expected” one at ~ 100 nm and the much smaller one at ~ 2 × the diameter. On the other
hand, the glycerol-based isolate shows a very broad distribution of sizes, with subpopulations at ~ 60 and 120 nm. As the same immobilization chemistry is employed, the
differences here may reflect the two organic environments. It would not be hard to
postulate that the smaller size could be glycerol globules, with perhaps the larger being
EVs that are solvated in glycerol to yield larger sizes. The melding of the two populations
perhaps reflects the high viscosity of the solvent.
Just as the two tip isolates exhibit differences in the size of the recovered EVs, the
two polymer kit approaches also reveal differences in this regard. In the case of the
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exoEasy kit, one can readily interpret a population of protein aggregates of ~ 75 nm and a
broad EV population ~ 100–180 nm. In addition, ~ 15% of the particles exist in a size
fraction from 275 to 300 nm. In the case of the ExoQuick process, a number of distinct
size populations are seen, which can likely be attributed to different EV classes, protein
aggregates, and perhaps vesicle-protein complexes. To be clear, these distinct groups may
be shifted/merged in different measurement cycles. Ultimately, while very different in
profile, the two polymer precipitation methods yield similar “average” particle sizes
of ~ 130 nm. Finally, the NTA size distribution of the EVs isolated via UC again shows a
variety of size groupings, but with much broader population breadths than the one seen
for the ExoQuick data. That said, it is clear that there are families of protein aggregates,
likely isolated EVs, and species that are either vesicle or vesicle-protein aggregates. As
cautioned above, while the results of these NTA analyses suggest that all of the methods
yield particles of the anticipated size range of exosomes, with contributions from
proteinaceous material present in most, the profiles are still subject to interpretation and
presuppositions. That said, the NTA profile of the C-CP tip isolates using acetonitrile as
the organic modifier most clearly represents eluates composed predominately of EVs,
with little to no contributions from protein impurities as suggested in MS proteomics
analyses [42, 48].
4.3.4 Recovery Assessment via Indirect Enzyme-Linked Immunosorbent Assay
While physical methods of TEM and NTA are valuable components of the EVs
characterization toolbox, they must be complemented by bioassays to confirm that
vesicles/particles are indeed EVs. To confirm the presence of EVs and assess biomarker
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activity of EVs recovered by the employed isolation method, indirect ELISAs to the
CD81 and CD63 tetraspanin proteins were used. The CD81 and CD63 transmembrane
proteins are cell membrane structural components commonly associated with the
trafficking and compartmental organization of EVs during their biogenesis through the
proposed MVB-mediated endosomal pathway.[61] The antibodies to the CD63 and CD81
proteins were used in this study to confirm the presence of active EVs. The commercial
exosome standard stock and the EVs recovered from the various isolation methods were
evaluated (in triplicate) by ELISA.
As shown in Fig. 4.4, a significant antibody response is observed for both the
CD81 and CD63 tetraspanin proteins from EVs originating from the commercial
exosome standard stock and in the EV recoveries from urine after processing with all five
isolation methods.

Figure 4.4: Indirect ELISA for identification of the CD81 and CD63 tetraspanin EV marker in the
commercial exosome standard and EVs recovered from urine by the C-CP tip (acetonitrile and glycerol),
exoEasy, ExoQuick, and ultracentrifugation methods. All samples applied in triplicate and the average of
the triplicate measurements minus the average response of the blank are presented.

117

It is critical to point out that the isolate aliquots employed in the assay were of the
same volume across the methods and were sampled from the same isolates as the
concentration determinations. Thus the values determined by both assays should provide
a level of comparability. The CD63 and CD81 proteins were readily detected in the
commercial exosome stock, with an approximately 2X higher response for CD81 than
CD63. The EVs recovered by the C-CP tip method using the glycerol solvent resulted in
the highest ELISA responses for both the CD81 and CD63 proteins. This result is not
surprising given that this is the sample having highest EV concentration, as depicted in
Fig. 4.2. High concentrations of glycerol have previously been reported to decrease the
overall performance of antibody-based immunoassays, specifically in cases of ELISAs,
by interfering with the mechanisms of antibody binding.[50,51] But even with this
potential cause for diminished antibody activity (and therefore ELISA response), the
addition of the solvent removal step using the centrifugal filter to remove the latent
glycerol allows for a sufficient ELISA response to be obtained and tetraspanin targets in
the C-CP tip eluates to be detected. Based on the respective EV concentration
determinations (Fig. 4.2), the slightly reduced response seen for the C-CP tip method
employing the acetonitrile organic modifier falls nicely in line. What may be somewhat
surprising is the fact that the ELISA responses for the polymer precipitation and UC
methods are very much on par with the tip methods, though the determined EV number
densities were higher in the tip isolates by a factor of 2-4. The disagreement here, while
certainly not out of line based on the accuracy of the assays (the precision for the
triplicates is quite good), may be due to carryover of “free” tetraspanin proteins (i.e., not
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EV associated) in those approaches. This is not surprising as it has been shown that UC,
for example, causes rupture of urine-derived vesicles during the isolation process.[62]
Even so, based on the starting material volumes (200 µL vs. 8-45 mL of urine), the EV
recoveries, based on ELISA determinations, is still a factor of 50-250 higher in
comparison to the commercial kit and UC approaches.
4.3.5 Purity Assessment Based on Ratio of EV Concentration per µg Protein Determine
via BCA
BCA determinations of total protein content are common across many biological
matrices and media. The basic premise of the assay is based on the amino acid content as
reflected in the absorbance measurement. In the present case of urine (and most
matrices), a BCA analysis will reflect the free protein content but will also register
positive results based on the amino acid/proteins present on the surface of EVs. As stated
previously, the ‘purity’ of an exosome isolate relates to any free protein carryover (e.g.
serum proteins or lipoproteins). Therefore, as a measure of the isolate purity, the total
concentration of EVs as determined by absorbance was compared to the protein
concentration of the EV eluate as measured using a microBCA assay, a commonly used
measure of EV purity.[63] Thus, what is desired is a large number of EVs versus a low
total protein value, presented in the units of numbers of EV per microgram of total
protein (EV µg-1). Presented in Fig. 4.5 are the determined “total” protein concentrations
of the exosome standard and those for the urine isolates by the respective methods.
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Figure 4.5: A microBCA assay was employed to determine the concentration of total protein in the
exosome standards and EVs isolated from urine using the C-CP tip (acetonitrile and glycerol), exoEasy,
ExoQuick, and ultracentrifugation methods. The concentration of EVs was compared to the total protein
content as a measure of EV purity. All samples applied in triplicate and the average of the triplicate
measurements minus the average response of the blank are presented.

What is desired here are low values of protein in isolates. As would be
anticipated, the raw exosome standard and the UC method of isolation yield the highest
protein values. The protein content of the recovery from the kit-based isolates are a
factor of 4 – 8X lower, with those of the spin-down tip isolates being a factor of 3X
lower, still. Thus, the C-CP tip urine EV isolates have a much lower protein content than
the other methods.
As noted, the critical metric is the ratio of the number of EVs per unit volume
versus the protein content for the same volume. As anticipated based on previous MS
proteomic evaluations, [42,48] Fig. 4.5 confirms that the EV recoveries having the
highest purity were those from the C-CP tip isolation methods, with 1 - 2 x 1011 EVs μg-1
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of total protein. On the other hand, a factor of 10X lower levels of purity are observed in
the exoEasy and ExoQuick polymeric precipitation techniques (2 x 1010 EVs μg-1 of
protein), and the lowest EV purity (8 x 109 EVs μg-1) observed in the EVs from the
ultracentrifugation-based isolation method. As would be anticipated, the low purity of the
exosome standard source was confirmed here with only 3 x 109 EVs μg-1 of protein, on
the same order of magnitude as the UC urine isolate. Based on this purity assay, the EVs
isolated using the C-CP tip glycerol method were found to be most pure in comparison to
all other isolation methods employed here. Further, this purity assay confirms the ability
of the C-CP tip method to provide highly pure vesicle preparations, providing values very
much higher than the literature recommendation of EV-to-protein ratios of >3 x 1010
particles μg-1of protein. [63,64]

4.4 Conclusions
The novel capillary-channeled polymer fiber spin-down tip method has been
demonstrated here as a more efficient means of EV isolation in comparison to the
traditionally used ultracentrifugation and polymeric precipitation kits. As the first point
of practical relevance, the C-CP fiber tip method requires human urine volumes of only
200 µL for the assays employed here versus volumes ranging from 4 – 45 mL. Second,
the spin-down processing is readily performed on a tabletop centrifuge, with 12 samples
completely processed in less than 15 mins. Third, the C-CP tip method can be adapted to
either the acetonitrile or the glycerol elution solvent systems, enabling efficient isolations
to be tailored to the downstream analyses of the recovered vesicles, e.g., acetonitrile for
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further MS proteomics analysis. Fourth, though not yet commercially available as a “kit”,
the commercial purchase of the materials required for C-CP tip processing of EV-rich
samples (fibers, tips, etc.) is < $5 per spin-down tip. Finally, as applied to urine-derived
EVs, the method produces EV recoveries of > 40X higher concentration and > 10X
higher purity than the other methods. The EVs collected by the C-CP tip isolation
methods will allow for the isolation of EVs from a full range of relevant biofluid samples
(urine, plasma/serum, milk, seminal fluid, culture, media, etc.). Indeed, while the initial
concentration of EVs will vary with the matrix, each tip has a capacity of >1012 EVs.
This novel isolation method will enable more comprehensive EV assessments of clinical
and fundamental significance to be performed with higher efficiency – towards the end
goal of non-invasive diagnostics based on the analysis of EVs. Of course, larger numbers
of EVs can be secured by the use of the C-CP fiber columns implemented on
conventional liquid chromatography platforms. [43-45] Indeed, the methodology can be
readily scaled up for applications where EVs are cultured for use as therapeutic agent
vectors, following a comprehensive assessment of the long-term EV stability in the
elution solvents employed here.
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CHAPTER FIVE
FACILE, GENERIC CAPTURE AND ON-FIBER DIFFERENTIATION OF
EXOSOMES VIA CONFOCAL IMMUNOFLUORESCENCE MICROSCOPY USING
A CAPILLARY-CHANNELED POLYMER FIBER SOLID-PHASE EXTRACTION
TIP

5.1 Introduction
The concept of the liquid biopsy, wherein a readily accessible biofluid is used to
harvest relevant biomarkers versus the excision of tissue specimens, is moving towards
realization.1,2 Crucial treatment time is often lost in early instances of infection, tumor
growth, and disease progression simply because of the lack of efficient, early detection,
diagnostic tools. Particularly in the case of aggressive cancers like ovarian cancer (OC), 3,4
much time is lost due to the inability to identify malignant ailments non-invasively, as
many cancers are asymptomatic during early stages of disease.1,5 The introduction of
accessible, non-invasive methods for disease detection would open the door for a head-on
approach to clinical diagnostics. Taken a step further, this would allow routine screenings
for diseases such as OC to become commonplace. This would drastically increase patient
survival rates by identifying cancerous instances prior to the presentation of noticeable
symptoms.
Exosomes are 30–150 nm-sized, cell-derived extracellular vesicles (EVs) released
from most cell types by multivesicular bodies (MVBs) uniquely created through the
endosomal pathway,6,7 allowing them to consist of origin-representative genetic and
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molecular cargoes. Exosomes are essential elements in cell-to-cell communication,
disease progression, cancer metastasis, tumor growth, and other physiological
processes.6,7 Because exosomes contain molecular constituents of their host cells,
including DNA, microRNA, and biomarker surface proteins, they are a treasure trove of
biomarkers. Likewise, as they are present in many bodily fluids, including urine, blood
serum and plasma, saliva, and in cell culture media, they can be harvested to assess the
status of the biosystem. Importantly, mother cell-derived exosome surface proteins allow
for the identification of the originating environment without direct contact to the primary
area of concern (i.e., tumor or infection site).8,9 Profiling of genetic material from the
interior of disease-derived exosomes allows for monitoring of disease progression and
perhaps treatment effectiveness. To that end, liquid biopsies based on the biomarker
analysis of exosome cargoes from readily available biofluids have been investigated. 2,10,11
An issue limiting exosome-based biochemical research and their implementation
in diagnostics is the lack of efficient tools to isolate the vesicles. Exosome isolations have
proven to be a challenge due to their relative size, protein affinity, and innate
heterogeneity in size and surface protein makeup.1 Though many techniques are widely
used, i.e., ultracentrifugation (UC), density gradient centrifugation, size exclusion
chromatography, microfiltration, affinity isolation, and polymer precipitation,12,13 all
available isolation methods present concerns regarding purity and recovery efficiency.
Because these techniques rely on the density, size, or affinity for antibodies to specific
proteins, purification of exosomes from free protein or lipoprotein aggregates is
particularly challenging.4,14 Many of these isolation techniques require expensive, time-

136

consuming, and tedious processes, and still produce impure, low yield recoveries,
limiting the ultimate progress of the study and use of exosomes. Another limiting factor
in the clinical arena is the required primary sample volume, often a few milliliters of the
original biofluid. To reduce these sample volume requirements, several microfluidic
approaches for EV isolation have been recently explored, using immunoaffinity capture,15
nanoporous membrane sieving,16 and physical EV trapping17 (via nanowires/micropillars)
approaches. Despite reductions in applied sample/reagent volume, concerns of purity and
yield remain, especially since pre-concentration steps using the common EV isolation
methods (e.g., UC) are still required.18
In the realm of EV biochemical assessment, few methods are available for
simultaneous imaging and EV biomarker characterization; all fall short in providing both
on the same platform. The ExoView R100 (NanoView Biosciences, Boston, MA, USA)
is a recently-introduced EV analysis method, consisting of an immunoaffinity capture
array chip and interferometry imaging module – designed to assess EV size and surface
biomarker content. In theory, this technique would allow for simultaneous insight into the
size and tetraspanin compositions of an EV population. However, with the relatively high
limits of detection (3.94 × 109 particles per mL) and low specificity of the
immunoaffinity capture chip,19 EV pre-purification steps are required. Hence, the
challenges faced by impure EV recoveries obtained using the above-mentioned isolation
methods remain. Ultimately, while small volumes of material are subjected to these sorts
of assays, the volume of the primary sample is not reduced. The introduction of an
isolation method to provide highly concentrated, biologically-active, and pure EV
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populations fit for immunological assessment methods, from minute (μL) initial sample
volumes, is of much interest. The future of exosome-based clinical and diagnostic
applications relies on the implementation of timely, yet efficient exosome isolation and
screening methods, able to be tailored to a diversity of relevant biomarkers.
Demonstrated here is a method for rapid EV isolations using a hydrophobic
interaction chromatography (HIC) immobilization/purification process and the
subsequent immunofluorescence (IF) labeling of exosomes based on their surface marker
proteins; on a singular platform. This is done using a capillary-channeled polymer (C-CP)
fiber stationary phase and a solid phase extraction (SPE) spin-down tip process. The
generic capture of EVs is driven by the HIC solvent system, wherein ionic species and
proteins are sequentially removed from the host matrix, allowing exosome isolations
from diverse biofluids and culture media.20–22 The capture and sequential release of free
proteins and EVs are induced by a solvent change from high (2M (NH 4)2SO4) – to – zero
salt content in either continuous or step gradient workflows. The method's efficiency has
been demonstrated in protein and exosome separations on C-CP fiber columns via
HPLC20–22 and by SPE on spin-down tips.23,24 Overall, the process has proven to provide
high EV yields (up to 1 × 1012 EVs per mL) and extremely low concomitant protein
content (<0.5% lipoprotein carryover in serum),25,26 on time scales of less than 10 min,
without any other form of pre-isolation. While no direct comparisons have been made,
the SPE tips have yielded total exosome binding capacities of ∼8 × 1011 EVs from
commercial standards,23 while the 30 cm columns more fitting for downstream
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processing have shown capacities ~5 × 1012 for the far more complex, direct cell milieu
purification.22
In this demonstration, EVs from different sources are captured and retained on the
fiber surfaces, contaminating host cell proteins (HCPs) are eluted, and the exosome
isolates are subjected to immunolabeling and on-fiber identification via confocal
fluorescence microscopy. Specifically, exosomes are visualized by fluorescent antibody
tagging of the ubiquitous CD81 tetraspanin surface protein and the CA125 protein, a
biomarker previously identified as being common to OC.27,28 Other tetraspanins such as
CD9 and CD63 have been identified in isolated EVs; however, their contents are highly
variable. CD81 is of most prevalence and interest in the populations under study here, as
CD81 is also reported to be overexpressed in cancerous EV populations.29,30 EVs
originating from known cancer cell lines and patients are readily distinguished from those
where OC (or other gynecologic ailments presenting CA125) are not anticipated. In the
first demonstration, fiber-immobilized exosomes are processed using standard IF
incubation protocols prior to imaging analysis. In this instance, the primary benefits lie in
the ability to remove potentially-interfering HCPs and performance of in situ imaging,
albeit on much shorter time scales than other methods. Confocal microscopy provides for
IF screening on the single-vesicle level. In the subsequent demonstration, a more rapid IF
processing concept is broached, wherein EVs are efficiently captured, immunolabeled,
and imaged in under 5 hours (a 3× reduction in processing time). The novelty of this
work lies in the ability to isolate, purify, immunolabel, and image EVs on a single
substrate. While confocal microscopy may not be practical for clinical screening, the
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rapid, high purity isolation, followed by IF analysis on a single platform, points to
significant advances in exosome processing, regardless of the subsequent mode of
characterization, biomarker identification, and quantification.

5.2 Experimental
5.2.1

Chemicals and reagents
In order to demonstrate the concept of exosome capture and differentiation via

immunofluorescence labeling and imaging techniques, EVs were isolated from distinct
sources. One example of a generic, non-cancerous source was a cell culture of
Dictyostelium discoideum (D. discoideum, a soil-dwelling amoeba), AX2 cells, which
were obtained from The Dicty Stock Center (Northwestern University, Chicago, IL,
USA). The D. discoideum cells were grown and maintained axenically in HL5 medium
supplemented with 100 g mL-1 ampicillin at room temperature in 25 mL culture flasks.
Likewise, HEK293 (human embryonic kidney) cells obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA) were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% exosome-depleted fetal bovine serum
(FBS), and 1% penicillin/streptomycin in a standard humidified incubator at 37°C with
5% CO2. As an example of an exosome sample derived from a representative human
biofluid source, a commercial exosome stock was obtained (HansaBioMed, Tallinn,
Estonia), consisting of a urine-derived exosome isolate from supposedly healthy subjects
was employed. The example sources that should definitively present biomarkers for OC
were the IHOE (immortalized human ovarian epithelial), SKOV-3 (human ovarian
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adenocarcinoma), and CaOv-3 (human ovarian adenocarcinoma) cell lines. The IHOE
cell line was obtained from Applied Biological Materials (Richmond, BC, Canada) and
the SKOV-3 and CaOv-3 cell lines were obtained from the ATCC (Manassas, VA, USA).
The IHOE and CaOv-3 cells were grown in DMEM, and the SKOV3 cells were grown in
McCoy’s 5a media. All of the aforementioned ovarian cell lines were supplemented with
10% exosome-depleted FBS and 1% penicillin/streptomycin and cultured in a standard
humidified incubator at 37°C with 5% CO2. Finally, the practical (clinical) efficacy of the
method was demonstrated in the extraction and immunofluorescent assay of exosomes
derived from a urine sample obtained from an unidentified patient currently under
treatment for OC.
Ultra-pure ammonium sulfate and biotechnology-grade glycerol were purchased
from VWR (Radnor, PA, USA). Bovine serum albumin (BSA) was purchased from
Sigma-Aldrich (St. Louis, MO USA). Phosphate-buffered saline (PBS, 0.067 M (PO4),
pH 7.4) was obtained from ThermoFisher Scientific (Waltham, MA, USA). The VWR®
Symphony™ 4417/R table-top centrifuge (Radnor, PA, USA) was used for SPE spindown tip processing. A mouse monoclonal antibody to CD81 (1 mg mL-1) was obtained
from Santa Cruz Biotechnology (Dallas, TX, USA). A rabbit monoclonal antibody to
CA125/MUC16 (1 mg mL-1) was obtained from ThermoFisher (Waltham, MA, USA). A
goat anti-rabbit IgG (H+L) cross-adsorbed secondary antibody (Alexa Fluor 488, 2 mg
mL-1) and a goat anti-mouse IgG (H+L) cross-adsorbed secondary antibody (Alexa Fluor
647, 2 mg mL-1) were obtained from ThermoFisher Scientific (Waltham, MA).
5.2.2

C-CP fiber spin-down tip SPE procedure
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The exosome isolation and on-fiber immunofluorescence labeling steps are
depicted diagrammatically in Fig. 5.1.

Figure 5.1: Graphic depiction of the on-fiber exosome extraction and immunolabeling process.

The isolation method, to the point of presenting purified EVs on the fiber surface, was
executed as described previously,24, 25 with the initial labeling and imaging procedures
following what is normal in the fluorescence immunoimaging field.26 Following the basic
demonstration of the methodology, efforts towards more rapid on-fiber processing were
initiated.
The polyester (PET) SPE tips were prepared as previously published24 using an
eight-rotation loop of PET fibers (a total of 448 fibers) collinearly pulled through 30 cm
of 0.8 mm ID fluorinated ethylene polypropylene (FEP) polymer tubing (Cole Parmer,
Vernon Hills, IL, USA). The fiber bundle hanging from the end of the 30 cm piece of
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FEP tubing was pulled and repeatedly cut to create 1 cm fiber-packed tips with a 0.5 cm
open space for attachment to a 200 L micropipette tip (Fisherbrand, Waltham, MA).
During spin-down processing, the fiber stationary phase was attached to a 200 μL
micropipette tip using super glue and placed inside a 1000 μL micropipette tip
(Fisherbrand, Waltham, MA) to provide structural support. The spin-down tip set-up was
held in place within a 1.5 mL microfuge tube cut laterally, then placed inside of a
hollowed center cap of a 15 mL centrifuge tube. The C-CP fiber tips were conditioned by
washing with water, acetonitrile, and the starting mobile phase solution before
application.
5.2.3

Exosome SPE immobilization
The isolation of EVs from the test matrices was accomplished by first mixing 100

L of the sample supernatants with 100 L of 4M ammonium sulfate to achieve a 2M
final concentration before being applied to the tip. The total volume (200 L) of the
sample loading mixture was applied to the PET C-CP fiber SPE tip and centrifuged at
300 x g for 60 s. Under these conditions, salts and low molecular weight polar species
pass through the tip, while proteinaceous materials and vesicles were retained on the fiber
surface. The elution of free proteins and protein aggregates was induced using a mobile
phase of 1M (NH4)2SO4 in 25% glycerol (200 L, 300 x g, 60 s). Before beginning the
immunolabeling process, the fiber surface was further washed five times with 200 µL
aliquots of PBS (300 x g, 60 s each, 15 min. incubation, 3 buffer changes). For the
STEM imaging, the captured exosomes were fixed and imaged directly on the fiber
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surface after the protein elution step and after release from the fiber surface using 50%
glycerol (200 L, 300 x g, 60 s) upon fixation to a silica wafer, as described in Appendix
B.
5.2.4

Immunolabeling and Imaging
The initial demonstration of the exosome differentiation via immunofluorescence

microscopy employed what would be termed a standard labeling protocol.26 In brief,
after the sample HIC capture step, the fiber-captured vesicles were washed with PBS and
incubated with 5% BSA before and after primary antibody incubation overnight, and
incubation of the secondary antibody for 2 hours. That procedure, based on a limited
amount of optimization of the antibody concentration and incubation times, is detailed in
ESI. An alternative, higher throughput method was investigated as a means of expediting
the labeling process. After the tip capture process, the immobilized and washed exosomes
were exposed to a 5% BSA blocking solution in PBS (5 times, 200 L ea. 300 x g, 60 s
ea.) and allowed to incubate in 1 mL of blocking solution for 15 min. to decrease
potential non-specific binding between the antibodies to target the exosomal surface
biomarkers as well as the PET C-CP fiber surface. Following the blocking step, the fiber
surface was washed three times using 200 µl aliquots of PBS and allowed to wash in 1
mL of PBS on a shaker for 15 min (3 buffer changes). Next, antibodies (1:1000 in PBS)
to the CD81 EV marker protein (mouse) and CA125 (rabbit) biomarker protein were
applied to the fiber-captured vesicles (200 L), allowed to wick down the fiber tip for 5
minutes, then placed in the centrifuge for a spin-down at 150 x g for 3 min before
incubation in 1 mL of antibody (2 hours, RT). The blocking step was repeated (5 times,
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200 L, 300 x g, 1 min each, 15 min., RT), followed by another PBS wash (5 times, 50
L, 300 x g, 1 min each, 15 min, RT) to reduce non-specific binding. After this blocking
step, more centrifugal force was required to allow the solutions to pass through the fiber
tip due to the stationary phase surface saturation. The primary antibody-labeled exosomes
on the tip surface were then exposed to AlexaFluor 488 (anti-rabbit) and Alexa Fluor 647
(anti-mouse) secondary antibodies (1:1000, 200 L, 500 x g, 3 min) and allowed to
incubate in 1 mL of antibody for 1 hour at room temperature. With the addition of the
secondary antibody, the solution was allowed to wick down the fiber surface, like
previously done with the addition of the primary antibody (200 L, 5 min), then spun
down using the table-top centrifuge (500 x g, 5 min), and allowed to incubate in 1 mL of
solution (1 hr, RT). Finally, a PBS wash (5 times, 200 L, 1,500 x g, 1 min ea, 15 min.)
was used to remove unbound secondary antibodies from the fiber tip before confocal
microscopy imaging. This entire process is completed in less than 5 hours (with multiple
samples processed in parallel) but is by no means rigorously optimized at this point. To
be clear, the presented confocal fluorescence approach is not directed at direct antigen
quantification. However, the presence of disease states are qualitatively assessed
(screened) based on the comparison of the fluorescent images from “healthy” (HEK293,
Dictyostelium discoideum) and CA125 protein-upregulating EV sources (SKOV3, CaOv3). Among other limitations discussed subsequently, without the ability to apply
specimen-specific reference material controls in parallel during this experimental
workflow, a quantitative microscopic approach remains a challenge. That said, multiple
previous efforts have demonstrated the ability to employ simple optical absorbance
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detection to quantify the total EV content from very diverse biological and culture
media.3, 4, 24, 25, 27, 28 Those methods have been validated through use of diverse
quantification modes (e.g. direct response functions and standard addition) as well as the
common standard, nanoparticle tracking analysis (NTA).
To perform the confocal imaging, the PET C-CP fibers (with the immunolabeled
exosomes on the surface) were removed from the FEP tubing and placed in one chamber
of a 2-well Nunc Lab-Tek Chambered cover glass with a No. 1 borosilicate glass bottom
(ThermoFisher Scientific, Waltham, MA). Optimized excitation wavelengths of 499 and
653 nm were chosen using the Leica Dye Assistant and used to visualize the CA125 and
CD81 antigens, respectively, during the confocal imaging using the Leica SP8 confocal
microscope. All microscope settings, including the white light laser intensity and power,
gain, offset, pinhole, and frame count, remained consistent for the confocal imaging.
With this, the localized fluorescence was used to identify specific biomarker protein
antigens on the captured EVs. It is important to note that due to the optical resolution
limitations of the confocal microscope, it is possible that the vesicles observed as the
CD81 and CA125-positive species captured on the C-CP tip may not be individual EVs,
but instead, a collection of vesicles in very close proximity, creating the collective
fluorescent immune response.
Clean C-CP fiber tips (without the exposure to the EV solution) were run in
parallel during the two isolation and immunolabeling protocols to serve as relevant
negative controls and are presented with the relevant diagnostic images, herein.
Additionally, negative control imaging experiments were carried out using the standard
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antibody labeling protocol, inclusive of fluorescent imaging of blank fibers, purified
CD81 protein exposed to the native fiber surfaces, and a CD81 protein-antibody complex
exposed to exosome-immobilized fibers. The latter two situations illustrate the freedom
from non-specific binding of the proteins (and subsequently their antibodies) to the native
fiber surfaces as well those subjected to the exosome immobilization step. These
essential results are included as Figs. B-1a-c.

5.3 Results and Discussion
5.3.1

Confirmation of Exosome Physical Integrity
To confirm the capture and release of intact vesicles on the C-CP tip surface

during the course of the HIC workflow, SEM imaging was performed directly on the
surface of the fiber tips as well as on eluted particles. The electron microscopy techniques
were employed to investigate the morphological nature and structural integrity of the
exosomes captured on the C-CP tip surface. EVs were imaged after fixation, dehydration,
and negative staining (as described in Appendix B). The SEM images revealed the
vesicles' intact morphology on the stationary phase and highlight the channeled structure
of the C-CP fibers, affecting highly efficient EV binding. Fig. B-2a presents an SEM
micrograph of the commercial-sourced, human urine-derived exosomes bound to the
fiber surface after the HIC workflow to the point of the protein wash using 25% glycerol
and PBS. As seen, the vast majority of the EVs captured on the fiber surface fall under
the 150 nm size cut-off for exosomes and display their expected spherical shape. The
visually smooth fiber surface is reflective of the efficient removal of media components
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b)

and host cell proteins, as needed for high fidelity imaging or chemical characterization.
a)
To observe the integrity of the EVs after they are fully processed, the complete spindown tip method was performed, with the eluted vesicles deposited onto a silica wafer for
STEM imaging. Just as an efficient capture of EVs is essential, the release of pure and
biologically relevant populations of EVs is vital for further downstream processing,
whether for further characterization or biological testing. The STEM micrograph
presented in Fig. B-2b provides a magnified view of the exosomes, wherein it is clear that
the vesicular structures (as evidenced by the “rings” on the periphery) are indeed retained
following complete C-CP fiber tip processing. Because the aim was to capture, retain,
and characterize the EVs directly on the fiber tip surface, the vesicles were not
2X
1X
subsequently eluted from the stationary phase as demonstrated in previous works.24, 25
However, the ability to capture and release of cell-derived EVs (in the exosome size
range) using this C-CP tip method was confirmed using nanoparticle tracking analysis
(NTA). As shown in Fig. B-3, the NTA size determinations revealed that >93% of the
EVs recovered from 100 µL of HEK293 cell culture milieu, fell within the 30 – 150 nm
size range (100.1 nm average diameter, 5.6 x 1010 particles mL-1). This confirms the
ability to capture and release highly concentrated, structurally-preserved exosomes using
the C-CP tip method.

5.3.2

Differentiation of Exosome Types using a Standard Immunolabeling Protocol
The ability to differentiate exosome populations via on-fiber immunofluorescence

imaging is demonstrated in Fig. 5.2.
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b)

Figure 5.2: Confocal fluorescence images of C-CP fibers from process blank and test specimens following
standard immunolabeling procedure. Red color depicts presence of the CD81 tetraspanin protein on
exosome membranes, with green color representing the presence of CA125.

The fluorescence micrographs encompass the process negative control (blank) and the
four EV sources, with the two distinct surface biomarkers probed in situ. It is important
to point out that the scales of these images equate to only a couple of channels of a single
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fiber, making up a very small fraction of the full SPE tip. In this example, the tetraspanin
CD81, which is fairly ubiquitous among all EV populations, is used as the benchmark
exosome identifier and thus is a positive indication of the vesicles. The target for this
analysis is the presence of the CA125 protein, which is one of the primary cancer
antigens associated with OC.29, 30 To be clear, CA125 is not solely related to OC, as it is
also known to be associated with other cancers.31, 32 The images presented in Fig. 5.2
provide confirmation of the presence/location of EVs based on the CD81 (red) responses
and those which have CA125 (green) present on the vesicle surfaces (taken
simultaneously), following the overnight immunolabeling protocol. The third column is
an overlay of the respective responses, providing a correlative verification of the presence
of these antigens in close proximity, presumably associated with a given exosomal
particle.
Going through the exosome sources, the immunofluorescence method yields the
anticipated results in each case, along with some unanticipated ones. In the case of the
non-mammalian D. discoideum amoeba, the imaging only yields positive results towards
the CD81 tetraspanin moiety. D. discoideum have previously been reported to contain
active homologs to the CD81 EV tetraspanin protein, 33 this is further confirmed here. The
commercially-sourced sample derived from the urine of supposedly healthy individuals
provides positive responses for CD81, but perhaps not anticipated is the fact that some
positive responses for CA125 are seen as well. Indeed, the overlay reflects the
coexistence of the two proteins on many particles. High levels of CA125 are often
released in the body during states of ovarian-related ailments (i.e., endometriosis or
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ovarian cancers), but healthy women also express low levels of CA125.34 Thus, while
CA125 is clearly present on the isolated exosomes, this is not a direct indication of OC
because of the comparatively low fluorescent response. As would be expected, the
isolates from the CaOv-3 cell line are replete with exosomes presenting both the CD81
and CA125 markers. Again the overlay of the fluorescent images verifies the presence of
the same-source exosomes. Finally, the images of the exosomes isolated from the urine of
the anonymous OC patient likewise show a high density of particles whose surfaces are
populated with both CD81 and CA125. In this way, while CA125 is not solely attributed
to OC, it is fairly convincing evidence that a CA125-upregulating source of malignancy
(presumably cancer) is present. As a final comment, it is no coincidence that the isolated
particle densities (as reflected in the CD81 responses) from the cancerous subject sources
appear far higher than the corresponding non-cancerous sources; i.e., the CaOv-3 culture
distributions appear far more dense than the D. discoiduem culture, and the patient urine
yields far more than the “healthy-source” urine. Certainly, no direct quantitative
conclusion can be made here, but it is well known that systems under the stress of disease
exhibit far higher EV production and excretion rates.35, 36 Ultimately, the method
presented suggests a route to a facile, multi-biomarker EV screening and source
differentiation.
It is important to note that, as an extension of the SEM images of Fig. B-2, the
presence of discrete sources of fluorescence on the EV size scale, provides evidence that
the EVs remain intact through the course of the isolation and immunolabeling processes.
Should the vesicles have ruptured in the processing, the corresponding fluorescence
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images would be very diffuse across the fiber surface. Additionally, one might also wish
to extend the imaging methodology to the quantitative determination of CD81 and
CA125, but that would come with many future challenges, including the detailed
characterization of potential non-specific binding, autofluorescence of the fiber substrate,
and indeed the ability to generate analytical EV blanks.
5.3.3

Differentiation of Exosome Type Using a Higher-Throughput Immunolabeling
Protocol
As presented, the method demonstrated above holds particular promise in terms of

the use of minute (100 L) sample volumes, providing high purity isolates on an inert
substrate and ready imaging capabilities, and the possibility to recover exosomes for
further characterization or biochemical study. The advantage of sample processing time
versus other isolation methods is somewhat negated by the typical overnight
antibody/labeling incubation times. As an initial demonstration of the potential to affect
higher throughput in the immunolabeling step, Fig. 5.3 depicts the blank and product
images obtained for various-sourced samples following the 5-hour immunolabeling
procedure detailed above. In this instance, the commercial, human urine-derived
exosomes and a HEK293 culture supernatant are used as presumably CA125-free
samples, with the IHOE and SKOV3 cell lines used as likely CA125-positive sources.
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Figure 5.3 Confocal fluorescence images of C-CP fibers from process blank and test specimens following
higher-throughput immunolabeling procedure. Red color depicts presence of the CD81 tetraspanin protein
on exosome membranes, with green color representing the presence of CA125.
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As seen in the case of the standard immunolabeling protocol, the higherthroughput approach does indeed yield the anticipated results regarding the presence of
the expected biomarkers on the exosome surfaces. Here, the commercially sourced
exosomes (derived from human urine) and the HEK293 cell line supernatant yield
positive results towards the CD81 tetraspanin but little-to-no response towards CA125.
The particles providing response to CA125 show little correlation with CD81 in the
overlays. Admittedly, the CA125 response seen for the commercial specimen here is far
less than the extended incubation time method, which may reflect some sacrifice in
sensitivity towards low-abundance proteins (presumably due to the shorter incubation
time). As depicted in Fig. 5.3, the responses towards both immunolabels (CD81 and
CA125) are dramatically enhanced in density and correlation for the case of the SKOV3
and IHOE cell lines. While not quantified at this point, this result is surely reflective of
the presence of a cancer, with results obtained in less than 5 hours on primary sample
volumes of 100 L. Both metrics lie well in line with what would be desired for a liquid
biopsy. Certainly, an extension of the method to urine specimens and a liquid biopsy, as
in the case of Fig. 5.3, is the target following optimization of the high-throughput
labeling methodology.

5.4 Conclusions
This work has demonstrated a novel platform for the isolation and
immunolabeling of extracellular vesicles, allowing imaging to be performed directly on
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the capture fiber. The HIC capture and immunolabeling of EVs isolated on the C-CP
fibers opens the door for many research, clinical, and diagnostic applications to be
developed. The rapid concentration and classification of exosomal materials based on
vesicle-associated biomarker proteins can be tailored to a variety of diagnostic
challenges. Advantages in the method are first realized in terms of the sample sizes and
the speed and purity of affecting the immobilization. Once isolated, the exosomes’
quantity and identity can be determined by multiple on-fiber and post-elution methods.
In the example presented here, confocal fluorescence immunoassays provide exquisite
sensitivity and specificity, with as few as 10s of EVs being present in the illumination
volume. While this method of determination is not suitable for portable point-of-care
applications, based on instrument cost and complexity, it is certainly appropriate for
many research and clinical laboratories. Further, the biochemical mechanisms of the
work demonstrated here can surely be extended to other, more clinically practical,
detection approaches (i.e., a C-CP lateral flow immunoassay) for the batch processing of
large clinical cohorts on necessary scales of time and cost. Even in the research and
clinical laboratory environments, the potential for further optimization of the highthroughput immunolabeling method would be advantageous. For example, Cappi et al.
have described an automated 4-plex multistaining technique with 15 min. immunolabel
incubation times using horseradish peroxidase (HRP)-labeled primary antibodies with
tyramide signal amplification-Alexa Fluor secondary antibodies.37 A similar abbreviated
EV immunolabeling process is an obvious avenue for future exploration.
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Beyond the on-fiber single particle detection, one can readily imagine less
expensive fluorometric methods applied to the fiber bundles in-mass. Alternatively, onfiber labeling could be followed by exosome release into microliter volumes for solutionphase immunofluorescence assay, again on very short time scales. Rapid isolation and
purification could also be followed by use of conventional dot blot assays, targeting
specific biomarkers. Eluted exosomes could also be subsequently lysed for genetic
profiling of the vesicle contents. Finally, as has been demonstrated using the C-CP fibers
in a column format, the spin-down approach could be readily applied as an isolation stage
prior to mass spectrometric exosome proteomics analysis. Ultimately, this method's main
benefit may lie in its ease of tailoring to capture nanovesicles from various origins,
including viruses, bacteria-derived outer membrane vesicles, lipoproteins, liposomes, and
synthetic nanoparticles.

Electronic supplementary information (ESI)/Appendix B: Experimental details for
“standard” exosome immunolabeling procedure and methods employed, images resulting
from negative control experiments, and images for SEM/STEM confirmation of captured
exosomes.
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CHAPTER SIX
A RAPID CAPILLARY-CHANNELED POLYMER (C-CP) FIBER SPIN-DOWN TIP
APPROACH FOR THE ISOLATION OF PLANT-DERIVED EXTRACELLULAR
VESICLES (PDEVS) FROM 20 COMMON FRUIT AND VEGETABLE SOURCES

6.1 Introduction
It is now becoming clear that in many organisms, intercellular communication
processes are facilitated by nanometer-scale extracellular vesicles (EVs), which contain
host cell-specific proteins, lipids, and genetic content. [1, 2] Though the EV creation and
transport mechanisms are not well understood, EVs are generically classified as apoptotic
bodies, microvesicles, or exosomes, based on their creation pathway and size [3].
Apoptotic bodies are large, 500 – 4,000 nm vesicles formed through the spontaneous
bulging of the plasma membrane during cellular apoptosis [4]. Microvesicles (MVs) are
50 – 2,000 nm EVs formed by the outward membrane budding and fission of the origin
cell’s plasma membrane [5, 6]. Exosomes are 30 to ~200 nm EVs, created through the
multivesicular body (MVB)-mediated endosomal pathway [7, 8]. Due to the overlapping
MV and exosome size ranges, the similarities in content, and the inability to determine
EV origin, the collection of EVs in the exosome size range is often generically referred to
as EVs or small EVs (sEVs). Still, because sEVs characteristically contain the
biomolecular contents of the secreting cell and may be collected non-invasively through
biofluids, this class of EVs has been widely proposed in clinical diagnostic applications
[9, 10] and for large-scale therapeutic vector production approaches [11, 12].
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To date, much of EV research has been performed using EVs sourced from human
patient biofluid samples or from cell culture media, with hopes of assessing the critical
roles these vesicles play in disease prevention and progression [13-15]. Additionally, the
therapeutic application of EVs introduces unique advantages, including the ability to
strategically deliver drug and gene therapies to local tissues of neighboring cells or
distant organs throughout the circulatory system [10, 11, 16]. Since exosomes are cell
secretion products, obtaining concentrated collections of EVs depends upon the ability to
harvest them from large quantities of cell or biofluid sources without significant
alterations to EV structure and/or function. However, with many of the large-scale cell
culture conditions, transformations are often performed within the cell line, which alters
the cellular phenotype, and thereby, the composition and function of the EVs obtained
from these cell stocks [11]. The primary limitations of using mammalian-sourced EVs for
therapeutics are 1) insufficient methods for isolation and characterization preventing EVs
from being fully understood, 2) biocompatibility concerns of the transformed EVs, and 3)
time, capital, and labor-consuming methods for large-scale EV production [16].
As EV vector technologies continue to develop, researchers have begun to explore
alternative, natural sources for EVs to use as novel therapeutic delivery vectors. With
this, a growing body of literature has revealed that several natural EV sources produce
nanovesicles that display many of the exosome-characteristic structural and functional
features. [1, 2] To date, exosome-like vesicles have been discovered in all three domains
of life, including species such as bacteria (outer-membrane vesicles, OMVs), [17, 18]
fungi [19, 20], parasites [21], and plants [19, 22-25]. Still, though the nanovesicles from
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all sources remain poorly understood, researchers have suggested the use of plant-derived
extracellular vesicles (PDEVs) in therapeutic applications because of the prominent roles
they play in the transport of bioactive molecules from plants to human cells [24, 26].
PDEVs have shown to be a promising candidate for use as therapeutic delivery
vectors because of their non-immunogenic traits and potentially cost-effective production
from natural renewable sources [27]. The first examples of PDEVs were identified in
wheat-sourced mesophyll cells by Shaw et al. [28] and carrot sample stocks by Jensen et
al. [29] in the 1960s, even before human-sourced “exosomes” were identified. During the
initial PDEV assessment using electron microscopy, the EV-characteristic size and
structural features were revealed, though not fully appreciated due in part to the recent
emphasis on mammalian EV research [28]. Continued works have confirmed these initial
findings and have shown that PDEVs, like human-sourced EVs, do indeed contain a cellderived lipid bilayer membrane and miRNAs, mRNAs, proteins, lipids, and metabolites
from the originating plant cell [30]. Further, works by Zhang et al. [31] have
demonstrated that the PDEVs obtained from common edible plant sources are actively
endocytosed by macrophages and intestinal stem cells and are able to activate signaling
pathways in murine (mice) cells.
Though little is known about the biogenesis, uptake, release, composition, function,
and stability of PDEVs relative to their mammalian counterparts [24], it is known that
PDEVs contain specific surface marker proteins that are incorporated through the
biogenesis process such as Penetration1 (PEN1) or Syntaxin121 (SYP121) [32-36].
Though there are some differences in function, the PEN1 protein seems to serve a similar
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role to that of tetraspanin proteins (i.e., CD9, CD81, CD63) in human-sourced EVs for
vesicle identification purposes. The PEN1 protein generically functions as a positioning
anchor for the KAT1 K+ channel protein on the plasma membrane and is involved in
biological processes such as endo- and exo-cytosis, intracellular protein transport, and
vesicle docking and fusion [33]. Likewise, the PEN1 protein has been previously found
in high concentrations when PDEVs are present and have allowed for the identification of
PDEVs based on PEN1 protein detection via immunoassays. Alongside PEN1 protein
assessment, the assessment of other biomolecular targets, like lipids and microRNAs,
have allowed for correlations to be made between PDEV composition and function [37].
But further, PDEVs can be modified to provide a means of targeted drug transport to
specific areas where homeostasis regulation is required [37, 38]. Regardless of the many
promising applications of PDEVs (and EVs of all origins), the exact mechanisms of these
interactions are largely unknown and require additional investigation. A recent review
by Rutter and Innes very succinctly lays out the state of the art and challenges in PDEV
research [26]. Additionally, much work is needed to standardize the processing and
characterization of PDEVs before their full implementational impacts can be realized [24,
39].
One of the most limiting factors to the understanding of PDEV fundamentals is the
lack of methods for the isolation of these nanometer-scale vesicles. Several studies have
demonstrated that PDEVs may be isolated from various parts of plants, including plant
juices, [40-42] roots, [43, 44] seeds, [45, 46] and dried plant materials [47]. Most
commonly, fluids from these sample types are obtained through a
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blending/homogenization process and then applied to standard EV isolation protocols
(i.e., ultracentrifugation, UC). Though multiple techniques are available for the isolation
of EVs from mammalian sources, the majority of published works have reported the use
of the ultracentrifugation (UC) method for PDEV sample processing. [27, 30] But as seen
with human EVs, the UC method is likely to produce PDEV recoveries that are
compromised by concomitant matrix species and low yields [48-50]. Overall, the
performance of the available isolation methods does not yield the concentration and
purity of EVs needed for fundamental research, much less therapeutic applications. [26,
27, 51] In a recent review by Innes and colleagues, it was recommended that PDEV
researchers pay close attention to the progression of the EV field, so that the “pitfalls”
and challenges commonly experienced during EV research can potentially be evaded.
[26] For instance, the standardization of relevant isolation and characterization protocols
for EVs and PDEVs is largely lacking. Because EVs are not able to be well
isolated/characterized, they are not able to be well-classified, causing there to be a lack of
field-wide agreement on standard protocols, fundamental structure-function correlations,
and EV nomenclature [39]. These disagreements have been limiting in the mammalian
EV field as a whole, but particularly in the development of exosome/EV standardized
reference materials. With all of these concerns being relevant to PDEV research as well,
it is essential for researchers in the PDEV realm to consider these as the field continues to
progress. Though all of these shortcomings limit the pursuit of novel PDEV therapeutic
approaches, the lack of isolation methods to efficiently provide representative
populations of PDEVs is potentially most limiting to the progression of research [26].
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Hence, the introduction of an isolation method to provide highly pure, concentrated, and
functionally-preserved collections of PDEVs is necessary for the fundamental
characterization of PDEVs to be performed and the therapeutic vector potential to be
explored.
As the potential pitfalls in mammalian exosome isolation are well known, there
are two primary sources of error/contamination in PDEV isolation. The first, is a high
possibility that the populations included in extracts are co-inclusive of vesicles both of
extracellular origin and endosomal vesicles which were released due to the destruction of
plant cellular membranes by homogenization. As an alternative to this destructive
sample preparation method, Innes et al. [23, 25, 26, 35, 52, 53] have developed a protocol
for non-destructive PDEV harvest through the collection of apoplastic wash from
Arabidopsis thaliana plants, where these plant biofluids are employed in UC protocols to
obtain PDEVs of true extracellular origin. The second source of non-targeted vesicles is
the due to possible carryover of EVs originating from plant material having bacteria of
various sorts on their surface. Works by Gourabathini et al. have revealed the presence
of bacterial pathogens in high concentrations in produce stocks obtained from local
grocery stores [54]. These pathogens expel vesicles that settle on vegetable leaves and
aid in the proliferation and survival of these bacterial species on these surfaces [17, 18,
55]. While these EVs would certainly have different surface and cargo makeup from the
PDEVs, their presence would certainly bear on the results of fundamental studies as well
as further use of extracted EV populations in vector applications. Eventually, all
proposed methods of PDEV recovery and use must address these potential challenges.
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Ongoing work by Marcus and colleagues has produced a novel EV isolation
method based on hydrophobic interaction chromatography (HIC) via a polyester (PET)
capillary-channeled polymer (C-CP) fiber stationary phase [56-60]. The C-CP fiber phase
consists of melt-extruded fibers with an 8-legged peripheral shape, creating single-micron
sized channels when collinearly aligned and packed into a column format. The relative
hydrophobicity of the PET C-CP phase and gentle HIC solvent system allows for
effective, vesicle-preserving EV isolations to be performed, where a high-to-low salt
solvent transition drives the capture and subsequent release of EVs based on the vesicle’s
intrinsic hydrophobicity. The straightforward and cost-effective HIC C-CP method was
first performed using a traditional HPLC workflow, where the simultaneous isolation and
quantification of EVs was allowed using on-line absorbance (scattering) detection [56-58,
60]. More recently, the method has been adapted to a clinically practical solid-phase
extraction (SPE) spin-down tip format, where the batch processing of EVs is only limited
by the capacity of the table-top centrifuge [59, 61, 62]. The C-CP spin-down tip method
has demonstrated the ability to produce highly concentrated (up to 1 x 1012 particles mL1),

high-purity (>90% removal of protein/lipoprotein contaminants), and bioactive EV

recoveries from a plethora of biofluids in less than 15 minutes [59, 62-64]. Here, the
capabilities of the fiber spin-down tip method for the isolation of PDEVs from various
plant sample stocks is explored. The recovered PDEVs are evaluated using absorbance
(scattering), multi-angle light scattering (MALS) detection, and transmission electron
microscopy (TEM). The purity of the PDEVs was assessed using a Bradford assay based
on the removal of unwanted free/matrix proteins. The identity of the PDEVs is confirmed
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using antibodies to the PEN1 protein via an indirect enzyme-linked immunosorbent assay
(ELISA), allowing differentiation from bacteria-originating EVs. The methodology
presented here addresses the limitations in isolation hindering the fundamental research
and downstream application of PDEVs, which will enable future studies of therapeutic
relevance to be performed.

6.2 Materials and Methods
6.2.1 Chemicals and reagents - Deionized water (DI-H2O, 18.2 MΩ cm) was
obtained from a Milli-Q water purification system (Millipore Sigma, Merck, Darmstadt,
Germany). Biotechnology-grade glycerol and ammonium sulfate were purchased from
VWR (Sokon, OH, USA). Phosphate buffered saline (PBS, pH = 7.4), bovine serum
albumin (BSA), and Pierce™ Coomassie Plus (Bradford) Assay Reagent were purchased
from ThermoFisher Scientific (Waltham, MA, USA).
6.2.2 Instrumentation - A NanoVue Plus UV-Vis spectrophotometer (GE
Healthcare, Chicago, IL, USA) was used during the PDEV absorbance quantification
(203 nm). The DAWN multi-angle light scattering (MALS) detector (Wyatt Technology,
Goleta, CA, USA) was used for size determination efforts. A Synergy H1 Hybrid MultiMode Plate Reader (BioTek, Winooski, VT, USA) was used to measure the UV-Vis
absorbance (595 nm) of samples in the 96 cell-well format, where the colorimetric
Pierce™ Coomassie Plus (Bradford) Assay Reagent was used for Bradford assay
detection. The Hitachi HT7830 transmission electron microscope (Chiyoda City, Tokyo,
Japan) was used for TEM imaging for EV visualization and structural characterizations.

171

6.2.3 Extracellular Vesicle Sources - Exosome standards employed during the
quantification work were sourced from a commercial lyophilized exosome standard stock
from HEK293 cell culture media by HansaBioMed (Tallinn, Estonia). To clarify, the
“exosome standards” employed here are not standardized EV reference materials, and
with this, no purity or classification metrics were supplied by the manufacturer. However,
the product does serve as an EV source of known concentration (2.7 × 1012 particles mL1).

Concerns with the size (including EVs of < 30 nm and > 200 nm diameter) and purity

(the absence of contaminant matrix species like lipoproteins and other protein
contaminants) of the exosomes included in these materials have previously been
expressed, and this potential avenue for systematic error is acknowledged here.
The raw fruits and vegetables used in this study were obtained from the produce section
of the local Walmart (Central, SC, USA). The produce stocks included in this study were
loosely categorized by type: leafy greens (represented in green font in data sets),
vegetables (represented in red), and fruit (represented in blue). Shown in Table 6.1 are
the plant samples in each category, along with the scientific name of each plant. If
PDEVs from the presented sample stock have been previously identified in the literature,
the size of PDEVs obtained from each, and the employed isolation method used to obtain
such, are also presented in the Table.
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Common
Name

Species Name

Size (nm)

Isolation Method

References

Baby
Spinach

Spinacia
oleracea

-

-

-

Lettuce

Lactuca sativa

-

-

-

Green
Onions

Allium
fistulosum

-

-

-

Cilantro

Coriandrum
sativum

-

-

-

Carrots

Daucus carota
subsp. sativus

150 nm
(Average)

Size-Exclusion
Chromatography

[65]

Roma
Tomato

Solanum
lycopersicum
'Roma'

-

-

-

Beefsteak
Tomato

Solanum
lycopersicum
'Beefsteak'

100 – 1000
nm

Ultracentrifugation,
Density Gradient
Centrifugation, and
Filtration

[42, 66, 67]

Cucumber

Cucumis
sativus

-

-

-

Sweet
Onion

Allium cepa
‘White onion’

113 – 153 nm

Ultracentrifugation

[68]

Red Onion

Allium cepa
‘Red onion’

113– 153 nm

Ultracentrifugation

[68]

Ginger

Zingiber
officinale

50-800 nm
(Average 189
nm)

Ultracentrifugation

[42, 69, 70]

Blueberries

Vaccinium
sect.
Cyanococcus

100 – 800 nm

Ultracentrifugation,
Differential
Centrifugation

[42, 71]

Cherries

Prunus avium

-

-

-
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Red Apple

Malus
domestica 'Red
Delicious'

-

-

-

Green
Apple

Malus
domestica
‘Granny
Smith’

-

-

-

Strawberries

Fragaria ×
ananassa

30 – 191 nm

Ultracentrifugation

[72]

Lime

Citrus ×
aurantiifolia

-

-

-

[66]

Lemon
Juice

Citrus
limon L.

50 – 100 nm

Differential
Centrifugation,
Filtration,
Ultracentrifugation

Orange

Citrus sinensis

100 – 800 nm

Differential
Centrifugation

[42]

50 – 200 nm

Ultracentrifugation,
Ultrafiltration,
Tangential Flow
Fractionation

[73]

Aloe Vera
Juice

Aloe vera
barbadensis

Table 6.2: Scientific name, reported size, and isolation method used for the extraction of plant-derived EVs.
Sample categories: leafy greens (represented in green), vegetables (represented in red), and fruit
(represented in blue).

The raw plant samples were first rinsed with DI water, then chopped into
manageable portions, placed into a weighing boat, and weighed using a standard
analytical scale. For the solid plant samples, 10 mL of Milli-Q water was added, then the
sample was placed in a Magic Bullet™ (Homeland Housewares, Los Angeles, CA)
blender and blended until a homogeneous liquid was obtained. For the difficult-to-blend
samples (ginger, cilantro, carrots, and strawberry), a mortar and pestle were used for
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further sample homogenization. The resulting fluid from each sample was aspirated using
a sterile, 3 mL single-use syringe (with a 21 G x 1 1/2 in. needle attached; BD, Franklin
Lakes, NJ), then filtered using a 0.22 µm PES syringe filter. Finally, 100 µL of the
filtered fluid from each sample was processed through the C-CP tip isolation workflow.
A visual representation of the sample preparation process is presented in Fig. 6.1.

Figure 6.1: Diagrammatic representation of the sample processing workflow for the isolation of plantderived extracellular vesicles (PDEVs) using the capillary-channeled polymer (C-CP) fiber solid-phase
extraction tip and a tabletop centrifuge.

For the already-liquid samples included here (aloe vera juice and lemon juice), the
samples were filtered using a 0.22 µm PES syringe filter before C-CP tip processing.
6.2.4 C-CP Fiber Spin Down Tip Assembly and Sample Processing - The C-CP
fiber SPE spin-down tips were assembled following the previously reported protocols,
and the same HIC isolation workflow was performed [59, 62]. To summarize, 1 cm C-CP
fiber-packed tips (with an additional 0.5 cm of void space for attachment) were cut from
a 30 cm long, 0.8 mm inner diameter fluorinated ethylene–propylene (FEP) C-CP packed
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columns consisting of 456 individual PET C-CP fibers to create an interstitial fraction of
∼0.6, and bed volume of ∼3 μL. The 1.5-cm C-CP fiber-packed tips were press-fit to the
narrow end of a 200 μL low retention micropipette tip and held in place using a small
amount of liquid adhesive around the periphery of the 200 μL tip.
The PDEV isolations were performed as previously described [59, 62]. After
sample processing, 100 μL of the resultant filtered plant supernatant was mixed with 100
μL of ammonium sulfate (2M final concentration) and deposited inside the sample
reservoir of the C-CP tip. The C-CP tip was secured into a 15 mL conical tube using a
tip-modified conical adapter cap, then placed inside the table-top centrifuge tube and
spun at 300 x g (rcf) for 1 minute. The tip-bound EVs were then washed with 200 μL of
PBS (300 x g, 1 min), and the matrix proteins eluted using 200 μL of 25% glycerol with
1M ammonium sulfate in PBS (300 x g, 1 min). Finally, the PDEVs were eluted from the
C-CP tip surface using 50 μL of 50% glycerol in PBS (300 x g, 1 min) into an Eppendorf
tube conical insert.
6.2.5 Absorbance/Scattering Detection – As previous reports have demonstrated,
absorbance (technically, scattering) measurements are a valid means of EV quantification
based on the generation of standard response (calibration) curves using commercial
exosome standard stocks or via the method of standard addition [59, 62]. The two
methods have been compared in detail in previous works for the quantification of EVs in
human biofluids [62]. In this case, the method of standard addition was applied because
of the potential for matrix effects across the diverse plant specimens, which could cause
the absorbance quantification of EVs to be skewed. Across the previous work with
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biofluids, the method was able to overcome the intense sample matrix effects, and the
absorbance quantification of the EVs using the standard addition method was also able to
determine EV concentrations with high precision (<5% RSD) [62]. As done previously,
serial additions of the commercially-obtained exosome standard stock were used to create
a standard addition response curve. In these experiments, the absorbance of each sample
was measured at 203 nm (n = 5) using the NanoVue spectrophotometer. The resulting
linear regression was used to determine the concentration of the recovered PDEVs.
Several recent works have employed multiangle light scattering (MALS)
detection for human EV size determinations [74-76]. Here, the diameters (actually the
root-mean-square (RMS) radii) of the PDEVs of the recovered particles were determined
using the DAWN multi-angle light scattering (MALS) detector (Wyatt Technology,
Goleta, CA, USA), controlled using the ASTRA software. After the C-CP tip isolation
process, the recovered EVs were passed through to the MALS detector cell using a
Dionex (Thermo Fisher Scientific, Sunnyvale, CA, USA) Ultimate 3000 HPLC system
(LPG-3400SD quaternary pump with MWD-3000 UV-Vis absorbance detector), which
was controlled by the Chromeleon 7 software. The experimentally-determined RMS radii
were multiplied by 2 to represent the approximate diameter/size of the PDEVs. For the
entirety of MALS analyses, the refractive index was set to that of 50% glycerol in PBS,
1.4096 (experimentally determined using a Reichert AR7 Series Automatic
Refractometer at 22ºC). Three replicate measurements were collected for each sample in
60-second increments.
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6.2.6 Transmission Electron Microscopy (TEM) – The biophysical characteristics
of the collected PDEVs, including size and shape, were evaluated using a Hitachi
HR7830 TEM. The TEM sample preparation was performed as previously reported [59,
62-64]. Briefly, 7 µL of each EV sample was applied to a copper/formvar grid and
incubated at room temperature for 20 min. before the excess sample liquid was removed.
Next, the EVs were fixed on the grids using 2% paraformaldehyde (RT, 5 min).
Afterward, the excess paraformaldehyde was removed from the grids, and they were
washed with 50 µL droplets of water for 5 min. The grid was then negatively stained
using 50 µL of a filtered 1% uranyl acetate solution (RT, 1 min). After staining, the
excess uranyl acetate solution was removed using a paper towel, and the prepared grid
was again washed with water before being allowed to dry in a desiccator for 30 minutes.
The size of the vesicles visualized in the TEM micrographs was determined using
ImageJ.
6.2.7 Bradford Assay – As stated previously, the removal of matrix proteins is
perhaps the most significant challenge in isolation of EVs, whether for fundamental
studies or in vector applications. The Bradford assay is the classic means of determining
free protein content in diverse media and was used here to assess the presence of free
proteins in the plant sample stocks and the removal of those ‘contaminants’ from the test
solution following isolation of the PDEVs using the C-CP tips. For this, 250 µL of
Bradford reagent was added to 25 µL of each sample stock or the PDEV recovery in a 96
well plate before incubation at room temperature for 20 minutes and absorbance detection
of the Bradford reagent at 595 nm using the Synergy H1 Plate Reader. A standard curve
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using serial dilutions of a BSA solution was used to determine the total protein
concentration of the samples. All samples and standards were applied to the well plate in
triplicate.
6.2.8 Enzyme-Linked Immunosorbent Assay (ELISA) – Analogous to the
identification of mammalian EVs based on the presence of the tetraspanin proteins (e.g.,
CD81), the PEN1 protein serves as a surface marker for PDEVs. A polyclonal antibody
to the PEN1 protein (custom-prepared by CUSABIO, Houston, TX) was employed in an
indirect ELISA assay to confirm both the presence and bioactivity of PDEVs after
isolation using the C-CP tip method. Prior, the tip-isolated PDEVs were applied to a 100
kDa filter unit, and the latent glycerol was removed, as glycerol is known to interfere
with antibody binding [77, 78]. The ELISA protocol was performed as previously
described [61, 62], with samples applied in triplicate. The PEN1 purified protein,
obtained from the manufacturer, was used as the positive control, and the neat EV elution
buffer – 50% glycerol in PBS was used as the negative control. The Synergy H1
microplate reader was used to detect the chemiluminescent response of the HRPcatalyzed oxidation of the detection substrate.

6.3 Results and Discussion
6.3.1 Verification of C-CP Tip Isolated PDEV Structure and Size by Transmission
Electron Microscopy (TEM) - As a complement to other EV characterization methods,
TEM is used to confirm the presence of EVs based on the presentation of the
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characteristic spherical or cup-shaped structure. TEM is used to assess the size, shape,
and vesicular integrity of the PDEVs collected using the C-CP fiber tip method.
Representative micrographs of a) HEK293 EVs from a commercial standard stock, and b)
PDEVs from green onion, c) blueberry, d) ginger, e) strawberry, f) red onion, g) baby
spinach, and h) beefsteak tomato samples are shown in Fig. 6.2.

Figure 6.2: Transmission electron micrographs of commercial EVs from a) HEK293 exosome standards,
and plant-derived extracellular vesicles (PDEVs) from b) green onion, c) blueberry, d) ginger, e)
strawberry, f) red onion, g) baby spinach, and h) beefsteak tomato samples following isolation using the CCP fiber spin-down tip method. The TEM images were taken using the Hitachi HT7830. Scalebar = 100
nm.

The TEM micrographs confirm the presence of vesicles in the sEV size range (<
200 nm) from both the exosome standard stock and the PDEVs isolated from the bulk
plant supernatant, all exhibiting the characteristic spherical, membranous shape. Intact
exosome-like vesicles are visualized, showing the preservation of the membrane integrity
after isolation via the C-CP tip method. Of note, there is little evidence of contaminants
(debris), despite the complexity of the original sample matrices. Individual vesicles are
present in the majority of the samples, but some small vesicle aggregates are observed in
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the micrographs from the green onion, ginger, and beefsteak tomato samples. Still, the
TEM micrographs confirm the presence of 50-200 nm particles with apparent
phospholipid bilayer membranes isolated from the plant extracellular fluids using the CCP fiber spin-down tip.
6.3.2 Size Determination of C-CP Tip-Isolated EVs using MALS - In addition to
TEM sizing of the vesicles, Nanosight nanoparticle tracking analysis (NTA) is commonly
used for size determinations of EVs [79, 80]. However, many reports reveal concerns
with the accuracy of EV size determinations via NTA due to variability/irreproducibility
in size determinations and number densities, and because the method is not able to
differentiate between EVs and large protein aggregates of EV-like size [81, 82]. In order
to address these limitations during the PDEV size determinations, the MALS detection
method has been previously suggested [74, 83, 84].
The average sizes of the PDEVs recovered from each plant sample type as
determined by MALS are shown in Fig. 6.3.
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Figure 6.3: Size determinations of the C-CP tip isolated PDEVs using the Wyatt Dawn MALS instrument.
Presented are the average sizes of the PDEVs resulting from 3 consecutive 60-second runs.

The C-CP tip-isolated PDEVs yield average diameters of 32 – 580 nm across the plant
sample stocks, with an average diameter of 189 nm across all sample types. These PDEV
size determinations align well with the previously-reported diameters as presented in
Table 1 for those plant samples subjected to other EV isolation workflows, and with the
TEM micrographs shown in Fig. 6.2, where the exosome/EV-like size and structure of
the recovered vesicles are shown. The MALS analysis average diameters of the C-CP tipeluted PDEVs are also in line with EVs recovered from human biofluids using the C-CP
tip isolation method [59, 62]. Despite the vast differences in the PDEV sources, the
relative precision of the MALS determinations of average PDEV diameters is remarkable
versus NTA analysis, with less than 5% RSD across the triplicate size determinations of
the PDEVs recovered from each plant source.
6.3.3 Quantification of Recovered PDEVs via UV-Vis Absorbance - The
quantification of EVs from human biofluid and cell culture sources by optical absorbance
at 203 nm has been previously demonstrated [59, 62, 64], using response curves
generated from exosome stock solutions or via the standard addition method. To clarify,
the “absorbance” response observed at the 203 nm wavelength is not accredited to
electronic transitions of individual analyte molecules. More accurately, the absorbance
detection is due to the Mie scattering by the EV nanobodies, which is proportional to the
concentration of EVs in solution. Conveniently, the absorbance spectra obtained for the
PDEVs from all sample types follow the EV-characteristic scattering/absorbance
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responses, where an exponential decrease in absorbance response is observed (200 – 700
nm, λmax = 203 nm).
The EV standard addition quantification method is applied here for the
quantification of PDEVs recovered from the plant sample extracts after isolation using
the C-CP tip method, as shown in Fig. 6.4.

Figure 6.4: a) Numbers of recovered PDEVs using the C-CP spin-down tip isolation method, determined
using the method of standard addition, and b) recovered PDEV concentrations with respect to the mass of
starting material.

Using this quantitative approach, number densities of 1 x 1010 to 2 x 1011 PDEVs were
obtained via processing of only 100 µL of plant sample extracts (Fig. 6.4a). The largest
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numbers of PDEVs were obtained from the beefsteak tomato and red onion samples.
However, as shown in Fig. 6.4b, the PDEVs from the butter lettuce and cilantro samples
were recovered in higher concentrations with respect to starting material mass,
accounting for ~3.6 x 109 EVs per gram of starting material. Alternatively, those PDEVs
obtained from the fruit sample category were approximately 4 times lower with respect to
starting mass, with 8.4 x 108 EVs per gram of starting material obtained on average. At
this point, there is no body of literature suggesting which sorts of species should produce
more or less EVs. There are also aspects of growth conditions, stress, etc. which surely
will contribute to variation within species. Despite the growing body of PDEV literature,
none of the identified previous works have attempted to provide a means of efficient
vesicle quantification, as again the methodologies are sorely lacking. At this point, there
is no way to verify the accuracy of this quantification effort, but the absorbance
quantification-determined values agree with the MALS particle count by plus/minus
10%, based on the flow rate and dilution factor of the PDEVs upon injection into the
instrument. Additionally, in the realm of mammalian EV determinations, the C-CP tip
isolation coupled with absorbance detection has proven to be a reliable approach [59, 64].
6.3.4 Purity Assessment of PDEV isolates via Bradford Assay - Bradford assays
are commonly employed for total protein content determinations in diverse biospecimens
and were used here to determine the concentration of protein in the native plant sample
extracts, then to quantify the removal of the contaminant protein species by the C-CP tip
isolation/purification method. To be clear, there is the expectation that some detectible
proteins would be present in the PDEV isolate solutions, as proteins decorating the
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vesicle shells will register positively via the Bradford assay. Presented in Fig. 6.5 are the
Bradford assay-determined total protein concentrations for each plant sample extract and
their respective PDEV isolate solutions.

Figure 6.5: Total protein content (as determined by Bradford assays) of raw samples and the resulting
PDEV isolates using the C-CP spin-down tip isolation method. All samples were analyzed in triplicate,
corrected for the average response of triplicate blanks.

The Roma tomato, red onion, and cherry sample stocks contained the highest starting
protein concentrations (> 1000 µg mL-1), which intuitively makes sense due to the
original masses of these samples ranging from 45-60 g of starting material, which is in
the upper quartile of mass for the samples employed in this study (average: 35 g, range:
11 to 60 g). Regardless of the significant differences in original protein content, after
processing the plant stocks using the C-CP tip method, the total protein concentrations for
each PDEV extract were reduced by 48-95%. All of the recovered PDEV collections
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resulted in total protein concentrations of less than 100 µg mL-1, which is sufficient given
the high concentration of PDEVs recovered in the assessed fraction, and with precise (<
6% RSD) determinations of the total protein concentration of the PDEV stocks. The
purification of the PDEVs from matrix contaminants based on the decrease in total
protein content is also comparable to that obtained from the EVs purified from human
biofluids [62]. Again, Bradford assays have not been widely employed for the plant or
PDEV stocks, so a point of comparison study comparing the total protein concentration
of plant and PDEV stocks is undoubtedly warranted. It is hypothesized that the high
purity and high yields using the C-CP tip will translate to broad use of the materials for
PDEV isolations in comparison to UC sample processing.
A critical EV purity metric is the concentration of EVs versus the total protein
content with respect to volume in the isolate solutions [85, 86]. In this regard, an EV-toprotein purity ratio of 3 x 1010 particles μg-1 of protein is the metric used to qualify a
population of EVs as “pure” [85, 87]. In comparing to the absorbance-determined
concentrations of the recovered PDEVs to the total protein values from this Bradford
assay, all of the PDEV recoveries here are considered to be pure, as shown in Fig. 6.6.
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Figure 6.6: Determined PDEV purities based on the EV recoveries presented in Fig. 4, and the residual
protein content presented in Fig. 6.5.

On average, the PDEVs recovered from the leafy green (1.95 x 1011 PDEVs μg-1)
sample category were of the highest purity, followed by those from the vegetable (1.87 x
1011 PDEVs μg-1) and fruit (7.05 x 1010 PDEVs μg-1) categories respectively.
Importantly, the purity of the PDEVs obtained here are quite comparable to those
obtained for human urine samples using an identical C-CP tip isolation protocol [62].
Furthermore, as a point of reference, the EVs obtained using this isolation method have
10 times higher purity than EVs processed using competitive UC and polymeric
precipitation EV isolation methods [62]. Future works to directly compare the isolation
performance of the C-CP tip to other traditionally-used EV isolation techniques are
necessary for the case of PDEVs. Still, the data presented here suggest that the previously
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demonstrated benefits of high purity and yield through the processing of EV-containing
biofluids using C-CP tip methods will translate to PDEVs.
6.3.5 PEN1 Assessment via an Indirect Enzyme-Linked Immunosorbent Assay
(ELISA) - Just as tetraspanin proteins have been used to verify the identity and bioactivity
of mammalian EVs [39, 88, 89], immunoassays to the PEN1 protein have been employed
to confirm the presence and activity of PDEVs [25, 26, 35, 90]. While no universallyexpressed PDEV marker exists, the PEN1 protein has been identified at significant
concentrations in PDEV isolates. As such, PEN1 has been employed as a PDEV marker
protein during immunoassays and is also applied for this purpose. It should be reiterated
here that positive response to PEN1 does not allow for differentiation between those EVs
that existed in the intra- or extracellular regions of the original plant samples, but there
will be no response for those EVs which are bacterial in nature.

Figure 6.7: Indirect ELISA confirmation of the presence of the PEN1 marker protein for
PDEVs recovered from plant samples using the C-CP spin-down tip method. Samples were
analyzed in triplicate, corrected for the average response of triplicate blanks.

As shown in Fig. 6.7, each of the PDEV isolates yields a positive response in the
PEN1 ELISA. Serial dilutions of the PEN1 purified protein were used to create a
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standard curve of linear response (R2 = 0.995) for ELISA quantification purposes, and the
concentration of PEN1 in each sample’s PDEV recovery was determined. With this, the
presence of the PEN1 protein in the eluates is semi-quantitatively assessed. As shown,
315 – 1,079 ng of PEN1 were detected in the PDEV eluates, with the highest response for
the PEN1 seen in the red apple recovery. It must be emphasized, that the preponderance
of expression of PEN1 in each of these plant species has not been thoroughly explored.
Indeed, just as in the case of different mammalian cells from the same species, which
display highly variable levels of the respective tetraspanins, it would not be expected that
PEN1 would be expressed to the same extents in these species.

6.4 Conclusions
While the evolution of methodologies for the isolation of EVs from mammalian
sources is very much in a mode of expansion, methodologies applicable to plant-derived
EVs are very much in their infancy. The C-CP fiber spin down tip method has been
demonstrated as an efficient, practical method for the isolation of PDEVs from 20 plant
sample sources, including those from vegetable, fruit, and leafy green sample categories.
It is important to note that the present authors have not yet identified works describing
the isolation of exosome-like vesicles in baby spinach, butter lettuce, green onion,
cilantro, Roma tomato, cucumber, cherry, apple (green and red), and lime samples.
Because of this, the presented work is potentially the first application of PDEV isolations
from these plant types. The C-CP spin-down tip method yields representative collections
of PDEVs, with significant benefits relative to standard methods based on centrifugation
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or size exclusion isolation. The HIC-based C-CP fiber spin down tip method is
demonstrated to provide the sample integrity, yield, and purity required to allow for
critical PDEV characterization studies to be performed. High purity recoveries are
achieved in less than 15 min processing times, using sample extract volumes of only 100
mL. The materials costs for each isolation are <$1 and are affected on simple benchtop
centrifuges.
While much promise is demonstrated here, challenges remain in terms of
implemented methods of extraction which ensure that the isolated vesicles are truly
extracellular in nature [26]. The use of mechanical homogenization certainly has the
potential to disrupt the cellular structure of plant materials and so means of assuring
proper sampling are required as discussed by Innes and co-workers [35, 53].
Additionally, methods of sample preparation which alleviate potential contamination
from bacterially-generated EVs must be part of the overall processing protocol.
This innovative approach to PDEV isolations will enable more comprehensive
assessments of both fundamental and therapeutic relevance to be performed with higher
efficiency and using a practical workflow. It is anticipated that future developments of
the isolation method presented during this work can be scaled-up towards volume and
concentration levels of relevance towards the production of PDEV therapeutic vectors.
Credit author statement
Kaylan K. Jackson: Methodology, Data Curation, Visualization, Writing – Original Draft
Preparation; Carolina Mata: Methodology; R. Kenneth Marcus: Conceptualization,
Supervision, Writing – Reviewing and Editing

190

Declaration of competing interest
The authors declare that they have no known competing financial interests or personal
relationships that could have appeared to influence the work reported in this paper.

6.5 Acknowledgements
Financial support from the National Science Foundation under grant no. CHE-2107882 is
gratefully acknowledged.

6.6 References
[1] S. Gill, R. Catchpole, P. Forterre, Extracellular membrane vesicles in the three
domains of life and beyond, FEMS Microbiol. Rev. 43(3) (2018) 273-303.
[2] E. Woith, G. Fuhrmann, M.F. Melzig, Extracellular Vesicles—Connecting Kingdoms,
Int. J. Mol. Sci. 20(22) (2019) 5695.
[3] J.C. Akers, D. Gonda, R. Kim, B.S. Carter, C.C. Chen, Biogenesis of extracellular
vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic
bodies, J. Neurooncol. 113(1) (2013) 1-11.
[4] M. Battistelli, E. Falcieri, Apoptotic Bodies: Particular Extracellular Vesicles
Involved in Intercellular Communication, Biology (Basel) 9(1) (2020) 21.
[5] E. Cocucci, G. Racchetti, J. Meldolesi, Shedding microvesicles: artefacts no more,
Trends Cell Biol. 19(2) (2009) 43-51.

191

[6] V. Muralidharan-Chari, J.W. Clancy, A. Sedgwick, C. D'Souza-Schorey,
Microvesicles: mediators of extracellular communication during cancer
progression, J. Cell Sci. 123(Pt 10) (2010) 1603-11.
[7] R. Kalluri, V.S. LeBleu, The biology, function, and biomedical applications of
exosomes, Science 367(6478) (2020) eaau6977.
[8] D.M. Pegtel, S.J. Gould, Exosomes, Annu. Rev. Biochem. 88(1) (2019) 487-514.
[9] J. Lin, J. Li, B. Huang, J. Liu, X. Chen, X.M. Chen, Y.M. Xu, L.F. Huang, X.Z.
Wang, Exosomes: novel biomarkers for clinical diagnosis, Sci. World J. 2015
(2015) 657086.
[10] Y. Zhang, Y. Liu, H. Liu, W.H. Tang, Exosomes: biogenesis, biologic function and
clinical potential, Cell Biosci. 9(1) (2019) 19.
[11] I.L. Colao, R. Corteling, D. Bracewell, I. Wall, Manufacturing Exosomes: A
Promising Therapeutic Platform, Trends Mol. Med. 24(3) (2018) 242-256.
[12] S. Kourembanas, Exosomes: vehicles of intercellular signaling, biomarkers, and
vectors of cell therapy, Annu. Rev. Physiol. 77(1) (2015) 13-27.
[13] E.I. Buzas, B. Gyorgy, G. Nagy, A. Falus, S. Gay, Emerging role of extracellular
vesicles in inflammatory diseases, Nat. Rev. Rheumatol. 10(6) (2014) 356-64.
[14] C.M. Boulanger, X. Loyer, P.E. Rautou, N. Amabile, Extracellular vesicles in
coronary artery disease, Nat. Rev. Cardiol. 14(5) (2017) 259-272.
[15] A.G. Thompson, E. Gray, S.M. Heman-Ackah, I. Mager, K. Talbot, S.E. Andaloussi,
M.J. Wood, M.R. Turner, Extracellular vesicles in neurodegenerative disease pathogenesis to biomarkers, Nat. Rev. Neurol. 12(6) (2016) 346-57.

192

[16] T. Yamashita, Y. Takahashi, Y. Takakura, Possibility of Exosome-Based
Therapeutics and Challenges in Production of Exosomes Eligible for Therapeutic
Application, Biol. Pharm. Bull. 41(6) (2018) 835-842.
[17] A.T. Jan, Outer Membrane Vesicles (OMVs) of Gram-negative Bacteria: A
Perspective Update, Front. Microbiol. 8 (2017) 1053.
[18] A. Kulp, M.J. Kuehn, Biological functions and biogenesis of secreted bacterial outer
membrane vesicles, Annu. Rev. Microbiol. 64(1) (2010) 163-84.
[19] M. Samuel, M. Bleackley, M. Anderson, S. Mathivanan, Extracellular vesicles
including exosomes in cross kingdom regulation: a viewpoint from plant-fungal
interactions, Front. Plant. Sci. 6 (2015) 766.
[20] J.S. Schorey, Y. Cheng, P.P. Singh, V.L. Smith, Exosomes and other extracellular
vesicles in host-pathogen interactions, EMBO Rep. 16(1) (2015) 24-43.
[21] G. Coakley, R.M. Maizels, A.H. Buck, Exosomes and Other Extracellular Vesicles:
The New Communicators in Parasite Infections, Trends Parasitol. 31(10) (2015)
477-489.
[22] Q. An, A.J. van Bel, R. Huckelhoven, Do plant cells secrete exosomes derived from
multivesicular bodies?, Plant Signal Behav. 2(1) (2007) 4-7.
[23] P. Baldrich, B.D. Rutter, H.Z. Karimi, R. Podicheti, B.C. Meyers, R.W. Innes, Plant
Extracellular Vesicles Contain Diverse Small RNA Species and Are Enriched in
10- to 17-Nucleotide "Tiny" RNAs, Plant Cell 31(2) (2019) 315-324.
[24] M. Pinedo, L. de la Canal, C. de Marcos Lousa, A call for Rigor and standardization
in plant extracellular vesicle research, J. Extracell. Vesicles 10(6) (2021) e12048.

193

[25] B.D. Rutter, R.W. Innes, Extracellular vesicles as key mediators of plant-microbe
interactions, Curr. Opin. Plant Biol. 44 (2018) 16-22.
[26] B.D. Rutter, R.W. Innes, Growing pains: addressing the pitfalls of plant extracellular
vesicle research, New Phytol. 228(5) (2020) 1505-1510.
[27] N. Kameli, A. Dragojlovic-Kerkache, P. Savelkoul, F.R. Stassen, Plant-Derived
Extracellular Vesicles: Current Findings, Challenges, and Future Applications,
Membranes (Basel) 11(6) (2021) 411.
[28] M.S. Manocha, M. Shaw, Occurrence of Lomasomes in Mesophyll Cells of ‘Khapli’
Wheat, Nature 203(4952) (1964) 1402-1403.
[29] W. Halperin, W.A. Jensen, Ultrastructural changes during growth and
embryogenesis in carrot cell cultures, J. Ultrastruct. Res. 18(3) (1967) 428-43.
[30] T. Karamanidou, A. Tsouknidas, Plant-Derived Extracellular Vesicles as
Therapeutic Nanocarriers, Int. J. Mol. Sci. 23(1) (2022) 191.
[31] J. Mu, X. Zhuang, Q. Wang, H. Jiang, Z.B. Deng, B. Wang, L. Zhang, S. Kakar, Y.
Jun, D. Miller, H.G. Zhang, Interspecies communication between plant and mouse
gut host cells through edible plant derived exosome-like nanoparticles, Mol. Nutr.
Food Res. 58(7) (2014) 1561-73.
[32] Q. An, R. Huckelhoven, K.H. Kogel, A.J. van Bel, Multivesicular bodies participate
in a cell wall-associated defence response in barley leaves attacked by the
pathogenic powdery mildew fungus, Cell Microbiol. 8(6) (2006) 1009-19.
[33] O.N. Johansson, E. Fantozzi, P. Fahlberg, A.K. Nilsson, N. Buhot, M. Tor, M.X.
Andersson, Role of the penetration-resistance genes PEN1, PEN2 and PEN3 in

194

the hypersensitive response and race-specific resistance in Arabidopsis thaliana,
Plant J. 79(3) (2014) 466-76.
[34] G. Liu, G. Kang, S. Wang, Y. Huang, Q. Cai, Extracellular Vesicles: Emerging
Players in Plant Defense Against Pathogens, Front. Plant Sci. 12 (2021) 757925.
[35] B.D. Rutter, R.W. Innes, Extracellular Vesicles Isolated from the Leaf Apoplast
Carry Stress-Response Proteins, Plant Physiol. 173(1) (2017) 728-741.
[36] J. Zhang, Y. Qiu, K. Xu, Characterization of GFP-AtPEN1 as a marker protein for
extracellular vesicles isolated from Nicotiana benthamiana leaves, Plant Signal
Behav. 15(9) (2020) 1791519.
[37] S. Rome, Biological properties of plant-derived extracellular vesicles, Food Funct.
10(2) (2019) 529-538.
[38] J. Kim, S. Li, S. Zhang, J. Wang, Plant-derived exosome-like nanoparticles and their
therapeutic activities, Asian J. Pharm. Sci. 17(1) (2022) 53-69.
[39] C. Thery, K.W. Witwer, E. Aikawa, et. al, Minimal information for studies of
extracellular vesicles 2018 (MISEV2018): a position statement of the
International Society for Extracellular Vesicles and update of the MISEV2014
guidelines, J. Extracell. Vesicles 7(1) (2018) 1535750.
[40] S. Raimondo, F. Naselli, S. Fontana, F. Monteleone, A. Lo Dico, L. Saieva, G. Zito,
A. Flugy, M. Manno, M.A. Di Bella, G. De Leo, R. Alessandro, Citrus limon derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft
growth by inducing TRAIL-mediated cell death, Oncotarget; Vol 6, No 23
(2015).

195

[41] G. Pocsfalvi, L. Turiák, A. Ambrosone, P. del Gaudio, G. Puska, I. Fiume, T.
Silvestre, K. Vékey, Protein biocargo of citrus fruit-derived vesicles reveals
heterogeneous transport and extracellular vesicle populations, J. Plant Physiol.
229 (2018) 111-121.
[42] J. Xiao, S. Feng, X. Wang, K. Long, Y. Luo, Y. Wang, J. Ma, Q. Tang, L. Jin, X. Li,
M. Li, Identification of exosome-like nanoparticle-derived microRNAs from 11
edible fruits and vegetables, PeerJ 6 (2018) e5186.
[43] X. Zhuang, Z.-B. Deng, J. Mu, L. Zhang, J. Yan, D. Miller, W. Feng, C.J. McClain,
H.-G. Zhang, Ginger-derived nanoparticles protect against alcohol-induced liver
damage, J. Extracell. Vesicles 4(1) (2015) 28713.
[44] Y. Teng, Y. Ren, M. Sayed, X. Hu, C. Lei, A. Kumar, E. Hutchins, J. Mu, Z. Deng,
C. Luo, K. Sundaram, M.K. Sriwastva, L. Zhang, M. Hsieh, R. Reiman, B.
Haribabu, J. Yan, V.R. Jala, D.M. Miller, K. Van Keuren-Jensen, M.L. Merchant,
C.J. McClain, J.W. Park, N.K. Egilmez, H.G. Zhang, Plant-Derived Exosomal
MicroRNAs Shape the Gut Microbiota, Cell Host Microbe 24(5) (2018) 637652.e8.
[45] M. Potestà, A. Minutolo, A. Gismondi, L. Canuti, M. Kenzo, V. Roglia, F. Macchi,
S. Grelli, A. Canini, V. Colizzi, C. Montesano, Cytotoxic and apoptotic effects of
different extracts of Moringa oleifera Lam on lymphoid and monocytoid cells,
Exp. Ther. Med. 18(1) (2019) 5-17.
[46] M. Potestà, V. Roglia, M. Fanelli, E. Pietrobono, A. Gismondi, S. Vumbaca, R.G.
Nguedia Tsangueu, A. Canini, V. Colizzi, S. Grelli, A. Minutolo, C. Montesano,

196

Effect of microvesicles from Moringa oleifera containing miRNA on proliferation
and apoptosis in tumor cell lines, Cell Death Discov. 6(1) (2020) 43.
[47] E. Woith, M.F. Melzig, Extracellular Vesicles from Fresh and Dried Plants—
Simultaneous Purification and Visualization Using Gel Electrophoresis, Int. J.
Mol. Sci. 20(2) (2019) 357.
[48] P. Li, M. Kaslan, S.H. Lee, J. Yao, Z. Gao, Progress in Exosome Isolation
Techniques, Theranostics 7(3) (2017) 789-804.
[49] G.K. Patel, M.A. Khan, H. Zubair, S.K. Srivastava, M. Khushman, S. Singh, A.P.
Singh, Comparative analysis of exosome isolation methods using culture
supernatant for optimum yield, purity and downstream applications, Sci. Rep. 9(1)
(2019) 5335.
[50] N. Ludwig, T.L. Whiteside, T.E. Reichert, Challenges in Exosome Isolation and
Analysis in Health and Disease, Int. J. Mol. Sci. 20(19) (2019) 4684.
[51] Y. Cui, J. Gao, Y. He, L. Jiang, Plant extracellular vesicles, Protoplasma 257(1)
(2020) 3-12.
[52] H. Zand Karimi, P. Baldrich, B.D. Rutter, L. Borniego, K.K. Zajt, B.C. Meyers,
R.W. Innes, Arabidopsis apoplastic fluid contains sRNA- and circular RNA–
protein complexes that are located outside extracellular vesicles, Plant Cell 34(5)
(2022) 1863-1881.
[53] B.D. Rutter, K.L. Rutter, R.W. Innes, Isolation and Quantification of Plant
Extracellular Vesicles, Bio. Protoc. 7(17) (2017) e2533-e2533.

197

[54] P. Gourabathini, M.T. Brandl, K.S. Redding, J.H. Gunderson, S.G. Berk,
Interactions between food-borne pathogens and protozoa isolated from lettuce and
spinach, Appl. Environ. Microbiol. 74(8) (2008) 2518-25.
[55] R. Acevedo, S. Fernandez, C. Zayas, A. Acosta, M.E. Sarmiento, V.A. Ferro, E.
Rosenqvist, C. Campa, D. Cardoso, L. Garcia, J.L. Perez, Bacterial outer
membrane vesicles and vaccine applications, Front. Immunol. 5 (2014) 121.
[56] T.F. Bruce, T.J. Slonecki, L. Wang, S. Huang, R.R. Powell, R.K. Marcus, Exosome
isolation and purification via hydrophobic interaction chromatography using a
polyester, capillary-channeled polymer fiber phase, Electrophoresis 40(4) (2019)
571-581.
[57] S. Huang, L. Wang, T.F. Bruce, R.K. Marcus, Isolation and quantification of human
urinary exosomes by hydrophobic interaction chromatography on a polyester
capillary-channeled polymer fiber stationary phase, Anal. Bioanal. Chem. 411(25)
(2019) 6591-6601.
[58] S. Huang, L. Wang, T.F. Bruce, R.K. Marcus, Evaluation of exosome loading
characteristics in their purification via a glycerol-assisted hydrophobic interaction
chromatography method on a polyester, capillary-channeled polymer fiber phase,
Biotechnol. Prog. 36(5) (2020) e2998.
[59] K.K. Jackson, R.R. Powell, T.F. Bruce, R.K. Marcus, Solid-phase extraction of
exosomes from diverse matrices via a polyester capillary-channeled polymer (CCP) fiber stationary phase in a spin-down tip format, Anal. Bioanal. Chem.
412(19) (2020) 4713-4724.

198

[60] L. Wang, T.F. Bruce, S. Huang, R.K. Marcus, Isolation and quantitation of
exosomes isolated from human plasma via hydrophobic interaction
chromatography using a polyester, capillary-channeled polymer fiber phase, Anal.
Chim. Acta. 1082 (2019) 186-193.
[61] S. Huang, X. Ji, K.K. Jackson, D.M. Lubman, M.B. Ard, T.F. Bruce, R.K. Marcus,
Rapid separation of blood plasma exosomes from low-density lipoproteins via a
hydrophobic interaction chromatography method on a polyester capillarychanneled polymer fiber phase, Anal. Chim. Acta. 1167 (2021) 338578.
[62] K.K. Jackson, R.R. Powell, T.F. Bruce, R.K. Marcus, Rapid isolation of extracellular
vesicles from diverse biofluid matrices via capillary-channeled polymer fiber
solid-phase extraction micropipette tips, Analyst 146(13) (2021) 4314-4325.
[63] K.K. Jackson, R.R. Powell, T.F. Bruce, R.K. Marcus, Facile, generic capture and onfiber differentiation of exosomes via confocal immunofluorescence microscopy
using a capillary-channeled polymer fiber solid-phase extraction tip, Sens. Diagn.
in press. (2022).
[64] K.K. Jackson, R.R. Powell, R.K. Marcus, T.F. Bruce, Comparison of the capillarychanneled polymer (C-CP) fiber spin-down tip approach to traditional methods
for the isolation of extracellular vesicles from human urine, Anal. Bioanal. Chem.
414(13) (2022) 3813-3825.
[65] D.K. Kim, W.J. Rhee, Antioxidative Effects of Carrot-Derived Nanovesicles in
Cardiomyoblast and Neuroblastoma Cells, Pharmaceutics 13(8) (2021) 1203.

199

[66] P. Akuma, O.D. Okagu, C.C. Udenigwe, Naturally Occurring Exosome Vesicles as
Potential Delivery Vehicle for Bioactive Compounds, Front. Sustain. Food Syst. 3
(2019).
[67] P. Perez-Bermudez, J. Blesa, J.M. Soriano, A. Marcilla, Extracellular vesicles in
food: Experimental evidence of their secretion in grape fruits, Eur. J. Pharm. Sci.
98 (2017) 40-50.
[68] B. Liu, X. Li, H. Yu, X. Shi, Y. Zhou, S. Alvarez, M.J. Naldrett, S.D. Kachman,
S.H. Ro, X. Sun, S. Chung, L. Jing, J. Yu, Therapeutic potential of garlic chivederived vesicle-like nanoparticles in NLRP3 inflammasome-mediated
inflammatory diseases, Theranostics 11(19) (2021) 9311-9330.
[69] M. Zhang, X. Wang, M.K. Han, J.F. Collins, D. Merlin, Oral administration of
ginger-derived nanolipids loaded with siRNA as a novel approach for efficient
siRNA drug delivery to treat ulcerative colitis, Nanomedicine (Lond) 12(16)
(2017) 1927-1943.
[70] F. Man, C. Meng, Y. Liu, Y. Wang, Y. Zhou, J. Ma, R. Lu, The Study of GingerDerived Extracellular Vesicles as a Natural Nanoscale Drug Carrier and Their
Intestinal Absorption in Rats, AAPS PharmSciTech. 22(6) (2021) 206.
[71] M. De Robertis, A. Sarra, V. D’Oria, F. Mura, F. Bordi, P. Postorino, D.
Fratantonio, Blueberry-Derived Exosome-Like Nanoparticles Counter the
Response to TNF-α-Induced Change on Gene Expression in EA.hy926 Cells,
Biomolecules 10(5) (2020) 742.

200

[72] F. Perut, L. Roncuzzi, S. Avnet, A. Massa, N. Zini, S. Sabbadini, F. Giampieri, B.
Mezzetti, N. Baldini, Strawberry-Derived Exosome-Like Nanoparticles Prevent
Oxidative Stress in Human Mesenchymal Stromal Cells, Biomolecules 11(1)
(2021) 87.
[73] M.K. Kim, Y.C. Choi, S.H. Cho, J.S. Choi, Y.W. Cho, The Antioxidant Effect of
Small Extracellular Vesicles Derived from Aloe vera Peels for Wound Healing,
Tissue Eng. Regen. Med. 18(4) (2021) 561-571.
[74] P. Pužar Dominkuš, M. Stenovec, S. Sitar, E. Lasič, R. Zorec, A. Plemenitaš, E.
Žagar, M. Kreft, M. Lenassi, PKH26 labeling of extracellular vesicles:
Characterization and cellular internalization of contaminating PKH26
nanoparticles, Biochim. Biophys. Acta. Biomembr. 1860(6) (2018) 1350-1361.
[75] H. Zhang, D. Lyden, Asymmetric-flow field-flow fractionation technology for
exomere and small extracellular vesicle separation and characterization, Nat.
Protoc. 14(4) (2019) 1027-1053.
[76] S. Sharma, M. LeClaire, J. Wohlschlegel, J. Gimzewski, Impact of isolation methods
on the biophysical heterogeneity of single extracellular vesicles, Sci. Rep. 10(1)
(2020) 13327.
[77] V. Vagenende, A.X. Han, M. Mueller, B.L. Trout, Protein-associated cation clusters
in aqueous arginine solutions and their effects on protein stability and size, ACS
Chem. Biol. 8(2) (2013) 416-22.

201

[78] V. Vagenende, M.G. Yap, B.L. Trout, Mechanisms of protein stabilization and
prevention of protein aggregation by glycerol, Biochemistry 48(46) (2009) 1108496.
[79] C.Y. Soo, Y. Song, Y. Zheng, E.C. Campbell, A.C. Riches, F. Gunn‐Moore, S.J.
Powis, Nanoparticle tracking analysis monitors microvesicle and exosome
secretion from immune cells, Immunology 136(2) (2012) 192-197.
[80] J.M. Noble, L.M. Roberts, N. Vidavsky, A.E. Chiou, C. Fischbach, M.J. Paszek,
L.A. Estroff, L.F. Kourkoutis, Direct comparison of optical and electron
microscopy methods for structural characterization of extracellular vesicles, J.
Struct. Biol. 210(1) (2020) 107474.
[81] E. Van der Pol, F. Coumans, A. Grootemaat, C. Gardiner, I.L. Sargent, P. Harrison,
A. Sturk, T. Van Leeuwen, R. Nieuwland, Particle size distribution of exosomes
and microvesicles determined by transmission electron microscopy, flow
cytometry, nanoparticle tracking analysis, and resistive pulse sensing, J. Thromb.
Haemostasis 12(7) (2014) 1182-1192.
[82] C. Gardiner, Y.J. Ferreira, R.A. Dragovic, C.W.G. Redman, I.L. Sargent,
Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis, J.
Extracell. Vesicles 2(1) (2013) 19671.
[83] M. Holcar, J. Ferdin, S. Sitar, M. Tušek-Žnidarič, V. Dolžan, A. Plemenitaš, E.
Žagar, M. Lenassi, Enrichment of plasma extracellular vesicles for reliable
quantification of their size and concentration for biomarker discovery, Sci. Rep.
10(1) (2020) 1-13.

202

[84] E. Oeyen, K. Van Mol, G. Baggerman, H. Willems, K. Boonen, C. Rolfo, P.
Pauwels, A. Jacobs, K. Schildermans, W.C. Cho, Ultrafiltration and size
exclusion chromatography combined with asymmetrical-flow field-flow
fractionation for the isolation and characterisation of extracellular vesicles from
urine, J. Extracell. Vesicles 7(1) (2018) 1490143.
[85] J. Webber, A. Clayton, How pure are your vesicles?, J. Extracell. Vesicles 2(1)
(2013) 19861.
[86] M.Y. Konoshenko, E.A. Lekchnov, A.V. Vlassov, P.P. Laktionov, Isolation of
extracellular vesicles: general methodologies and latest trends, BioMed Res. Int.
2018 (2018).
[87] R.J. Lobb, M. Becker, S.W. Wen, C.S. Wong, A.P. Wiegmans, A. Leimgruber, A.
Moller, Optimized exosome isolation protocol for cell culture supernatant and
human plasma, J. Extracell. Vesicles 4(1) (2015) 27031.
[88] B.J. Tauro, D.W. Greening, R.A. Mathias, H. Ji, S. Mathivanan, A.M. Scott, R.J.
Simpson, Comparison of ultracentrifugation, density gradient separation, and
immunoaffinity capture methods for isolating human colon cancer cell line
LIM1863-derived exosomes, Methods 56(2) (2012) 293-304.
[89] J. Kowal, G. Arras, M. Colombo, M. Jouve, J.P. Morath, B. Primdal-Bengtson, F.
Dingli, D. Loew, M. Tkach, C. Théry, Proteomic comparison defines novel
markers to characterize heterogeneous populations of extracellular vesicle
subtypes, Proc. Nat. Acad. Sci. U. S. A. 113(8) (2016) E968-E977.

203

[90] H.A. Dad, T.W. Gu, A.Q. Zhu, L.Q. Huang, L.H. Peng, Plant Exosome-like
Nanovesicles: Emerging Therapeutics and Drug Delivery Nanoplatforms, Mol.
Ther. 29(1) (2021) 13-31.

204

CHAPTER SEVEN
RAPID ISOLATION AND QUANTIFICATION OF EXTRACELLULAR VESICLES
FROM SUSPENSION-ADAPTED HUMAN EMBRYONIC KIDNEY CELLS USING
CAPILLARY-CHANNELED POLYMER FIBER SPIN-DOWN TIPS

7.1

Introduction
As primary vehicles of intercellular communication, nanometer-scale extracellular

vesicles (EVs) allow for bioactive cargos to be transferred between cells in close and far
proximity, even crossing barriers of bodily systems [1]. EVs are secreted by all living
cells and are composed of a phospholipid bilayer membrane, and contain lipid, protein,
and genetic (DNA, mRNA, miRNA) cargos from the cell of origin [1-4]. Overall, EV
populations are heterogeneous in size (30-4000 nm), composition, and function,
reflecting the original microenvironment from which they were secreted and their mode
of creation [5]. Depending on the state of the origin cell, secreted EVs can contribute to
either the maintenance of normal/healthy physiology or the progression of disease [6-9].
The abundance of EVs in excreted biofluids (i.e., urine, saliva, blood) has made them
ideal targets for liquid biopsies and other bioassays, while the collection of EVs from cell
culture milieu (CCM) has proven beneficial for therapeutic vector production [10,11].
Limiting EV applications are the lack of understanding of EV fundamentals, the
inability to well characterize EV subtypes, and potentially most limiting: the absence of
scalable methods to isolate pure, populated collections of EVs and quantify them
efficiently [12-14]. EVs are generically classified into three main subtypes based on the
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biogenesis process used to create them and their size. The three main sub-classes of EVs
are 1) microvesicles (MVs) which are shed from the cell membrane of living cells,
ranging from 50 – 1000 nm in size [1,15]; 2) apoptotic bodies of 50 – 4000 nm diameter,
which are stochastically released from dying cells [16,17]; and 3) exosomes, smaller EVs
(sEVs) of roughly 30 – 200 nm diameter, uniquely created through the multivesicular
body (MVB)-mediated endosomal pathway and released via exocytosis [10-12]. Of the
EV subtypes, exosomes are considered the “main mediators” of cellular communication
to affect functional changes in the recipient cell [18]. However, the effective isolation of
exosomes from other EV types is particularly challenging, so the assignment of exosomespecific activities to functional responses has been impeded [19]. Moreover, the
overlapping of the exosome and MV size ranges and similarities in composition and
morphology have led to collections of vesicles in the sEV size range (50-200 nm) to be
generically referred to as EVs [12,20].
Because EVs are cell secretion products, the production of concentrated pools of EVs
depends upon the ability to provide large quantities of cells in a way that does not cause
alterations in the cellular phenotype (thereby, EV cargos) [13,21,22]. Of the many cell
types, human embryonic kidney (HEK293) cells are prime candidates for the scalable
production of EVs because of the previous success with this host cell line in the
production of recombinant proteins, monoclonal antibodies (mAbs), and adenoassociated virus (AAV) vectors for biotherapeutics [23-27]. Previous works have
demonstrated that after the harvest of the EVs from HEK293 cells, they can be
bioengineered to contain specific gene, drug, or protein contents for therapeutic
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applications ranging from opioid addiction [28] to cancer [29]. In all, HEK293-derived
EVs hold the potential to provide a means of delivering powerful drug and gene therapies
in a way that is practical in terms of cost and scalability.
A downfall of the use of traditional HEK293 cell lines for EV production is that
standard protocols require the cells to be grown in cell culture media that is supplemented
with fetal bovine serum (FBS) [24]. FBS is widely used as a universal growth supplement
for in vitro cell culture, which is composed of many of the factors required for cell
attachment, growth, and proliferation [30]. There are over 1000 components found in the
bovine-sourced biofluid, including proteins, lipids, hormones, enzymes, carbohydrates,
and EVs [30,31]. This causes an inevitable challenge: an additional EV source, especially
since to date, the definitive determination of EV origin has been a challenge [32-35].
Many FBS manufacturers have introduced “exosome-depleted” FBS, which is often
produced using an ultracentrifugation (UC) process. But with the incredibly low
percentage recovery of the EVs obtained using the UC method, the “exosome-free” FBS
stock remains significantly contaminated with high concentrations of EVs [32-37]. These
vesicles thereby contaminate the cell culture media stock with non-human EVs to be
detected downstream in future characterization approaches. Alternatively, several
HEK293 cell lines have been conditioned for growth in suspension serum-free cell
culture environments to eliminate this external EV source, such as the HEK293T/17 SF
cell line from ATCC [30,31]. However, the downstream alterations of the EVs obtained
from these modified HEK293 sources have not been thoroughly explored because of the
lack of efficient isolation methods to provide representative populations of EVs.
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To be clear, while the challenges of production-scale isolation/purification of EVs
are immense, the inability to perform high-throughput, high-purity separations on
clinical/research scales of single milliliters has prevented better fundamental research.
(The same can be said for potential clinical diagnostic applications of EVs.) There is
much to be learned to affect the better production of targeted EV populations, and so
there are gains to be made in terms of fundamental biochemistry if better analytical
strategies could be implemented. Along the same lines, suitable analytical-scale methods
would take a position as part of the process monitoring toolbox for EV production. Taken
a step further, demonstration of strategies for high fidelity isolation/purification from
production CCM could yield platforms suitable for implementation on the preparative
scale.
Marcus and colleagues have developed a hydrophobicity-based EV isolation
method employing capillary-channeled polymer (C-CP) fiber stationary phases to address
the shortcomings of the currently available EV isolation methods [37-45]. These C-CP
fiber phases have been employed in highly efficient EV isolations via high-performance
liquid chromatography (HPLC) [38-40,43,44] and solid-phase extraction (SPE) tip
[37,41,42,45] formats, concentrating on what would be called analytical-scale processing.
In both cases, the isolation of EVs is driven by an organic modifier-assisted hydrophobic
interaction chromatography (HIC) solvent system, where EVs have been obtained from
several complex biofluids, including urine, saliva, blood serum, cervical mucus, and
CCM from Dictyostelium discoideum cell culture [38,41]. In all cases, high
concentrations of EVs (up to 7 x 1012 EVs mL-1) have been obtained from microliter-
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scale initial sample volumes, with over 95% removal of contaminating proteins and
lipoproteins as confirmed by mass spectrometric proteomics analysis [37,40]. Thus the
method allows collections of EVs fit for fundamental research and clinical assays, as well
as potential use for production system monitoring.
In previous C-CP-based HIC isolations of EVs, ACN and glycerol solvent
additives were utilized to aid the elution of the vesicles from the fiber surface [38,44].
The ACN solvent additive was proven most compatible for EVs subsequently analyzed
by mass spectrometric, RNA sequencing, and immune characterization approaches [40].
Nevertheless, high concentrations of ACN are not ideal for the long-term stability of
EVs—as externally-exposed proteins may begin to degrade over time, and ACN is toxic
to living cells, so EVs eluted using this solvent could not be used in cell-feeding assays.
Despite these shortcomings, most of the latent ACN can be removed using a simple offgassing process under a low vacuum. Alternatively, a glycerol solvent modifier was
introduced for use in the case when the long-term structural preservation of the EVs was
the end goal [44,45]. Though the glycerol solvent does provide cryopreservative
properties, the high viscosity of the solvent can prevent the accurate assessment of the
vesicles during proteomic analysis, immunoassays, and flow cytometry assays [46,47].
Though some latent glycerol can be removed via a post-processing ultrafiltration step,
there can still be some interference with downstream analyses due to remnant glycerol
content blocking access to surface proteins, etc. Overall, though the ACN and glycerol
HIC solvent additives were able to provide high concentrations of pure EVs, both solvent
types can limit the characterization and utilization of recovered EVs [45]. To affect EV
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separations without the required post-isolation solvent removal steps, where a portion of
the recovered EVs may be lost due to transfer, the identification of alternative elution
solvents is of interest. As an alternative to the formerly used solvent additives, a Tween20 EV elution solvent was considered, since Tween-20-based solvents are common to
many standard immunoassays and EV analysis (i.e., Spectradyne) protocols [48,49].
Studies have also suggested that the exosome EV-subtype is resistant to detergent
activity, and the morphology of the exosomes is unaffected by low concentrations of
detergents (including Tween-20) [49,50]. Since the HIC C-CP tip isolation process is
driven by a high-to-low salt solvent transition, an aqueous Tween-20 solution could be
utilized as an organic modifier in the isolation workflow for the final elution of EVs.
In this report, a C-CP-based HIC isolation of EVs from suspension-adapted
human embryonic kidney cells (HEK293T/17 SF) grown in a serum-free environment is
performed. Aliquots of CCM from varying time points in cell growth were collected and
processed using the HIC C-CP spin-down tip method with the Tween-20-based EV
elution buffer to provide high concentrations of purified EVs. A comprehensive suite of
characterization methods has been employed to follow the recovery characteristics of
EVs in the course of the HEK293 cell culture cycle. Transmission electron microscopy
(TEM) was used to verify the size, shape, and structural integrity of the EVs recovered
using the C-CP tip method. A simple, flow-through multi-angle-light scattering (MALS)
detection apparatus was used to determine the size of the recovered EVs. The method of
standard addition using absorbance (scattering) detection was used for the efficient
quantification of EVs. A Bradford assay was used to monitor the concentration of protein
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eluted at each step in the isolation process and assess the purity of the vesicles based on
the removal of host cell proteins. An indirect enzyme-linked immunosorbent assay
(ELISA) using antibodies to the CD9 and CD81 exosomal surface marker proteins was
used to confirm the presence and bioactivity of the collected EVs. In summary, the C-CP
tip isolation method employing the Tween-20 solvent additive was able to rapidly
provide high concentrations of high-purity EVs while being compatible with every
characterization method utilized. While the intent of this report is not to make specific
implications to cell culture biochemistry, it is believed that the approach demonstrated
here has immediate relevance in research and analytical laboratories, with opportunities
for production-level scale-up projected.

7.2

Materials and Methods
7.2.1 Chemicals, solvents, and antibodies – Deionized water (DI-H2O, 18.2 MΩ-cm)

was obtained from a Milli-Q water purification system (Millipore Sigma, Merck,
Darmstadt, Germany). Ammonium sulfate and Tween-20 were purchased from VWR
(Sokon, OH, USA). Phosphate-buffered saline (PBS, pH = 7.4) and bovine serum
albumin (BSA) were purchased from ThermoFisher Scientific (Waltham, MA, USA).
Paraformaldehyde and formvar/carbon 200 mesh copper grids were obtained from
Electron Microscopy Science (Hatfield, PA). Polyclonal rabbit anti-CD9 and CD81
primary antibodies and a goat anti-rabbit HRP-conjugated secondary antibody were
obtained from System Biosciences (SBI, Palo Alto, California). The Pierce™ Coomassie
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Plus (Bradford) Assay Reagent was purchased from ThermoFisher Scientific (Waltham,
MA, USA).
7.2.2 Commercial Exosomes – Lyophilized exosomes of 3.6 x 1011 particles mL-1
concentration from the cell culture media of human embryonic kidney (HEK293) cells
were obtained from Hansa BioMed (Tallinn, Estonia). Per the manufacturer’s
instructions, the 100 µg of lyophilized exosomes were reconstituted in 100 µL of Milli-Q
water before being applied to future characterization and quantification approaches.
Though the commercial exosome material provides a point of reference for the
quantification of EVs, this exosome stock is not a certified reference material; i.e., no
quantitative/qualitative values to reflect the purity and exclusivity of the exosome stock
are supplied. The shortcoming of implementing this material as an exosome “standard”
stock is acknowledged here.
7.2.3 HEK293T/17 SF Cell Culture – A human embryonic kidney (HEK293T/17 SF)
cell line, adapted for serum-free suspension cell culture conditions, was obtained from
American Type Culture Collection (ATCC, Manassas, VA, USA). The HEK293T/17 SF
cell line was cultured in BalanCD HEK293 cell culture media (Irvine Scientific, Santa
Ana, CA, USA), supplemented with 8 mM L-glutamine and 10 µm mL-1 of insulintransferrin-selenium (ITS, Corning, Corning, NY, USA) on a 37°C shaking incubator
(160 rpm) with 5% CO2. A Vi-CELL XR Cell Viability Analyzer (Beckman Coulter,
Brea, CA, USA) was used to determine the concentration and viability of the cell line,
employing the trypan blue dye exclusion method [51]. It must be noted that the
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conditions employed here are considered to be typical, and not intended to represent the
state of the art in HEK culture technology.
7.2.4 C-CP SPE Tip Assembly – C-CP fiber micropipette tips were prepared through
the previously described process [37,41,42,45]. Briefly, colleagues from the Clemson
University School of Materials Science used a melt-extrusion process to create the C-CP
fibers from bulk polyester (polyethylene terephthalate, PET), where they were formed to
have an 8-pronged shape of ~24 x 38 mm cross-section. To create the C-CP tips, eight
rotations of the PET fiber bundles (57 fibers per bundle, 456 polymer fibers total) were
collinearly aligned, pre-shrunk with boiling water, washed with ACN, water, then ACN
to remove any lingering static coatings, and pulled through a 30 cm-long segment of
fluorinated ethylene propylene (FEP) tubing of 0.8 mm inner diameter. The fibers colinearly packed inside of the column were cut to create 1 cm fiber-packed tips, with an
additional 0.5 cm of empty tubing allowing the columns to be attached to a 200 µL lowretention micropipette tip (SureOne™ Micropoint Pipette Tips, Universal Fit, NonFiltered, Fisherbrand™, Pittsburgh, Pennsylvania), which was held in place with a small
amount of liquid adhesive. The C-CP modified micropipette tip was then placed inside a
1 mL micropipette for structural support and secured inside a 15-mL conical tube using a
customized adapter cap to hold the C-CP tip.
7.2.5 EV Isolations using the HIC Elution Protocol – An HIC solvent system was
used with the C-CP tips to isolate the EVs from the HEK293T/17 SF EVs cell culture
media. For this, 200 µL of the cell culture supernatant was filtered using a 0.22 µm PES
filter, then mixed with an equal part of ammonium sulfate (2M final concentration), with
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the 400 mL mixture applied to the C-CP tip. The entire tip apparatus was placed in the
turret of a tabletop centrifuge (Symphony 4417, VWR) and spun down at 300 x g (rcf) for
one minute. The higher hydrophobicity species (i.e., proteins and EVs) are captured on
the fiber tip surface during the initial spin-down step, while the small ionic/hydrophilic
sample components (i.e., salts, sugars, amino acids) pass unretained. To remove the free
host-cell protein and lipoprotein contaminants, 200 µL of the protein elution buffer
containing 25% ACN with 1M ammonium sulfate was loaded into the C-CP tip reservoir
and spun down at 300 x g for one minute. This protein elution step was repeated to ensure
that all contaminant protein/lipoprotein species had been removed. Finally, to release the
now-purified EVs from the fiber tip surface, 100 µL of an EV elution buffer consisting of
1% Tween 20 in PBS was applied to the C-CP tip and centrifuged at 300 x g for one
minute.
7.2.6 Transmission Electron Microscopy (TEM) – TEM imaging, performed using
a Hitachi HR7830, was used to provide the physical identification of cup-shaped EVs
after processing the cell culture media collections via the C-CP tips. In preparation for
TEM imaging, 7 µL of each HEK-EV recovery was placed on an EM-grade
copper/formvar grid and incubated at room temperature for 20 min. The excess sample
liquid was then removed using a paper towel, and the EVs on the grids were immediately
fixed using 2% paraformaldehyde (RT, 5 min). After fixation, the excess
paraformaldehyde was removed from the grids using a paper towel before gently washing
them with water for 5 min. Next, the EVs immobilized on the grids were stained using a
filtered 1% uranyl acetate solution (RT, 1 min), the excess staining solution was
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removed, and the prepared grids were again washed with water. Finally, the prepared
TEM grids were allowed to dry in a cell culture dish for 30 minutes in a desiccator at
room temperature before imaging. The size of the vesicles visualized in the TEM
micrographs was determined using ImageJ.
7.2.7 Absorbance Quantification using the Method of Standard Addition - This
laboratory has previously reported the use of standalone UV–Vis spectrometers to
determine EV concentrations following spin-down tip processing, employing standard
response curves and the method of standard addition [37,41,45]. In this work, the EVs
from HEK293T/17 cell culture media were quantified via standard additions as it shows
greater precision for complex matrices. Here, recovered EVs are spiked once, twice, and
three times with the commercial exosome standards (3.6 x 1011 particles mL-1) derived
from HEK293 cells, using the absorbance at 203 nm using a NanoVue Plus UV–Vis
spectrophotometer (GE Healthcare, Chicago, IL, USA). Though this exosome standard
stock is not a standardized reference material, a general approximation of EV
quantification can be obtained.
7.2.8 Size Determinations using Multi-Angle Light Scattering (MALS) Detection –
A DAWN multi-angle light scattering (MALS) detector (Wyatt Technology, Goleta,
CA), controlled using the ASTRA software, was used for the size determination of the
recovered HEK-EVs. After isolating the EVs from the bulk cell culture media, 20 µL of
each eluate was injected and transferred to the MALS detector at 0.5 mL min -1 using a
Dionex Ultimate 3000 HPLC system (LPG-3400SD quaternary pump and MWD-3000
UV-Vis absorbance detector, Thermo Fisher Scientific, Sunnyvale, CA, USA) controlled
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by the Chromeleon 7 software. The MALS-determined RMS radii were then multiplied
by 2 to represent the approximate diameter/size of the vesicles. Throughout MALS
analysis, the refractive index was set to that of 1% Tween in PBS at 22ºC, 1.3363, which
was determined experimentally using a Reichert AR7 Series Automatic Refractometer.
Three replicate measurements were collected for each sample in 60-second increments.
7.2.9 Isolate Purity Verification by Bradford Assay – A critical EV purity metric
has become the number of EVs with respect to the total protein content in the isolates
[12,52]. A standard Bradford assay was used to determine the total protein concentration
of each CCM sampling and the protein content of the respective C-CP tip elution
fractions (protein and EV). Here, it is important to emphasize that even in the case of
pure EVs, there will be some positive response towards the Bradford assay due to the
proteins incorporated in the vesicle walls. For total protein determinations, 25 µL of each
sample was combined with 250 µL of Bradford reagent in a 96 cell well plate and
incubated on a shaker at room temperature for 20 minutes before the detection of
absorbance response at 595 nm using the Synergy H1 Hybrid Plate Reader (BioTek,
Winooski, VT). The sample absorbance responses were compared to a BSA standard
curve of linear response to determine the total protein concentration. All samples and
standards were applied to the 96 cell well plate in triplicate, and triplicate absorbance
measurements were performed.
7.2.10 EV Identity Confirmation using an Enzyme-Linked Immunosorbent Assay
(ELISA) – To verify the presence of bioactive EVs (based on tetraspanin protein
expression) after the C-CP tip isolation process, an indirect ELISA employing antibodies
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to the CD9 and CD81 tetraspanin proteins was used. For this, 50 µL of each C-CP tip
eluate was applied to the ELISA 96 cell well plate with equal volumes of ELISA coating
buffer (0.05 M carbonate-bicarbonate in PBS) and allowed to incubate overnight at 4ºC.
Each sample was applied in triplicate, along with triplicate applications of an exosome
standard positive control and negative controls of PBS and the respective protein and EV
elution buffers. Following this sample incubation, each well was washed with 200 µL of
sterile PBS (6 buffer changes, 30 min total) before a 5% BSA blocking solution was
applied and allowed to incubate on a shaker at room temperature for 30 minutes. 200 µL
of the anti-CD9 and anti-CD81 antibody solutions of 1 μg mL−1 concentration was added
to each sample well and allowed to incubate overnight on a shaker at 4ºC. Following
incubation, the washing and blocking steps were repeated as done previously. 200 µL of
the goat anti-rabbit HRP-conjugated secondary antibody (1 μg mL−1) was applied to each
sample well and allowed to incubate at room temperature for 2 hours. Here again, the cell
well plate was washed using 200 μL of PBS per well (6 buffer changes, 30 min. total)
before applying 50 μL of the 1-Step™ Ultra TMB-ELISA Substrate Solution. The
colorimetric ELISA reagent was allowed to incubate for 30 min. at room temperature
before the absorbance response was measured at 562 nm using the Synergy H1 Hybrid
Plate Reader.

7.3

Results and Discussion
7.3.1 Cell Concentration and Viability as a Function of Culture Time – Previous

reports have shown that changes in the concentration of EVs can be used to assess the
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health of a cell line [53], with the upregulated release of EVs being attributed to
environments or situations contributing to cell stress, and a decrease in release of EVs as
being a response to nutrient depletion. Because of these sorts of relationships, scientists
have suggested that a simple EV quantification/characterization method could provide
insight into the productivity of a cell line, which could be particularly useful in largescale bioreactor applications for therapeutics [13,54]. Herein lies the potential use of a
rapid EV characterization tool as in a process monitoring mode. Intuitively, essential
factors to assess are the viable cell concentration and the concentration of cell secretion
products. The purpose of this study is to potentially characterize the state of an HEK293
cell culture based on EV release at various time points in the cell culture process using
the C-CP spin-down tip method.
Shown in Fig. 7.1 are the growth characteristics of the HEK293T/17 SF cells as a
function of culture time.

Figure 7.1: Concentration of HEK293 cells in native CCM supernatant with the percentage viability on
each day of cell culture as determined using the Vi-Cell XR instrument via trypan blue cell exclusion assay.
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An exponential growth phase, which is characteristic of healthy HEK293 cell
growth [55-58], is observed (R2 = 0.9236), with 66 – 100% of the cells collected at each
time point determined as viable based on the trypan blue dye exclusion method.
Typically, a collection of cells with a percentage viability of greater than 80% is
considered to be a “healthy” culture [59,60]. In this case, the cells on days 0 – 7 of cell
culture fall within the healthy cell viability range but decreases below 80% viability on
days 8 – 14 of culture. To assess the EV release throughout the 14-day time window,
collections of CCM from each time point were processed using the C-CP tip isolation
method to provide concentrated, representative EV populations for further
characterization.
7.3.2 Structural Verification using Transmission Electron Microscopy (TEM) –
Though many EV characterization approaches are available, TEM remains the “gold
standard” technique to visually confirm EV characteristics such as size and the
cup/spherical EV shape [19]. TEM was used as a benchmarking approach to verify that
the EVs were present in the original cell culture milieu sample, and that their physical
characteristics were retained during the subsequent isolation of EVs from CCM using the
C-CP tip method with the 1% Tween EV elution buffer. Representative TEM
micrographs for the HEK293 cell culture milieu starting material (Fig. 7.2a) and the
eluate from each C-CP tip isolation step (Fig. 7.2 b-d) are presented in Fig. 7.2 (scalebar
= 200 nm).
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Figure 7.2: Transmission electron micrographs of eluates from each step in the HIC C-CP tip EV process.
Representative micrographs from the a) native HEK293 CCM supernatant, b and c) exposure to first and
second protein elution buffers and d) the EV elution buffer. The TEM images were taken using the Hitachi
HR7830, scalebar = 200 nm.

Indeed, in Fig. 7.2a, EVs of 110 nm average diameter are observed in the cell culture
milieu stock, with the characteristic spherical and dimpled shapes. Some EV aggregates
and potential proteinaceous contaminants are also observed in the field of view, with
some vesicles being > 200 nm or < 50 nm in diameter.
After applying the CCM sample to the C-CP tip and proceeding with the first
protein elution step, matrix-originating components such as cell debris and protein
contaminant aggregations were eluted from the C-CP tip, as shown in Fig. 7.2b. Also
present are many globules of salt due to the presence of the 1M ammonium sulfate in the
protein elution buffer. Interestingly, in Fig. 7.2c, the second protein elution step results in
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a much cleaner image in terms of spurious debris, along with the release of a
concentrated collection of small, vesicle-like species likely having hydrophobic
properties similar to proteins. The population of vesicles eluted during the second protein
elution step likely consists of lipoproteins, given their presence in cell culture conditions
and lesser hydrophobicity in comparison to EVs, with the average diameter of the
vesicles being 27 nm. Still, based on TEM analysis alone, no comments can be made on
the exclusivity of this elution fraction, given that small EVs, exomeres, or exosomes in
the 20-40 nm size range would likely have similar hydrophobicity characteristics because
of the similarities in size and content. But, based on previous mass spectrometric
proteomic studies [40,41], this elution fraction is inferred to be mainly enriched in
lipoproteins. The TEM micrograph of the targeted EV elution fraction is presented in Fig.
7.2d, where vesicles of 30 – 298 nm (144 nm average diameter) are observed. Many of
the vesicles visualized in Fig. 7.2d contain the characteristic cup or dimpled shape, with
few matrix contaminants shown and the absence of large protein aggregates and the 20 –
40 nm fraction of the vesicles. The presented TEM micrographs verify the ability to
obtain structurally-preserved EVs of the correct size from the HEK293 cell culture milieu
using the C-CP spin down tip method with the 1% Tween elution buffer.
7.3.3 Quantification of Recovered EVs as a Function of Culture Time and EV Yield
per Cell – The C-CP tip method allows for the isolation of highly concentrated EV
samples in a quantitative and reproducible manner, using minute (100 mL) sample
volumes [37,41,42,45]. These qualities are ideal in the case of small population
(analytical) sampling of large-scale cell culture conditions to monitor the health of the
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cell line based on EV production. The cell milieu collections from each time point were
processed by the C-CP tip EV isolation method, and the eluted EVs were quantified using
the method of standard addition with absorbance detection at 203 nm.

Figure 7.3: a) Concentration of EVs collected from each CCM aliquot using the C-CP tip isolation method
and b) concentration of EVs released per viable cell. Quantification performed using the method of
standard addition via absorbance detection at 203 nm.

As shown in Fig. 7.3a, the EVs isolated from the initial seeding aliquot of the cells
into the new media and suspension culture flask yielded an EV concentration of 8.9 x 108
particles mL-1. In only 24 hours, a ~40-fold increase in EV concentration was realized
(3.7 x 1010 particles mL-1). Further, with each day of cell culture, there was an increase in
EV secretion until day 7, where the secreted EV concentration plateaus (1.1-1.4 x 1011
EVs mL-1). This is representative of healthy cellular growth and proliferation on days 0 –
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7 of cell culture, where likely beyond the day 7 time-point, the cells become
overpopulated, and the cell multiplication begins to decrease as the cell culture nutrients
are depleted, and cell waste by-products, such as lactate, begin to inhibit cell growth
[56,61,62]. This is further confirmed by the total number and percentage of viable cells
shown in Fig. 7.1, where beyond day 7 of culture, the viability of the cells decreases
below 80%, remaining on the level of ~70%, and the total number reaches its maximum.
Important across this set of EV number determinations and the subsequent methods of
characterization is the very high level of measurement precision, wherein triplicate
determinations fall below 10% RSD; and impressive value in comparison to more
traditional EV isolation methods [45].
It is well known that there is a practical difference between the viability of cells in
a given culture and their productivity towards an end product [13,21,63]. This concept
would certainly be of relevance in the production of EVs as vectors, but also may allow
for EV production to provide insights into cellular processes. In Fig. 7.3b, the
concentration of recovered EVs is presented with respect to the viable cell concentration
on each day of the cell culture process. After isolation of EVs from the initially-seeded
cells, 7 x 104 EVs per viable HEK293 cell were collected, which is reasonable as the
viable cells were just released into the new media-containing suspension flasks, and a
minuscule amount of time was allowed to pass – lowering the probability for the
occurrence of cellular communication processes (therefore EV release). Still, the initially
collected EVs were likely released into the cell culture flask in response to the cell
seeding process, a physical stressor for the seeded cells [53,64-66]. After the first 24
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hours of incubation, a 17-fold increase in the concentration of EVs secreted per cell is
observed (1.2 x 106 EVs per cell). This high level of EV secretion per cell is observed on
days 1-5, with a dramatic 50% decrease in EV productivity observed on day 6, followed
by a steady decrease up to 14 days of culture. The drop in EV productivity corresponds
with the lower cell viability (Fig. 7.1), though it has been suggested that as culture media
components become depleted with time, they continuously become nutrient-deprived and
begin to prioritize cargo preservation, causing the EV output to decrease [61,62]. Though
none of the identified works have monitored EV release during the production of
therapeutic vectors/products, it would be interesting to assess potential relationships
between the productivity of mAb- or viral vector-producing cell lines and EV release
characteristics [67-70].
7.3.4 CD9 and CD81 Expression of HEK293T/17 EVs – Despite the absence of a
discrete EV biomarker to verify the bioactivity and quantity of EVs, antibodies to the
CD9 and CD81 tetraspanin proteins are commonly employed during immunoassays to
verify the identity of exosomes and other EVs based on the presence of the proteins on
the vesicular surfaces [1,71-73]. It is important to note that some individual tetraspanin
proteins (including CD9 and CD81) are also expressed in the plasma membranes and
endosomal/lysosomal compartments of cells, therefore these (free) proteins could be
present to some extent in CCM samples [71]. Regardless of the various origins of the
proteins, antibodies to CD9 and CD81 have been used in numerous immunoassays to
verify the presence of EVs [74,75]. An indirect ELISA approach was used here to
identify the C-CP tip-recovered EVs based on the tetraspanin proteins in the collections
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of CCM from each time point. Because of the heterogeneity of EV protein expression,
even for EVs of the same origin and exposed to identical conditions, one cannot assume
that the tetraspanin protein expression is directly correlated with the absolute
concentration of EVs [18,26]. That said, the absolute identification of tetraspanin proteins
on the surface of the EVs is a confirmation of their identity and is suggestive of their
retention of surface protein activity.
The responses to the ELISA assays for CD9 and CD81 over the course of the
culture program are presented in Fig. 7.4.

Figure 7.4: CD9 and CD81 tetraspanin protein responses of C-CP tip isolated EV recoveries from each
time point, determined using an indirect ELISA. All samples were applied in triplicate with the average of
the triplicate measurements minus the average response of the blank is presented.

As can be seen, the expression of the two tetraspanins remains relatively constant
across the incubation period, with the absolute responses for the two proteins being fairly
equivalent. This is a fortuitous situation and cannot be interpreted as meaning that the
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vesicular surface concentrations for the two species is actually the same. Across the entire
suite of analyses, it is clear that the triplicate isolation procedures (as well as the assay
steps) are indeed very reproducible; a consistent feature of the C-CP tip isolation
methodology. It is interesting that there are specific sampling days where the production
of CD9 is enhanced, but it is beyond the scope of this effort to interpret the underlying
reasons. As a final note, it is interesting that the ELISA responses remain consistent even
though the raw number of EVs changes in the course of the culture cycle. This might
suggest some sort of bias in the assay, but these samplings were all run in parallel with
suitable controls/blanks. It may be that the production of tetraspanins themselves may be
an indication of the health of the cell line. The ability to rapidly, and repeatably obtain
this information will provide researchers with the opportunities to investigate these
relationships.
7.3.5 Size of Recovered EVs via MALS – Most commonly in EV research,
nanoparticle tracking analysis (NTA) methods are used for EV size determinations
[76,77]. Previous use of the NTA instrument for evaluating EV size in this laboratory and
others has raised concerns about the accuracy and precision of determinations due to
significant inconsistencies in standard analyses [19,37,45,78,79]. The NTA methodology
is susceptible to many different forms of interference, with the results having a tendency
to be very operator dependent. To potentially circumvent the limitations of the NTA
approach, researchers have previously employed MALS instruments for EV size
determinations [14,80,81]. MALS size determination was used here to confirm that the
EVs collected from the CCM samples had sizes that were within expected ranges. More
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importantly, the use of MALS in combination with the C-CP tip isolation method was
hoped to yield far higher levels of precision than previously obtained using NTA. Finally,
as a flow-through detection method, it is anticipated that the approach can be integrated
into C-CP fiber column-based separations that are performed on standard HPLC
instruments [38,40,44,82]. The average diameters of the EVs isolated from the cellular
milieu samples are shown in Fig. 7.5.

Figure 7.5: Size determination of the EVs recovered using the C-CP tip isolation method on each day of
cell culture, performed using the Wyatt Dawn MALS instrument. Presented is the average size of the EVs
resulting from 3 consecutive 60-second runs.

The eluted EVs presented average diameters of 145 – 411 nm across the CCM
sample collections across the incubation period, with an average diameter of 249 nm
overall. In comparison to previously-obtained populations of EVs collected using the CCP tip, the average diameter of the vesicles is 50 – 100 nm larger than those obtained
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from human biofluids using the acetonitrile or glycerol solvent systems and NTA
determinations [41,45]. The significant difference in EV size could potentially be due to
the use of the Tween-20 EV elution buffer or could be a basic characteristic of the
suspension-adapted HEK293 source. Nonetheless, the relative precision of the EV size
determinations using the MALS instrument is excellent, with less than 7% RSD across
triplicate measurements of EV size. Given the high level of precision, the clear systemic
variations in EV sizes may be of biological significance. The assessment of the various
C-CP tip elution solvents in parallel isolations of EVs from identical sources is
undoubtedly warranted for future experimentation, as is a direct comparison of
determination methods, including NTA, MALS, and dynamic light scattering (DLS).
7.3.6 Protein Concentration of Cell Culture Milieu and Purity Assessment of
Recovered EVs – Bradford assays are commonly utilized to determine the total amino
acid/protein content of diverse biological samples [52]. Here, the Bradford assay was
used to investigate the purity of the EVs recovered from the HEK293 cell culture
collections based on the removal of host cell proteins. To clarify, the response to the
Bradford assay reflects the total proteinaceous material present in a sample. Therefore,
even in the case of “pure” EVs, a positive yet lower Bradford response results due to the
interaction between the Bradford reagent and the externally exposed EV-associated
proteins and amino acid residues. Figure 7.6 shows the Bradford assay-determined
protein concentrations for the raw CCM supernatants and the eluates of the subsequent CCP tip processing steps; i.e., the “protein” and “exosome” fractions.
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Figure 7.6: a) Concentration of protein in HEK293 sample stocks and EV eluates from the C-CP tip at
each step in the isolation, determined using a Bradford assay. b) EV purity ratio comparing number of EVs
to the mass of protein. All samples applied in triplicate and the average of the triplicate measurements
minus the average response of the blank is presented. Purity standard = 3 x 10 10 EVs µg-1.

As shown in Fig. 7.6a, the CCM supernatant collections from days 0 – 6 of cell
culture contained a consistent level of ~1800 µg mL-1 of protein. Then, on days 7 – 14 of
culture, the protein concentration drops to the level of ~1000 µg mL-1. Efforts by
Martinez-Monge and co-workers have suggested that with increasing cell culture time,
comes inhibited HEK293 cell growth due to the presence of harmful cell waste byproducts, which causes a decrease in protein expression efficiency [56]. Indeed, this
change in total protein content appears to correspond to the point where the percentage of
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cell viability drops significantly (Fig. 1). This drop in “protein” content in the supernatant
is not seen at all in the values derived in the first fiber tip wash step. Herein, the
complementary aspects of the determinations may provide significant insights. Many
previous efforts using the C-CP fiber phases have shown that small polar/ionic molecules
are not retained on the fibers, as such the first-wash eluates should not contain proteins;
but amino acids. The impact here is that the drop in “total protein” content in the
supernatant observed after day 6 may be more reflective of decreased amino acid content
in the CCM, not proteins per se. Processing the CCM samples using the complete C-CP
tip protocol reduces the apparent protein concentrations of each sampling by 76 – 95%
for the “EV” fractions. In each case, a high level of precision is seen following the
Bradford assay, with the variability of each triplicate determination being <5 %RSD. It is
noteworthy that the time response of the protein concentrations in the final eluate
parallels those of the supernatant samples, reflecting a very consistent level of overall
purification efficiency.
Ultimately, the goal of any EV extraction protocol, be the end application
fundamental research, clinical diagnostics, or vector production, is the isolation of the
vesicles to the exclusion of the diversity of CCM constituents; most specifically proteins.
The most common metric used to assess the purity of EV isolates is the fraction
relationship between the number of EVs per mass of protein in the isolate, with >3 x 10 10
EVs per µg of protein considered to be “high purity” [52]. As recently demonstrated for
the case of human urine-derived EVs, this is one of the metrics where the C-CP fiber tip
method excels in comparison to other methods [45]. The relationship between EV and the
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protein concentration (i.e., purity) is depicted across the culture cycle in Fig. 7.6b. Highly
pure EV collections were obtained on days 1-14 of cell culture, while those EVs collected
on day 0 are considered “impure” simply because of the low concentration of EVs
obtained at the initial cell seeding. In every other case, the determined values exceed the
purity target of 3 x 1010 EV mg-1 protein (designated by dashed line) by a full order of
magnitude. Indeed, in the case of the low-viability cell conditions (beyond day 7), the
values exceed the target by almost 2 orders of magnitude. In those latter data, the
variability observed (<10 %RSD) is due to the low protein values via the Bradford assay.
Overall these findings are in accordance with previous demonstrations of EV isolations
using the C-CP tip, where the purity of the tip-recovered vesicles well exceeds the purity
of vesicles processed using competitive UC or polymeric precipitation methods for EV
isolation [41,45], on shorter time scales, low sample volumes, and lower capital costs.

7.4

Conclusions
There is a pressing need for methods to rapidly isolate, purify, and characterize

extracellular vesicles (EVs) across very different size scales and matrices. The needs
touch areas of fundamental biochemical research, clinical diagnostics, and vector
production. In all, the C-CP tip isolation method employing the Tween solvent is able to
produce highly concentrated, pure, structurally-preserved collections of EVs in a manner
that is relevant in the scales of time, cost, and practicality, for fundamental research and
clinical applications, with downstream applications of cell culture-sourced EVs holding
promise using the fiber column format. The C-CP tip isolation method was applied here
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to the isolation of HEK293-derived EVs, suggested as a vector for the delivery of
biotherapeutics. The C-CP tip method provides rapid isolation, which provides highpurity materials for subsequent characterization via a multitude of analytical methods.
Initial characterization included the evolution of the purity of the materials via TEM
imaging. The absorbance-based quantification approach allows the tracking of EV release
during the course of the cell culture process, where rapid processing of small aliquots
(100 mL) of CCM would be advantageous for process monitoring. The C-CP tip isolation
method provided bioactive EVs of up to 1.4 x 1011 EVs mL-1 concentration, as verified
via ELISA determinations. Ultimately, the purity of the derived EVs exceeded the target
metrics in all relevant cases, by greater than one order of magnitude, with up to 95%
removal of contaminant host cell proteins at various time points in cell culture.
As presented, the method demonstrated here should allow researchers across
diverse fields to gain greater fundamental information as to the roles of EVs in cell
culture processes or as means of process monitoring. We make no biochemical inferences
here, only demonstrating capabilities to obtain information. Future iterations of this
technique will enable the collection of repeatable, active EV collections from cell culture
and bioreactor sources on the relevant scales of time, cost, and functionality, perhaps
providing a purification platform for the future production of EVs on the therapeutic
scale. Further research efforts will concentrate on comparison of the use of the various
elution solvents using the C-CP fiber tip method, perhaps identifying protocols that are
tailored for the end use of the EVs. Collaboration with bioengineers will look to bring the
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methods into the realm of bioprocess monitoring. Finally, a scale-up of the C-CP fiber
column platform to allow high-volume processing will be pursued.
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CHAPTER EIGHT
SUMMARY AND FUTURE WORK

The works presented in this dissertation describe the development and evaluation
of a polyester capillary-channeled polymer (C-CP) fiber solid-phase extraction spin-down
tip for the isolation of extracellular vesicles (EVs) from highly diverse biological sources,
which is driven by a hydrophobic interaction chromatography (HIC) solvent system. The
C-CP fiber spin-down tip has repeatedly demonstrated the ability to provide highly
concentrated, pure, bioactive EVs able to be employed in the physiochemical,
microscopic, and biochemical techniques necessary to allow EV fundamentals to be
thoroughly understood, and impactful EV biomedical approaches developed. Compared
to the traditionally used isolation methods, the innovative C-CP spin-down tip approach
introduces significant benefits in time, cost, practicality, and EV purity, yield, and
integrity. Though many questions remain, the introduction of the C-CP tip method for the
isolation of EVs has addressed many of the isolation-specific technological barriers
limiting the expansion of EV research, and with the use of this novel approach, the
development of potentially impactful EV-based diagnostics and therapeutics will be
permitted.
With the foundational methods of EV isolation and assessment established in the
works included here, the pursuit of future developments of the C-CP-based methods
would surely be of interest. In the future, C-CP fiber platforms could be tailored to the
processing of EVs for therapeutic product manufacturing on the relevant volume and
concentration scales fit for biomanufacturing, even with the potential to be paired with
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automated liquid handler systems on hands-free and labor-free workflows. Further, the
versatile chemistries available by the use of C-CP fiber phases allow for the ability to
customize each application to the required downstream intent of the recovered vesicles by
choice of the polymer used to create the fiber phases, solvent additives, and/or fiber
derivatization protocols allowing for alternative capture chemistries (i.e. biotinstreptavidin, affinity-based isolations, etc.) to be applied. Since much of the scope of this
work has focused on the development and evaluation of the C-CP tip isolation method,
there is much room for the exploration of the extent to which the HIC C-CP method can
be utilized for the separation of relevant biovesicle analytes, i.e. the separation of EV
subtypes, liposomes, synthetic nanoparticles, viruses/virus-like particles, and EVs of
origins not included here. Moreover, the downstream methods to which the C-CP tiprecovered EVs can be applied have yet to be assessed. The comprehensive assessment of
the biomolecular cargos of the recovered EVs using proteomic, RNA sequencing, cell
barcoding mass spectrometric, and next-generation sequencing approaches are of much
interest before the clinical and therapeutic applications of EVs can be pursued.
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APPENDICES
Appendix A:
Supplementary Information for Chapter Two - “Solid-phase extraction of exosomes from
diverse matrices via a polyester capillary-channeled polymer (C-CP) fiber stationary
phase in a spin-down tip format”

Appendix B:
Supplementary Information for Chapter Four - “Facile, Generic Capture and On-Fiber
Differentiation of Exosomes via Confocal Immunofluorescence Microscopy using a
Capillary-Channeled Polymer Fiber Solid-Phase Extraction Tip”
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APPENDIX A
SUPPLEMENTARY INFORMATION FOR “SOLID-PHASE EXTRACTION OF
EXOSOMES FROM DIVERSE MATRICES VIA A POLYESTER CAPILLARYCHANNELED POLYMER (C-CP) FIBER STATIONARY PHASE IN A SPIN-DOWN TIP
FORMAT”

A-1 Electron Microscopy
Scanning electron microscopy (SEM) was performed using a Hitachi S-4800 to
confirm the capture of intact exosomes on the C-CP fiber surface. The fiber-bound
vesicles were fixed with 1% osmium tetroxide for 1 hour, then washed in microcentrifuge
tubes on a shaker (3 times, 5 minutes each). The samples were then
dehydrated in an ethanol-distilled water gradient from 0% to 100% ethanol, followed by
3 washes of 100% ethanol for 3 minutes each. The sample was then washed in a 50–50
hexamethyldisilazane (HMDS)-ethanol solution for 3 minutes and allowed to dry in a
fume hood in 100% HMDS overnight. The dehydrated samples were sputter-coated with
platinum at 70 mTorr argon for 2 minutes.
Transmission electron microscopy (TEM) was performed using a Hitachi HT7830
(Chiyoda, Tokyo, Japan) to confirm the release of intact exosomes from the C-CP fiber
surface. In preparation, eluted exosomes were fixed with 1 mL of 2% paraformaldehyde
(PFA) for 5 min. An aliquot of 7 μL of the fixed exosome suspension was placed on a
thin formvar/carbon film-coated 200 mesh copper EM grid and incubated for 1 minute.
The grids were then stained using 20 drops of filtered 1% uranyl acetate. The excess
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uranyl acetate solution was removed, and the sample grids were allowed to dry for 10
minutes before imaging at 100 kV.

A-2 C-CP Fiber Tip Assembly and Centrifuge Adapter
An eight-rotation loop of the PET fibers (corresponding to a total of 450 fibers,
~241 μm each in circumference) were pulled collinearly through approximately 30 cm
lengths of 0.8 mm inner diameter fluorinated ethylene polypropylene (FEP) polymer
tubing (Cole Parmer, Vernon Hills, IL, USA), yielding an interstitial fraction of ~0.6. The
fibers were pulled out of the column to create a 3 mm open space at the opposite end for
attachment to a 200 μL micropipette tip (Molecular BioProducts, San Diego, CA, USA).
The capillary was cut to create a 1 cm length of fiber-packed tubing. This procedure was
repeated for the entire length of the capillary, yielding 10-15 PET C-CP fiber tips. The CCP fiber tips were prepared for application by washing with five successive, 100 μL
aliquots of 40% ACN in DI water at 300 x g for 1 minute each, to ensure the entire
aliquot had spun down through the tip.
For centrifugation processing, a means of holding the tips within the centrifuge
tube had to be created. A utility knife was used to remove the center portion of the cap of
a 15 mL centrifuge tube (Nalge Nunc International, Rochester, NY, USA), with the
bottom portion of a 1.5 mL microcentrifuge tube (Fisher Scientific, Pittsburgh, PA,
USA), placed into the center of the cap, to act as the micropipette tip receptacle. The CCP fiber tips could then be inserted in the microcentrifuge tube and placed in the rotor of
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a table-top centrifuge. A VWR® Symphony™ 4417/R table-top centrifuge (Radnor, PA,
USA) was used for spin-down processing.

A-3 Confocal Microscopy
After the induction of exosome adsorption to the fiber surface under the high salt
condition (1:1000 exosome standards in 2M NH3SO4), the captured vesicles were rinsed
with DI water (50 μL each, 300 x g, 1 minute, three times), and the elution of
contaminant-free proteins was induced by rinsing the fiber surface with 25% glycerol in
PBS (50 μL each, 300 x g, 1 minute, three times) to leave cleanly isolated exosomes on
the fiber surface. To prevent non-specific binding of subsequently used antibodies, the
free fiber surface was blocked using a blocking solution of 1% bovine serum albumin (2
hours at room temperature on a rotator). For the immuno-identification of the captured
EVs, the fibers were exposed (spin-down) then incubated with a rabbit primary antibody
to the CD81 protein on the exosome surface (1:1000, overnight incubation at 4° C on a
rotator). Following primary antibody incubation, the fibers were washed using 6 cycles of
spin-down (50 μL), then incubation with washing buffer (PBS) for 5 minutes each. To
prevent non-specific binding of the secondary antibody, the fiber surface was again
blocked using a blocking solution of 1% bovine serum albumin (2 hours at room
temperature on a rotator). The fibers were exposed to the secondary antibody solution
containing an Alexa Fluor 647 goat anti-rabbit secondary antibody by spin-down, then
incubated (1:1000, 1 hour at room temperature) with the solution to obtain a visualized
fluorescence response. After incubation with the secondary antibody, the fibers were
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washed with PBS to remove unbound secondary antibody in preparation for imaging
using the Leica SP8 Confocal Microscope.

A-4 ELISA
The mouse CD81 capture antibody was diluted 1:250 in coating buffer (0.2 M
sodium carbonate/carbonate, pH=9.4), and 50 μL of the coating antibody solution was
added to each well and incubated overnight at 4°C, then at 37°C for 2 hours on a shaking
platform. The solution was removed, and the plate was washed using 200 μL of wash
buffer (PBS) per well for 3 x 5 minutes each on a shaking platform. To prevent nonspecific binding, the wells were incubated with 200 μL of blocking buffer (1% BSA) at
room temperature for 1 hour. The samples were then applied to the 96-well plate in 50 μL
aliquots and incubated overnight at 4°C, then at 37°C for 2 hours on a shaking platform.
The solution was removed, and the plate was washed using 200 μL of wash buffer (PBS)
per well for 3 x 5 minutes each. A rabbit CD81 primary antibody of 1:1000 concentration
was added to each well and incubated at 4°C, then at 37°C for 2 hours on a shaking
platform. The solution was removed, and the plate was washed using 200 μL of wash
buffer (PBS) per well for 3 x 5 minutes each. Then, the wells were incubated with 200 μL
of blocking buffer (1% BSA) at room temperature for 1 hour. Next, the wells were
incubated with 50 μL of a goat anti-rabbit horseradish peroxidase (HRP) enzyme
conjugate of 1:1000 concentration for 1 hour at room temperature. The solution was
removed, and the plate was washed using 200 μL of wash buffer (PBS) per well for 6 x 5
minutes each. Finally, the well was incubated with the 1-Step Ultra TMB Substrate for 30
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minutes at room temperature, and the resulting UV-Vis absorbance at 450 nm was
measured using the Synergy H1 Hybrid Multi-Mode Reader (BioTek). The ELISA was
run in triplicate (n=3) with each obtained absorbance value an average of 9
measurements. The results were quantified based on the comparison of the absorbance
values to a standard curve of linear response (y = 3E-10x + 0.2093) using commercial
exosome standards.

A-5 Dot Blot
In preparation for the experiment, a piece of polyvinylidene fluoride (PVDF)
membrane was cut into three 1 cm by 4 cm strips. Next, the micropipette-attachment
side of a 10 μL micropipette tip was used to create 3 small indentations on the PVDF
strips to prevent sample run-off from the region of interest. The indentations on the
PVDF strip were then labeled for the samples applied as followed: + (positive control,
(sample), and – (negative control). The membranes were then wet in methanol for 15
seconds, then equilibrated in PBS buffer for 5 minutes. Next, a transfer stack assembly
was set up to promote sample adsorption while keeping the membrane hydrated. Dry
paper towels were placed on the lab bench surface, followed by a dry piece Whatman®
3MM filter paper, then a piece of Whatman® 3MM paper wet with PBS buffer, and
finally, the pre-wet PVDF membrane. A 1 μL dot of 1:1000 secondary antibody, sample,
and PBS were placed on their labeled regions on the membranes and allowed to wick into
the membrane. The blots were then placed in a 1% BSA blocking solution and incubated
for 1 hour at room temperature on a shaking platform. Next, each dot blot was placed in a
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conical tube containing rabbit primary antibody solutions of 1:1000 concentration to
CD9, CD81, and CD63 proteins, and incubated overnight at 4°C on a rotator. Next, the
dot blots were washed with PBS for 30 minutes total with 5 buffer changes. The dot blots
were then incubated with a goat anti-rabbit silver nanoparticle conjugate for 30 minutes
at room temperature on a shaking platform. Finally, the resulting dot blot signal was
enhanced using the silver enhancement kit for membranes (Cytodiagnostics), by
incubating the dot blots in 2 mL of equal parts solution A and
solution B for 45 minutes. The dot blots were finally washed for 5 minutes in PBS to
stop the enhancement reaction.

A-6 Nanoparticle Tracking Analysis (NTA)
Averaged Nanosight NTA distribution profiles for eluted exosomes from the
spiked aqueous and spiked exosome-depleted FBS samples. Tabulated statistics are
presented below each.
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APPENDIX B
SUPPLEMENTARY INFORMATION FOR CHAPTER FOUR - “FACILE, GENERIC
CAPTURE AND ON-FIBER DIFFERENTIATION OF EXOSOMES VIA CONFOCAL
IMMUNOFLUORESCENCE MICROSCOPY USING A CAPILLARY-CHANNELED
POLYMER FIBER SOLID-PHASE EXTRACTION TIP”

B-1 Standard (overnight) immunolabeling procedure
Following the HIC C-CP tip capture of EVs, the immobilized exosomes were
exposed to a 5% BSA blocking solution in PBS to decrease non-specific binding of the
primary and secondary antibodies. For this, 200 μL aliquots of 5% BSA were spun down
5 times at 300 x g for 60 s each. Then, the C-CP tips were submerged and incubated in 1
mL of blocking solution for 15 min on a shaker. After the blocking step, three 200 μl
aliquots of PBS were spun down the tip (300 x g for 60 s each), then washed in 1 mL of
PBS on a shaker for 15 min (employing 3 buffer changes where the PBS was replaced).
Antibodies to the CD81 (mouse) and CA125 (rabbit) biomarker proteins were diluted
1:1000 in PBS, then 200 μL of the solution was applied to the C-CP tip, where it was
allowed to wick down for 5 minutes, before centrifugation at 150 x g for 3 min. After the
initial spin down, the C-CP tip was submerged and incubated in 1 mL of the primary
antibody solution overnight at 4°C. Next, the washing and blocking steps were repeated
as previously described. The AlexaFluor 488 (anti-rabbit) and Alexa Fluor 647
(antimouse) secondary antibodies were then diluted 1:1000 in PBS, and 200 μL of the
secondary antibody solution was applied to the tip reservoir and allowed to wick for 5
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minutes. Then the C-CP tip was centrifuged at 500 x g for 3 min before incubation in 1
mL of the secondary antibody for 1 hour at room temperature. Prior to confocal imaging,
a final PBS wash was performed 5 times to remove the non-specifically bound secondary
antibody.
B-2 Negative control experiments
In order to demonstrate the essential concepts of generic exosome capture, with
the ability to affect selective immunofluorescence imaging, it is essential to demonstrate
that non-specific interactions between the target proteins (and subsequently the labeled
antibodies) and the fiber surfaces are not occurring. Shown below are
immunofluorescence images of blank fibers treated with the antibody labels (Fig. B-1a),
exposed to purified CD81 and then the antibody labels (Fig. B-1b), and the purified
CD81 incubated with the antibody and applied to the fibers previously exposed to
exosomes (Fig. B-1c). Essential experimental details are provided with each. In each
case, the desired response was realized, with virtually no indication of non-specific
binding occurring at the fiber surfaces.

Fig. B-1a. Antibody interaction with blank PET Fiber: Blank PET fiber was washed with
PBS, then the cleanup and labeling protocol was performed: 1-hour primary antibody
incubation, 30 min. secondary antibody incubation, wash and block cycles between each
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incubation. Very minimal non-specific binding of the primary and/or secondary
antibodies was observed.

Fig. B-1b. CD81 exposure to blank fiber: Purified CD81 protein was applied during the
load step in 2M ammonium sulfate, then the protein cleanup and labeling steps were
performed. Very minimal non-specific binding of the primary and/or secondary
antibodies was observed.

Fig. B-1c. CD81/antibody conjugate applied to fiber surface in presence exosomes:
Exosome Standards (1:100 dilution, ~3 x 1010) were loaded onto the fiber surface, and the
protein cleanup step was performed, CD81 protein was incubated with the CD81
antibody (1 hour) before applying to tip, and labeling protocol was continued. Evidence
is seen for excess antibody binding to captured exosomes, but very minimal nonspecific
binding of the antigen/antibody complex is observed.
Electron microscopy
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In preparation, exosomes from exosome standards were isolated using the
previously described C-CP tip method, then fixed by incubation with 1% osmium
tetroxide for 1 hour and washed in microcentrifuge tubes on a shaker (3 times, 5 minutes
each). After fixation, the samples were dehydrated using an ethanol-distilled water
gradient from 0% to 100% ethanol, followed by three washes of 100% ethanol for 3
minutes each. Following dehydration, the sample was washed in a 50–50
hexamethyldisilazane (HMDS)-ethanol solution for 3 minutes and allowed to dry in a
fume hood in 100% HMDS overnight. The dehydrated samples were sputter-coated with
imaging, the prepared EV-coated C-CP fibers were placed directly on carbon tape and
into the instrument. During the STEM imaging of the tip eluates, the liquid eluates were
dropcasted onto a small piece of EM-grade silica wafer for 60 seconds, and the sample
liquid was removed using a small piece of paper towel before imaging.

a)

b)

Figure B-2: a) SEM micrograph of exosome standards (using the Hitachi S4800) captured
on the C-CP fiber surface due to the HIC mode capture of the vesicles. b) STEM
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micrograph of exosome standards eluted from the C-CP fiber tip immobilized on a silica
wafer. (taken using Hitatchi SU9000)
B-3 Nanoparticle Tracking Analysis
The NanoSight NS300 nanoparticle tracking analysis (NTA) system (Malvern
Panalytical, Malvern, Worcestershire, United Kingdom) was used to determine the size
distribution and concentration of EVs isolated from 100 μL of HEK293 cell culture
media using the C-CP tip. The NTA determinations were performed as previously
reported. Briefly, the NTA system was equipped with a 532 nm laser, and five replicate
measurements were performed in 60-second intervals. Throughout experimentation, the
focal plane was manually adjusted for the best optical field of view. The syringe pump
was set to a constant flow rate of 50 μL per minute, the camera level was set to 14, and
the detection threshold was set to 3. Before NTA measurement, the EV recoveries were
diluted 1:1000 to be compatible with the working concentration range of the NanoSight
instrument (107–109 particles per mL). The EV concentration value presented in Fig. B-3
compensates for this dilution factor.
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Figure B-3: Size distribution and concentration of EVs isolated using the C-CP tip from
HEK293 cell culture milieu, as determined using the NanoSight NS300 NTA instrument.
The average of five 60-seconds runs is presented. A 1:1000 dilution of each EV aliquot
was made prior to NTA, and the determined EV concentration accounts for this dilution
factor.
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